



2021 No. 100

Analysis of Practice for the Physical Therapy Profession: Report Memo 2021

Prepared for: Federation of State Boards of Physical Therapy
124 West Street South
Alexandria, VA 22314

Prepared under: NA

Authors: Jessica L. Harris
Arielle P. Rogers
Joseph P. Caramagno

Date: TBD

Analysis of Practice for the Physical Therapy Profession: Report Memo 2021

Table of Contents

Background and Executive Summary	1
Summary of Practice Analysis Survey Changes.....	2
Background Questionnaires.....	2
WA and KSR Rating Scales.....	2
Sample Selection and Administration.....	3
Data Cleaning and Screening	3
Response Rates and Final Analysis Sample.....	4
Sample Description and Representativeness.....	4
Work Activity and Knowledge and Skill Requirements: Data Analytic Strategy.....	5
Work Activity and Knowledge and Skill Requirements: Results Summary.....	7
Recommendations for Future Practice Analysis Survey Cycles	13
References	14
Appendix A. Summary of Background Questionnaire Responses	A-1
Appendix B. Summary of Work Activity and Knowledge and Skill Requirements Survey Responses	B-1
Appendix C. Notable Mean Differences Across Years.....	C-1

List of Tables

Table 1. Data Quality Screens	4
Table 2. Survey Distribution and Response Rates	4
Table 3. Estimates of Inter-rater Reliability and Agreement.....	6
Table A.1. Descriptive Statistics for the 2021 Background Questionnaire	1

List of Figures

Figure 1. PT KSR Mean Importance by Modality.....	10
Figure 2. PTA KSR Mean Importance by Modality	10
Figure 3. PT and PTA 2021 Mean Importance ratings for telehealth by work setting.....	11
Figure 4. Dry Needling Importance ratings by Jurisdiction (2018-2021)	12

Analysis of Practice for the Physical Therapy Profession: Report Memo 2021

Background and Executive Summary

This memo summarizes the process and results of the analysis of practice for the physical therapy profession conducted by the Federation of State Boards of Physical Therapy (FSBPT) in partnership with the Human Resources Research Organization (HumRRO) and FSBPT's Exam Committee Chairs. The study documented in this memo was conducted between January and July 2021 and represents the fourth data collection cycle in the multi-year practice analysis methodology through 2022¹.

The methodology enables FSBPT to (a) monitor on-going and emerging trends in entry-level requirements, (b) respond quickly to changes in the profession that necessitate adjustments to the licensure examinations (e.g., removing test questions that assess skill areas of decreasing importance; increasing the numbers of test questions that assess skill areas of increasing importance), and (c) enhance awareness among current and prospective PTs and PTAs of FSBPT's mission, purpose, and the services it provides.

The approach to conduct the analysis of physical therapy practice in 2021 was similar to that taken in 2018, 2019, and 2020 (see Caramagno, 2018; Caramagno, Cogswell, & Waugh, 2018a; Caramagno, Cogswell, & Waugh, 2018b; Rogers & Caramagno, 2019; Rogers & Caramagno, 2020).

- In February 2021, FSBPT collected input on existing lists of work activities (WAs) and knowledge and skill requirements (KSRs)—prepared in 2020—from the Exam Committee Chairs.
- HumRRO used this input to prepare an electronic survey to gather ratings of the WAs and KSRs from a large sample of PTs and PTAs across 53 licensing jurisdictions comprising FSBPT's membership. The survey had two sections: a set of questions about the demographic characteristics of the sample and a set of WAs or KSRs that respondents evaluated using a five-point Likert-type *importance* rating scale.
- HumRRO analyzed the response data and compiled the results in summary tables and charts and shared the results with FSBPT and the Exam Committee Chairs.
- FSBPT convened a one-day, web-based meeting on July 16, 2021 with HumRRO and the Exam Committee Chairs to review the results and obtain recommendations for the remaining cycle of the multi-year methodology. The results and recommendations are described in detail in this memo.

¹ Due to the COVID-19 pandemic, the NPTE blueprint update for the PT and PTA exams was postponed from 2021 to 2022. In 2021, data collection for the fourth practice analysis cycle proceeded as originally planned. In 2022, an additional cycle of data will be collected in addition to the postponed blueprint update.

Summary of Practice Analysis Survey Changes

During each year of the multi-year practice analysis, FSBPT and HumRRO review prior year activities and results to determine whether adjustments are warranted to enhance the quantity, quality, and usefulness of information obtained during the forthcoming year. For the current iteration of the practice analysis, the work activities (WAs) and knowledge and skill requirements (KSRs) remained largely consistent with the 2018, 2019, and 2020 studies. Minor changes made to the background questionnaire and WA and KSR rating scales are detailed below.

Background Questionnaires

- Added a question to the PT/PTA survey to assess whether respondents have taken extended breaks in their careers: “Have you ever had an extended period of time (more than three months) away from actively working as a physical therapist assistant? Includes work in clinical, administration, consultation, education, or research activities.”
 - No, I have never had an extended break from my work
 - Yes, lasting 3 to 6 months
 - Yes, lasting 6 to 12 months
 - Yes, lasting 12 to 18 months
 - Yes, lasting 18 to 36 months
 - Yes, lasting 3 to 5 years
 - Yes, lasting 5 to 10 years
 - Yes, lasting greater than 10 years
- Added a question to the PT/PTA survey to assess how frequently respondents use telehealth to provide services: “Approximately what percentage of time over the past 12 months did you provide physical therapy services via telehealth or virtual/digital sessions? Includes direct patient care, consultation, patient advocacy, and indirect care.”
 - 0%
 - 1% to 25%
 - 26% to 50%
 - 51% to 75%
 - 76% to 100%

WA and KSR Rating Scales

- Split the PT and PTA KSRs “Applications, indications, contraindications, and precautions of: light modalities (e.g., laser light therapy, LED light therapy)” into two statements:
 - “Applications, indications, contraindications, and precautions of: laser light therapy”
 - “Applications, indications, contraindications, and precautions of: LED light therapy”

- Implemented minor wording deletions to the following KSR:
 - “**Applications and utilization of** health information technology (e.g., electronic medical records, ~~telemedicine~~)”
- Added to the PT and PTA KSR surveys: “The provision and utilization of telehealth (i.e., the use of telecommunication technologies to provide health care information and services)”

Sample Selection and Administration

- FSBPT selected participant samples from a list of licensure candidates who had passed the National Physical Therapy Exam (NPTE) stratified by exam, year of licensure, and jurisdiction.
- HumRRO conducted a soft launch on April 6, 2021 to test the email campaign programming and survey functionality. The soft launch included approximately 100 invitations for each survey.
- HumRRO sent remaining email invitations starting on April 8, 2021 (i.e., hard launch). Participants received reminder emails on April 21, 2021, May 12, 2021, and June 1, 2021.
- The survey closed on June 8, 2021.
- Consistent with the 2019 and 2020 process, respondents completed either the WA or KSR survey based on their years of professional experience. Individuals with two or fewer years of experience were assigned to the WA survey. Individuals with three or more years of experience completed the KSR survey. The PT KSR survey also incorporated branching logic to redirect respondents who indicated that they routinely supervise PTAs and have a good understanding of the knowledge and skills PTAs need to provide safe and effective care.²

Data Cleaning and Screening

- Examined the raw data to identify outliers and unexpected responses.
- Applied data screens to remove careless responder data based on logical, psychometric, structural, and substantive considerations including flat, hasty, and missing response patterns, and ineligible employment status.

² In prior years, the branching logic was “turned off” during survey administration once an adequate sample of PT KSR participants completed the PTA KSR survey. Starting in 2020, HumRRO programmed two separate PT KSR background questionnaires—one with branching logic and one without branching logic (i.e., questionnaires were the exact same except for the branching logic). FSBPT randomly selected 20% of PT KSR participants to be assigned to the background questionnaire containing the branching logic. This ensured an adequate sample of PT KSR participants completed the PTA KSR survey without needing to adjust any aspects of the survey during administration.

Table 1. Data Quality Screens

Data Screen	PT KSR		PTA KSR		PT WA		PTA WA	
	A	B	A	B	A	B	A	B
Flat Responding	44	53	39	44	30	5	45	14
Hasty Responding	5	5	6	1	6	3	6	5
Missing >90% of responses	215	170	120	93	101	77	56	58
Employment Status								
Retired	2	5	10	7	0	0	0	1
Unemployed and <i>not</i> looking for work as a PT or PTA	37	53	58	61	1	7	14	23
Total	291	271	209	185	137	88	108	90

Note. Flat Responding includes individuals who selected the same response value an unreasonably-high number of times in a row. Hasty Responding includes individuals who completed the survey too quickly to have been paying adequate attention to the survey questions. The values in the “Total” row account for overlap across the data screens and identify the absolute number of cases that were excluded (i.e., no double-counting).

Response Rates and Final Analysis Sample

- Table 2 summarizes the response rates for the 2021 practice analysis surveys.
- The “Responded” count is the number of individuals who started the survey and completed at least the background questions.
- The “Usable” count reflects the number of respondents who provided response data of acceptable quality based on the data screens noted above.
- The final analysis sample included data from 4,336 respondents across all survey forms.

Table 2. Survey Distribution and Response Rates

Sample	Invited	Responded			Usable	
		Form A	Form B	Total		
PT KSR	26,217	1,263	1,291	2,554	1,992	(8%)*
PTA KSR	14,279	672	706	1,378	984	(7%)*
PT WA	11,528	567	554	1,121	896	(8%)
PTA WA	6,850	352	310	662	464	(7%)

Note. * 253 PT KSR respondents were reassigned to the PTA KSR survey based on responses to the background question regarding supervision of PTAs.

Sample Description and Representativeness

HumRRO computed descriptive statistics for the background questionnaire response data to summarize and examine the representativeness of the sample. Below is a summary of the 2021 practice analysis sample on several key variables. The complete set of results of the background questionnaire are presented in Appendix A.

Overall, sample characteristics were comparable to those reported in 2020.

- Respondents tended to be female (70.4-75.4%), White (73.3-77.1%), and employed full time (67.7-86.0%).
- A large proportion of the PT WA respondents (90.1%) and PT KSR respondents (69.4%) possessed Doctor of Physical Therapy (DPT) degrees. Individuals in the PTA samples typically reported their highest degree as an Associate's degree (PTA WA: 75.9%; PTA KSR: 56.0%).
- Respondents to the PT WA and PT KSR surveys reported spending more than 50% of their time in private outpatient facilities (34.6% and 22.4%, respectively), health system or hospital-based outpatient facilities (24.8% and 21.5%), acute care hospital (8.8% and 9.9%), home health or home care facilities (4.0% and 13.4%), and skilled nursing facilities (4.6% and 9.2%).
- A larger portion of respondents to the PTA WA and KSR surveys reported they spend more than 50% of their time working in skilled nursing facilities (19.8% and 21.7%, respectively) compared to PTs responding to the PT WA and PT KSR surveys (4.6% and 9.2%, respectively).
- A majority of PTs and PTAs (63.1-75.4%) reported having only one employment position in the past 12 months.
- A majority of PTs and PTAs (75.8-83.9%) reported spending more than three-quarters of their time in direct patient care.

Work Activity and Knowledge and Skill Requirements: Data Analytic Strategy

Analysis of the WA and KSR survey data involved computing descriptive statistics to examine the distribution and magnitude of respondents' ratings and interrater agreement indices to evaluate the degree of agreement and consistency in the response sets. Below is a summary of the analytic strategy.

- For each WA statement, HumRRO computed:
 - Sample size: number of valid responses.
 - Percent Perform ($\%_{\text{Perf}}$): Sum of responses for scale points 1 through 5, divided by the total number of usable respondents.
 - Percent Important ($\%_{\text{Imp}}$): Sum of responses for scale points 2 through 5, divided by the total number of usable respondents.
 - Mean Importance (M): Based on responses for scale points 1 through 5. Mean WA importance ratings exclude respondents who selected the option *I have not performed this WA*.
 - Standard Deviation of Importance (SD): Based on responses for scale points 1 through 5.

- For each KSR statement, HumRRO computed:
 - Sample size: number of valid responses.
 - Percent Important (%_{imp}): Sum of responses for scale points 2 through 5, divided by the total number of usable respondents.
 - Mean Importance (M): Based on responses for scale points 1 through 5.
 - Standard Deviation of Importance (SD): Based on responses for scale points 1 through 5.

- For each WA and KSR statement, HumRRO computed differences in importance ratings by work setting:
 - We conducted independent samples *t* tests to examine differences in importance ratings by work setting. Specifically, importance ratings by PTs and PTAs who spent at least 50% of their time working in a particular setting over the past 12 months were compared to ratings by those who spent less than 50% of their time working in that setting.
 - We reported subgroup analyses only for work settings where greater than 30 PTs and/or PTAs reported spending at least 50% of their time. These settings include private outpatient facilities, health system or hospital-based outpatient facilities, acute care hospitals, home health or home care facilities and skilled nursing facilities.

- Two types of intraclass correlation coefficients (ICCs; McGraw & Wong, 1996; Shrout & Fleiss, 1979) were computed to estimate the degree of consistency and agreement among the survey respondents.
 - The single rater estimates can be interpreted as the level of consistency (or agreement) to be expected between the ratings provided by any single rater with any other randomly selected single rater.
 - The Observed estimates indicate the degree of consistency (or agreement) to be expected between the average among the sample of survey participants and the average that would be obtained if another random sample were to be drawn from the population.

Table 3. Estimates of Inter-rater Reliability and Agreement

Survey	Form	Number of Items	Type of ICC			
			Consistency		Agreement	
			1-Rater	Observed	1-Rater	Observed
PT KSR	A	76	0.38	>0.99	0.29	>0.99
	B	78	0.49	>0.99	0.38	>0.99
PTA KSR	A	67	0.30	0.99	0.23	0.99
	B	69	0.44	>0.99	0.34	>0.99
PT WA	A	120	0.39	>0.99	0.33	0.99
	B	122	0.50	>0.99	0.45	>0.99
PTA WA	A	99	0.26	0.99	0.20	0.98
	B	100	0.44	0.99	0.37	0.99

Note. Consistency and agreement ICCs estimated for a single rater (1-Rater) and for the total number of raters (Observed).

Work Activity and Knowledge and Skill Requirements: Results Summary

Descriptive statistics for all PT and PTA WAs and KSRs are presented in Appendix B. Based on the descriptive statistics, HumRRO flagged statements that:

- 1) fell at, just above, or below a criticality threshold for mean importance,
- 2) increased or decreased in mean importance by greater than 0.50 from 2016 to 2021, and
- 3) were of particular interest to FSBPT given current trends or changes in the field.

Findings for each of these three categories of statements are presented in Appendices B and C and are summarized below.

During the July 16th Exam Chair meeting, HumRRO and the meeting participants reviewed these statements and discussed professional and methodological issues that could have led to increases or decreases in importance ratings relative to the 2016, 2018, 2019, and 2020 practice analysis survey results.

- **Statements at, just above, or below the criticality threshold.** Using the criticality index of 2.50, representing halfway between scale point 2 (Minimally Important) and 3 (Important), HumRRO extracted statements that received mean importance ratings at, just above (between 2.50 and 3.00), or below (<2.50) the criticality index (see red and orange highlighted statements in Appendix B).
 - Overall, five PT KSR statements fell below the criticality threshold (<2.50), indicating relatively low mean importance ratings. These included:
 - Knowledge of:
 - diagnostic electrophysiology (EMG/NCV) using needle insertion
 - physical therapy ultrasound imaging of the genitourinary system
 - Knowledge of applications, indications, contraindications, and precautions of:
 - LED light therapy
 - shockwave therapy
 - diathermy

These results are consistent with prior practice analysis survey results—each of these five statements fell near or below the criticality threshold in 2018, 2019, and 2020.

- Consistent with the 2018, 2019, and 2020 results, none of the PTA KSR statements received mean importance ratings below the criticality threshold.
- Three PTA WA statements fell below the criticality threshold. These included:
 - Perform and/or train patient/client/caregiver in:
 - hyperbaric therapy
 - monochromatic infrared agent procedures (e.g., light emitting diodes [LEDs])

- Perform sharp debridement (e.g., removal of specific areas of devitalized tissue)

Each of these statements had mean importance ratings between 2.28 and 2.61 across all four cycles of data collection, and they are currently excluded from the test content outline.

- Of the PT WA statements, 14 fell below the criticality threshold. Consistent with the 2019 and 2020 results, the majority of these statements were associated with “Integumentary Repair & Protection Techniques” or “Therapeutic Modalities.”
- **Statements with mean differences greater than |0.50|.** HumRRO computed the difference between mean importance ratings across years and highlighted values that indicated an increase or decrease in mean importance of greater than 0.50 (see Appendix C).
 - Overall, ratings were relatively consistent from 2016 to 2021.
 - Four (4) PT WAs increased in mean importance from 2016 to 2021 and five (5) decreased in importance by greater than |0.50|:
 - Perform dry needling (+0.60)
 - Interpret each of the following types of data to determine the need for intervention or the response to intervention:
 - Neuromuscular system (+0.70)
 - Functional mobility, balance, and vestibular (+0.56)
 - Musculoskeletal system (+0.52)
 - ADLs/IADLs and home management (+0.50)
 - Perform and/or train patient/client/caregiver in:
 - phonophoresis (-0.69)
 - iontophoresis (-0.64)
 - ultrasound procedures (-0.75)
 - diathermy (-0.59)
 - Four (4) PTA WAs increased in mean importance from 2016 to 2021 and one (1) decreased in importance by greater than |0.50|:
 - Apply taping for pain management (+0.83)
 - Apply taping for neuromuscular reeducation (+0.69)
 - Apply and/or train patient/client/caregiver in intermittent pneumatic compression (+0.54)
- **Selected WAs and KSRs:** FSBPT indicated special interest in tracking specific WAs and KSRs overtime due to relevant changes and trends in the physical therapy field. These included:
 - PT and PTA therapeutic modalities
 - Telehealth by work setting
 - Dry needling by jurisdiction

Figures 1 and 2 (next page) depict mean importance ratings from 2018 to 2021 for each of the PT and PTA therapeutic modalities. The PT and PTA importance ratings were largely consistent from 2018 to 2021³, with slight decreases in PTA modalities from 2020 to 2021.

Figure 3 depicts mean importance ratings in 2021 for telehealth by work setting (rural vs. urban vs. suburban). Overall, importance ratings for telehealth were largely consistent across different work settings for both the PT and PTA KSR statement: “The provision and utilization of telehealth (i.e., the use of telecommunication technologies to provide health care information and services)”. PTs in urban settings ($M = 3.52$, $SD = 1.10$) and rural settings ($M = 3.55$, $SD = 1.13$) rated this KSR slightly higher than PTs in suburban settings ($M = 3.38$, $SD = 1.07$, $p = 0.054$). PTAs across work settings had mean importance ratings between 3.26 and 3.31, indicating no major differences in the use of telehealth in different settings. Note this may be due to an overall increase in telehealth importance during the COVID-19 pandemic.⁴

On the 2021 PT WA survey, less than half of PTs (43%) reported performing dry needling, consistent with prior years. Figure 4 depicts mean importance ratings for dry needling by jurisdiction in the combined sample of PT WA data collected between 2018 and 2021.⁵ There are 10 states where more than 50% of PTs reported performing dry needling: Kentucky, Colorado, Connecticut, Texas, Wisconsin, Tennessee, South Carolina, Arizona, North Carolina, and Indiana. PTs from Tennessee, Georgia, and Arizona rated dry needling as more important ($M = 3.45$ - 3.54) relative to PTs from other states (Overall $M = 2.88$). PTs from Oregon indicated the lowest importance ratings for dry needling ($M = 1.50$). Exam Chairs noted during the July 16th meeting that the usage and importance of dry needling is most likely the result of policy decisions made by state boards of physical therapy.

³ 2016 comparisons are excluded from these analyses due to non-trivial changes to the survey items in 2018.

⁴ Because the telehealth statement was new to the survey in 2021, we are unable to statistically examine whether there was an overall increase in telehealth importance this cycle compared to prior data collection cycles.

⁵ Data collected across four survey cycles (2018-2021) were merged to allow for meaningful comparisons between jurisdictions.




Figure 1. PT KSR Mean Importance by Modality




Figure 2. PTA KSR Mean Importance by Modality




Figure 3. PT and PTA 2021 Mean Importance ratings for telehealth by work setting




Figure 4. Dry Needling Importance ratings by Jurisdiction (2018-2021)

Recommendations for Future Practice Analysis Survey Cycles

HumRRO solicited feedback on the above results and the overall job analysis process from FSBPT and the Exam Committee Chairs. Their feedback and the data we collected suggest the following recommendations:

- Add topics to cover blood flow restriction (BFR) training and cupping as these are two emerging areas of research and education in physical therapy.
- Add a KSR topic to address non-pharmacologic treatment of chronic or persistent pain.
- Examine the importance of knowledge of the lymphatic system by work setting. The treatment of lymphedema has become more limited to specialized clinics over the last few years which could explain its downward importance trend.
- Examine importance of electrodiagnostics (e.g., electrophysiological function using surface electrodes) by work setting as these may be used at different rates across different environments.
- Continue to track trends overtime in KSRs and WAs to inform decisions regarding their inclusion and exclusion on the exam.

References

- Caramagno, J. P. (2018). *Analysis of Practice for the Physical Therapy Profession: Report Memo 2018* (No. 051). Alexandria, VA: Human Resources Research Organization.
- Caramagno, J. P., Cogswell, S., & Waugh, G. (2016a). *Analysis of practice for the physical therapy profession: Entry-level physical therapists* (FR16-83). Alexandria, VA: Human Resources Research Organization.
- Caramagno, J. P., Cogswell, S., & Waugh, G. (2016b). *Analysis of practice for the physical therapy profession: Entry-level physical therapist assistants* (FR16-84). Alexandria, VA: Human Resources Research Organization.
- McGraw, K. O., & Wong, S. P. (1996). Forming inferences about some intraclass correlation coefficients. *Psychological Methods*, 1, 30-46.
- Rogers, A. R., & Caramagno, J. P. (2019). *Analysis of Practice for the Physical Therapy Profession: Report Memo 2019* (No. 090). Alexandria, VA: Human Resources Research Organization.
- Rogers, A. R., & Caramagno, J. P. (2020). *Analysis of Practice for the Physical Therapy Profession: Report Memo 2020* (No. 092). Alexandria, VA: Human Resources Research Organization.
- Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. *Psychological Bulletin*, 86, 420-428.

Appendix A. Summary of Background Questionnaire Responses

Table A.1. Descriptive Statistics for the 2021 Background Questionnaire

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q1 What is your gender?								
I prefer not to respond	47	25	7	7	2.4	2.5	0.8	1.5
Female	1403	742	647	343	70.4	75.4	72.2	73.9
Male	538	214	242	114	27.0	21.7	27.0	24.6
[other]	2	1	0	0	0.1	0.1	0.0	0.0
Q2 Are you Hispanic or Latino?								
I prefer not to respond	67	37	13	15	3.4	3.8	1.5	3.2
Yes	79	65	58	51	4.0	6.6	6.5	11.0
No	1844	881	823	397	92.6	89.5	91.9	85.6
Q3 What is your race?								
I prefer not to respond	105	54	18	24	5.3	5.5	2.0	5.2
American Indian or Alaska Native	13	9	4	5	0.7	0.9	0.4	1.1
Asian	323	106	161	50	16.2	10.8	18.0	10.8
Black or African American	65	39	36	25	3.3	4.0	4.0	5.4
Native Hawaiian or Other Pacific Islander	13	12	5	4	0.7	1.2	0.6	0.9
White	1461	759	678	351	73.3	77.1	75.7	75.6
[other]	42	25	16	16	2.1	2.5	1.8	3.4
Q4 What is the highest academic degree related to physical therapy that you have earned?								
Certificate	2	0	0	1	0.1	0.0	0.0	0.2
Associate's	0	551	0	352	0.0	56.0	0.0	75.9
Bachelor's	198	172	58	94	9.9	17.5	6.5	20.3
Master's	364	65	24	9	18.3	6.6	2.7	1.9
Doctor of Physical Therapy (DPT)	1382	186	807	5	69.4	18.9	90.1	1.1
Doctoral degree (PhD, EdD, clinical doctorate, or other)	24	0	1	0	1.2	0.0	0.1	0.0
[other]	21	9	6	3	1.1	0.9	0.7	0.6
Q5 Where did you complete your entry-level physical therapy education?								
United States	1679	894	789	430	84.3	90.9	88.1	92.7
Canada	9	3	4	0	0.5	0.3	0.4	0.0
Egypt	4	2	1	1	0.2	0.2	0.1	0.2
India	79	25	20	6	4.0	2.5	2.2	1.3
Philippines	175	46	57	19	8.8	4.7	6.4	4.1
South Korea	4	0	2	1	0.2	0.0	0.2	0.2
United Kingdom	8	1	2	0	0.4	0.1	0.2	0.0
[other]	34	12	20	7	1.7	1.2	2.2	1.5

Table A.1. (continued)

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q6 In what year were you FIRST licensed as a physical therapist in the United States, the District of Columbia, U.S. Virgin Islands, or Puerto Rico?								
Not selected	0	7	2	1	0.0	0.7	0.2	0.2
1955-1959	0	0	0	0	0.0	0.0	0.0	0.0
1960-1969	0	0	0	0	0.0	0.0	0.0	0.0
1970-1979	1	0	0	0	0.1	0.0	0.0	0.0
1980-1989	8	3	1	1	0.4	0.3	0.1	0.2
1990-1999	233	90	1	1	11.7	9.1	0.1	0.2
2000-2009	755	306	0	0	37.9	31.1	0.0	0.0
2010-2019	995	577	865	452	49.9	58.6	96.5	97.4
2020-2029	0	1	27	9	0.0	0.1	3.0	1.9
Q7 In which one of the following United States physical therapy jurisdictions do you currently have your PRIMARY clinical work setting?								
Not selected	14	3	15	2	0.7	0.3	1.7	0.4
Alabama	9	17	11	7	0.5	1.7	1.2	1.5
Alaska	6	4	3	1	0.3	0.4	0.3	0.2
Arizona	40	19	21	11	2.0	1.9	2.3	2.4
Arkansas	26	14	9	0	1.3	1.4	1.0	0.0
California	159	59	77	43	8.0	6.0	8.6	9.3
Colorado	33	19	25	7	1.7	1.9	2.8	1.5
Connecticut	24	6	16	2	1.2	0.6	1.8	0.4
District of Columbia (Washington)	6	1	4	0	0.3	0.1	0.4	0.0
Delaware	11	3	4	3	0.6	0.3	0.4	0.6
Florida	82	67	26	30	4.1	6.8	2.9	6.5
Georgia	64	34	22	7	3.2	3.5	2.5	1.5
Guam	2	0	0	0	0.1	0.0	0.0	0.0
Hawaii	25	2	5	1	1.3	0.2	0.6	0.2
Idaho	9	6	11	4	0.5	0.6	1.2	0.9
Illinois	82	38	43	21	4.1	3.9	4.8	4.5
Indiana	49	37	14	13	2.5	3.8	1.6	2.8
Iowa	10	10	7	7	0.5	1.0	0.8	1.5
Kansas	15	6	12	7	0.8	0.6	1.3	1.5
Kentucky	26	20	16	5	1.3	2.0	1.8	1.1
Louisiana	25	13	9	8	1.3	1.3	1.0	1.7
Maine	15	7	3	2	0.8	0.7	0.3	0.4
Maryland	49	17	21	7	2.5	1.7	2.3	1.5
Massachusetts	43	13	32	8	2.2	1.3	3.6	1.7
Michigan	52	36	20	14	2.6	3.7	2.2	3.0

Table A.1. (continued)

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q7 (continued) In which one of the following United States physical therapy jurisdictions do you currently have your PRIMARY clinical work setting?								
Minnesota	41	11	15	8	2.1	1.1	1.7	1.7
Mississippi	16	12	4	5	0.8	1.2	0.4	1.1
Missouri	20	19	9	8	1.0	1.9	1.0	1.7
Montana	11	8	3	2	0.6	0.8	0.3	0.4
Nebraska	14	8	9	3	0.7	0.8	1.0	0.6
Nevada	16	9	7	7	0.8	0.9	0.8	1.5
New Hampshire	22	12	6	0	1.1	1.2	0.7	0.0
New Jersey	130	38	27	4	6.5	3.9	3.0	0.9
New Mexico	11	6	3	5	0.6	0.6	0.3	1.1
New York	152	42	89	37	7.6	4.3	9.9	8.0
North Carolina	49	22	30	8	2.5	2.2	3.3	1.7
North Dakota	6	2	7	0	0.3	0.2	0.8	0.0
Northern Mariana Islands	0	0	0	0	0.0	0.0	0.0	0.0
Ohio	54	29	22	25	2.7	2.9	2.5	5.4
Oklahoma	8	12	4	4	0.4	1.2	0.4	0.9
Oregon	37	12	13	6	1.9	1.2	1.5	1.3
Pennsylvania	75	44	33	19	2.8	4.5	3.7	4.1
Puerto Rico	0	0	2	0	0.0	0.0	0.2	0.0
Rhode Island	10	3	1	1	0.5	0.3	0.1	0.2
South Carolina	52	26	13	11	2.6	2.6	1.5	2.4
South Dakota	6	3	0	0	0.3	0.3	0.0	0.0
Tennessee	32	14	20	19	1.6	1.4	2.2	4.1
Texas	173	110	57	29	8.7	11.2	6.4	6.3
U.S. Virgin Islands	0	0	0	0	0.0	0.0	0.0	0.0
Utah	21	12	10	9	1.1	1.2	1.1	1.9
Vermont	4	4	3	1	0.2	0.4	0.3	0.2
Virginia	65	25	33	17	3.3	2.5	3.7	3.7
Washington	52	20	22	13	2.6	2.0	2.5	2.8
West Virginia	1	6	2	1	0.1	0.6	0.2	0.2
Wisconsin	31	24	24	10	1.6	2.4	2.7	2.2
Wyoming	7	0	2	2	0.4	0.0	0.2	0.4

Table A.1. (continued)

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q8 In which of the following United States physical therapy jurisdictions are you currently licensed (percentages may sum to more than 100%)?								
Alabama	12	17	14	5	0.6	1.7	1.6	1.1
Alaska	6	5	4	2	0.3	0.5	0.4	0.4
Arizona	42	22	24	12	2.1	2.2	2.7	2.6
Arkansas	24	13	8	1	1.2	1.3	0.9	0.2
California	155	54	88	34	7.8	5.5	9.8	7.3
Colorado	37	16	30	8	1.9	1.6	3.3	1.7
Connecticut	34	7	21	2	1.7	0.7	2.3	0.4
District of Columbia (Washington)	16	2	5	0	0.8	0.2	0.6	0.0
Delaware	16	6	4	4	0.8	0.6	0.4	0.9
Florida	89	63	33	29	4.5	6.4	3.7	6.3
Georgia	64	29	29	6	3.2	2.9	3.2	1.3
Guam	2	1	0	0	0.1	0.1	0.0	0.0
Hawaii	26	2	5	1	1.3	0.2	0.6	0.2
Idaho	14	6	9	5	0.7	0.6	1.0	1.1
Illinois	82	41	47	14	4.1	4.2	5.2	3.0
Indiana	45	38	17	13	2.3	3.9	1.9	2.8
Iowa	10	13	11	5	0.5	1.3	1.2	1.1
Kansas	17	8	9	8	0.9	0.8	1.0	1.7
Kentucky	22	17	15	5	1.1	1.7	1.7	1.1
Louisiana	16	13	12	6	0.8	1.3	1.3	1.3
Maine	16	7	4	2	0.8	0.7	0.4	0.4
Maryland	50	16	25	6	2.5	1.6	2.8	1.3
Massachusetts	63	16	35	7	3.2	1.6	3.9	1.5
Michigan	43	32	18	11	2.2	3.3	2.0	2.4
Minnesota	45	10	17	8	2.3	1.0	1.9	1.7
Mississippi	15	11	5	4	0.8	1.1	0.6	0.9
Missouri	33	15	15	9	1.7	1.5	1.7	1.9
Montana	10	7	7	3	0.5	0.7	0.8	0.6
Nebraska	12	7	8	4	0.6	0.7	0.9	0.9
Nevada	19	7	9	8	1.0	0.7	1.0	1.7
New Hampshire	26	16	8	0	1.3	1.6	0.9	0.0
New Jersey	123	34	35	3	6.2	3.5	3.9	0.6
New Mexico	13	6	5	3	0.7	0.6	0.6	0.6
New York	163	59	91	33	8.2	6.0	10.2	7.1
North Carolina	54	21	29	4	2.7	2.1	3.2	0.9
North Dakota	7	2	7	0	0.4	0.2	0.8	0.0
Northern Mariana Islands	0	0	0	0	0.0	0.0	0.0	0.0
Ohio	47	26	21	25	2.4	2.6	2.3	5.4

Table A.1. (continued)

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q8 (continued) In which of the following United States physical therapy jurisdictions are you currently licensed (percentages may sum to more than 100%)?								
Oklahoma	6	10	5	4	0.3	1.0	0.6	0.9
Oregon	45	15	16	5	2.3	1.5	1.8	1.1
Pennsylvania	78	38	33	16	3.9	3.9	3.7	3.4
Puerto Rico	0	0	2	0	0.0	0.0	0.2	0.0
Rhode Island	15	7	2	1	0.8	0.7	0.2	0.2
South Carolina	54	23	20	9	2.7	2.3	2.2	1.9
South Dakota	7	3	0	2	0.4	0.3	0.0	0.4
Tennessee	35	13	21	7	1.8	1.3	2.3	1.5
Texas	167	89	57	30	8.4	9.0	6.4	6.5
U.S. Virgin Islands	1	0	0	0	0.1	0.0	0.0	0.0
Utah	22	10	11	8	1.1	1.0	1.2	1.7
Vermont	7	7	4	1	0.4	0.7	0.4	0.2
Virginia	69	25	35	14	3.5	2.5	3.9	3.0
Washington	62	25	27	12	3.1	2.5	3.0	2.6
West Virginia	5	11	1	2	0.3	1.1	0.1	0.4
Wisconsin	33	22	27	7	1.7	2.2	3.0	1.5
Wyoming	7	1	3	2	0.4	0.1	0.3	0.4
Q9 Which best describes the location of your PRIMARY clinical work setting?								
Urban/Metropolitan	646	299	363	159	32.4	30.4	40.5	34.3
Suburban	1017	438	398	191	51.1	44.5	44.4	41.2
Rural	327	247	129	109	16.4	25.1	14.4	23.5
Q10 What is your employment status as a physical therapist (physical therapist assistant)?								
Actively employed full-time	1418	690	771	314	71.2	70.1	86.0	67.7
Actively employed part-time	345	174	67	94	17.3	17.7	7.5	20.3
Self-employed full-time	110	39	20	6	5.5	4.0	2.2	1.3
Self-employed part-time	73	25	7	7	3.7	2.5	0.8	1.5
Retired	0	0	0	0	0.0	0.0	0.0	0.0
Unemployed, seeking employment	46	56	31	43	2.3	5.7	3.5	9.3
NOT seeking employment	0	0	0	0	0.0	0.0	0.0	0.0
Q19 Have you ever had an extended period of time (more than three months) away from actively working as a physical therapist assistant? Includes work in clinical, administration, consultation, education, or research activities.								
No, I have never had an extended break	1481	713	742	330	74.3	72.5	82.8	71.1
Yes, lasting 3 to 6 months	306	138	113	85	15.4	14.0	12.6	18.3
Yes, lasting 6 to 12 months	88	63	18	30	4.4	6.4	2.0	6.5
Yes, lasting 12 to 18 months	38	28	10	10	1.9	2.8	1.1	2.2
Yes, lasting 18 to 36 months	27	13	7	5	1.4	1.3	0.8	1.1
Yes, lasting 3 to 5 years	31	20	3	1	1.6	2.0	0.3	0.2
Yes, lasting 5 to 10 years	10	9	2	2	0.5	0.9	0.2	0.4
Yes, lasting greater than 10 years	11	0	1	0	0.6	0.0	0.1	0.0

Table A.1. (continued)

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q11 How many physical therapist (physical therapist assistant) positions/jobs have you held in the past 12 months?								
1	1502	738	577	293	75.4	75.0	64.4	63.1
2 to 3	460	231	302	153	23.1	23.5	33.7	33.0
4 to 5	20	9	17	10	1.0	0.9	1.9	2.2
6 to 7	3	2	0	0	0.2	0.2	0.0	0.0
More than 7	4	0	0	1	0.2	0.0	0.0	0.2
Q12 Summary: Count of respondents spending at least 50% of their time in a facility.								
Academic institution (post-secondary)	68	12	14	2	3.4	1.2	1.6	0.5
School system (preschool/primary/secondary)	94	17	18	7	4.7	1.7	2.0	1.5
Acute care hospital	226	87	94	36	11.3	8.8	10.6	7.7
Health and wellness facility	9	3	4	3	0.5	0.3	0.4	0.6
Outpatient facility (health system or hospital-based)	459	178	256	54	23.1	18.2	28.5	11.8
Outpatient facility (private)	472	199	338	186	23.7	20.2	37.6	40.1
Industrial Rehabilitation	9	4	2	0	0.5	0.4	0.2	0.0
Inpatient Rehab Facility (IRF)	84	33	51	20	4.2	3.4	5.7	4.3
US Military/Veterans Administration/Indian Health Services	28	9	3	2	1.4	0.9	0.3	0.4
Patient's home/home care	302	176	50	29	15.2	17.9	5.6	6.2
Research center	1	1	0	0	0.0	0.1	0.0	0.0
Skilled Nursing Facility (SNF)	197	236	51	105	9.9	24.0	5.7	22.6
Assisted Living Facility (ALF)	21	16	11	4	1.1	1.6	1.2	0.8
Long-term Acute Care (LTAC)	10	10	6	4	0.5	1.0	0.7	0.9
Other	47	11	15	6	2.4	1.1	1.7	1.3
Q13 Approximately what percentage of your time over the past 12 months was spent in direct patient care?								
0%	41	17	5	11	2.1	1.7	0.6	2.4
1 to 25%	108	31	7	9	5.4	3.2	0.8	1.9
26 to 50%	65	35	20	17	3.3	3.6	2.2	3.7
51 to 75%	266	121	112	55	13.4	12.3	12.5	11.9
76 to 100%	1510	778	752	371	75.8	79.1	83.9	80.0
Approximately what percentage of time over the past 12 months did you provide physical therapy services via telehealth or virtual/digital sessions? Includes direct patient care, consultation, patient advocacy, and indirect care.								
0%	1048	715	390	340	52.6	72.7	43.5	73.3
1 to 25%	714	224	411	85	35.8	22.8	45.9	18.3
26 to 50%	111	25	64	20	5.6	2.5	7.1	4.3
51 to 75%	64	9	21	9	3.2	0.9	2.3	1.9
76 to 100%	53	9	10	9	2.7	0.9	1.1	1.9

Table A.1. (continued)

Question	Count				Percent			
	PT KSR	PTA KSR	PT WA	PTA WA	PT KSR	PTA KSR	PT WA	PTA WA
Q14 Other than direct patient care, what are your PRINCIPAL areas of responsibility at your primary work setting?								
None	537	470	348	261	27.0	47.8	38.8	56.3
Administration/Management	605	171	145	55	30.4	17.4	16.2	11.9
Supervision	741	178	244	35	37.2	18.1	27.2	7.5
Consultation	288	64	106	14	14.5	6.5	11.8	3.0
Research	90	28	40	20	4.5	2.8	4.5	4.3
Sales/Marketing	216	51	103	29	10.8	5.2	11.5	6.3
Academic education	120	37	54	27	6.0	3.8	6.0	5.8
Clinical education	601	225	263	103	30.2	22.9	29.4	22.2
Other	111	69	38	25	5.6	7.0	4.2	5.4
Q15 Summary: Count of respondents spending at least 50% of their time with a population group.								
18 and under	251	50	92	23	12.6	5.1	10.3	5.0
19 to 64	733	257	401	149	36.8	26.1	44.5	32.1
65 and over	972	664	349	266	48.9	67.5	39.1	57.3
Q16 Are you a current member of American Physical Therapy Association (APTA)?								
Yes	547	148	379	93	27.5	15.0	42.3	20.0
No	1415	793	487	334	71.0	80.6	54.4	72.0
I don't know	28	40	28	37	1.4	4.1	3.1	8.0
Q17 Have you completed or are you currently completing a Residency or Fellowship in a specialized area of Physical Therapy/an Advanced Proficiency Pathway through the American Physical Therapy Association?								
Yes	169	30	82	4	8.5	3.0	9.2	0.9
No	1821	950	814	460	91.4	96.5	90.8	99.1
Q18 Which of these statements is true regarding your experience supervising PTAs over the past 12 months?								
I routinely supervise PTAs and have a good understanding of the knowledge and skills they need to provide safe and effective care.	1205	253	544	--	60.5	25.7	60.7	--
I do NOT routinely supervise PTAs and/or I do NOT have a good understanding of the knowledge and skills they need to provide safe and effective care.	787	--	352	--	39.5	--	39.3	--

Note. Percentages are based on the observed values divided by the total number of usable cases. Missing data are not reported so within a question, the results may not sum to 100%. For questions 12 and 15, percentages may not sum to 100% because these items used a rate all that apply format. Question 18 was not administered to PTA respondents. The 258 respondents shown for Q18 within the PTA KSR sample are PT KSR survey respondents who were reassigned to complete the PTA survey based on their response to Q18.

Appendix B. Summary of Work Activity and Knowledge and Skill Requirements Survey Responses

Tables B.1-B.4: Statistics and Formatting Key:

- **Sample Size (n):** Count of respondents that provided usable data
- **Mean Importance (M):** Based on responses for scale points 1 through 5
- **Standard Deviation of Importance (SD):** Based on responses for scale points 1 through 5
- **Percent Important (%_{imp}):** Sum of responses for scale points 2 through 5, divided by the total number of usable respondents

- **Boldface Statement (Black):** Statement text was altered in 2021 in a non-trivial manner prior to survey administration
- **Boldface Mean (Red):** Mean importance value was less than 2.50 (Criticality Threshold)
- **Light Red Shading:** 2021 mean importance value was below 2.50 (Criticality Threshold)
- **Light Orange Shading:** 2021 mean importance value was between 2.50 (including) and 3.00 (excluding)

Table B.1. PT Work Activity Survey Results

PT WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
PATIENT/CLIENT ASSESSMENT																				
Information Gathering & Synthesis																				
<i>Interview patients/clients, caregivers, and family to obtain patient/client history and current information (e.g., medical, surgical, medications, social, cultural, language preference, economic) to</i>																				
- establish prior and current level of function/activity	460	489	819	750	430	4.66	4.74	4.79	4.80	4.80	0.51	0.55	0.48	0.47	0.56	100	100	100	100	100
- establish general health status	460	489	819	750	430	4.52	4.46	4.52	4.53	4.53	0.64	0.72	0.66	0.69	0.70	99	100	100	100	100
- identify red flags (e.g., fever, malaise, unexplained weight change) and contraindications	459	489	819	750	430	4.68	4.74	4.72	4.73	4.61	0.56	0.59	0.63	0.60	0.71	99	100	100	100	100
- identify risk factors and needs for preventative measures	460	489	819	750	430	4.34	4.37	4.41	4.44	4.33	0.76	0.78	0.83	0.74	0.86	98	100	100	100	100
- identify patient/client's, family/caregiver's goals, values, and preferences	458	489	819	750	430	4.46	4.45	4.54	4.58	4.59	0.62	0.73	0.69	0.67	0.67	99	100	100	100	100
- determine if patient/client is appropriate for PT	456	489	819	750	430	4.52	4.52	4.60	4.61	4.63	0.64	0.72	0.72	0.69	0.69	100	100	99	100	100
- determine insurance and financial resources and issues (e.g., co-pays, deductibles, insurance limitations)	445	489	819	750	430	3.50	3.29	3.39	3.38	3.35	1.05	1.17	1.16	1.09	1.13	82	90	86	88	87
- determine impact of medications on plan of care (e.g., medication reconciliation, timing of intervention delivery, adherence)	455	489	819	750	430	3.97	3.81	3.79	3.70	3.67	0.86	1.00	1.02	1.03	1.03	96	98	97	98	98
Administer standardized questionnaires (e.g., pain inventory, fall risk assessment)	454	489	818	750	430	4.03	3.73	3.70	3.75	3.72	0.88	1.04	1.12	1.04	1.16	95	97	95	97	94
Review medical records (e.g., lab values, diagnostic tests, imaging, specialty reports, narrative, consults)	459	489	818	750	430	4.22	4.16	4.10	4.12	4.17	0.75	0.92	0.99	0.91	0.91	98	100	99	99	99
Gather information/discuss patient/client's current health status with interprofessional/interdisciplinary team members	395	489	818	750	430	4.11	3.98	4.01	3.98	4.09	0.72	0.96	0.98	0.96	0.97	99	99	98	98	99

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Identify signs/symptoms of change in patient/client's health status that require intervention by interprofessional/interdisciplinary team members	395	489	818	750	430	4.33	4.40	4.42	4.37	4.42	0.69	0.79	0.79	0.79	0.82	99	99	100	100	100
Systems Review																				
<i>Perform screen of the</i>																				
- patient/client's current affect, cognition, communication, and learning preferences (e.g., ability to convey needs, consciousness, orientation, expected emotional/behavioral responses)	393	489	818	750	430	4.04	4.00	3.99	3.95	4.03	0.80	0.97	1.03	1.03	1.00	97	96	96	96	96
- patient/client's quality of speech, hearing, and vision (e.g., dysarthria, pitch/tone, use of corrective lenses, use of hearing aids)	376	489	818	750	430	3.43	3.25	3.27	3.29	3.24	0.99	1.18	1.15	1.15	1.15	83	89	86	87	85
- vestibular system (e.g., dizziness, vertigo)	383	481	794	732	420	3.57	3.50	3.50	3.49	3.52	0.89	1.04	1.09	1.09	1.05	91	93	90	90	90
- gastrointestinal system (e.g., difficulty swallowing, nausea, change in appetite/diet, change in bowel function)	372	481	794	732	420	3.19	2.90	2.98	2.94	3.00	1.01	1.05	1.10	1.08	1.06	75	85	81	83	82
- genitourinary system (e.g., changes in bladder function, catheter complications)	362	481	794	732	420	3.20	2.98	3.11	3.06	3.10	1.05	1.11	1.13	1.08	1.13	73	83	80	84	81
- reproductive system (e.g., sexual and/or menstrual dysfunction, menopause status)	350	481	794	732	420	2.75	2.45	2.49	2.52	2.56	1.08	1.07	1.16	1.07	1.11	55	67	65	69	65
- cardiovascular/pulmonary system (e.g., blood pressure, heart rate, respiration rate)	393	481	794	732	420	4.22	4.19	4.10	4.08	4.15	0.77	0.95	0.93	0.93	0.94	98	97	95	96	94
- lymphatic system (e.g., primary and/or secondary edema)	371	481	794	732	420	3.33	3.12	3.18	3.18	3.02	1.03	1.06	1.11	1.00	1.10	81	88	84	87	77

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- integumentary system (e.g., presence of scar formation, skin integrity, discoloration)	388	481	794	732	420	3.92	3.59	3.65	3.71	3.59	0.79	0.97	1.01	0.97	1.05	97	96	94	95	93
- musculoskeletal system (e.g., gross symmetry, strength, range of motion)	387	481	794	732	420	4.70	4.77	4.78	4.82	4.80	0.48	0.56	0.50	0.44	0.46	100	98	97	98	98
- neuromuscular system (e.g., gross coordination, motor function, balance, locomotion, gross sensory function)	388	481	794	732	420	4.67	4.73	4.76	4.76	4.74	0.49	0.56	0.52	0.50	0.52	100	98	97	98	98
Tests & Measures																				
Cardiovascular/Pulmonary																				
<i>Select and perform tests and measures of</i>																				
- cardiovascular function (e.g., blood pressure, heart rate, heart sounds)	364	474	769	715	412	4.25	4.24	4.18	4.13	4.15	0.72	0.93	0.97	0.97	1.05	98	96	92	93	92
- pulmonary function (e.g., respiratory rate, breathing patterns, breath sounds, chest excursion)	349	474	769	715	412	3.85	3.71	3.72	3.61	3.71	0.96	1.18	1.15	1.15	1.19	91	92	87	88	87
- perfusion and gas exchange (e.g., oxygen saturation)	342	474	769	715	412	3.83	3.65	3.67	3.61	3.71	1.01	1.21	1.19	1.18	1.24	88	85	82	85	83
- peripheral circulation (e.g., capillary refill, blood pressure in upper versus lower extremities)	342	474	769	715	412	3.54	3.24	3.30	3.24	3.30	1.01	1.16	1.13	1.10	1.09	85	85	83	86	84
- critical limb ischemia (e.g., peripheral pulses, skin perfusion pressure)	331	474	769	715	412	3.49	3.21	3.23	3.13	3.18	1.03	1.17	1.19	1.12	1.16	83	82	79	82	78
- physiological responses to position change (e.g., orthostatic hypotension, skin color, blood pressure, heart rate)	360	474	769	715	412	4.00	4.04	4.07	3.99	4.05	0.85	1.01	1.02	1.03	1.07	96	95	90	93	91
- aerobic capacity under maximal and submaximal conditions (e.g., endurance, exercise tolerance, metabolic equivalents, perceived exertion)	340	474	769	715	412	3.56	3.66	3.63	3.69	3.69	1.00	1.13	1.14	1.08	1.11	86	89	86	89	88

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Anthropometric																				
<i>Select and perform tests and measures of</i>																				
- body composition (e.g., percent body fat, lean muscle mass)	312	474	768	715	412	2.71	2.51	2.53	2.50	2.61	1.13	1.08	1.13	1.06	1.16	53	70	67	71	68
- body dimensions (e.g., height, weight, girth, limb length, head circumference/shape)	341	474	768	715	412	2.99	2.60	2.70	2.67	2.81	1.08	1.08	1.16	1.06	1.16	66	77	75	77	77
- Quantify and qualify edema (e.g., pitting, volume, circumference)	354	474	768	715	412	3.45	3.23	3.24	3.28	3.23	0.90	1.01	1.06	1.03	1.10	88	91	86	88	85
Arousal, Attention, & Cognition																				
<i>Select and perform tests and measures of</i>																				
- arousal and orientation (e.g., level of consciousness, time, person, place, situation)	328	465	746	698	404	3.86	3.76	3.78	3.68	3.84	0.91	1.19	1.23	1.26	1.17	92	86	79	77	81
- attention and cognition (e.g., ability to process commands, delirium, confusion)	325	465	746	698	404	3.76	3.80	3.83	3.70	3.86	0.94	1.12	1.13	1.16	1.14	91	87	81	81	82
- communication (e.g., expressive and receptive skills, following instructions)	321	465	746	698	404	3.70	3.78	3.81	3.76	3.86	0.96	1.04	1.07	1.10	1.08	88	89	84	83	85
- recall (including memory and retention)	318	465	746	698	404	3.47	3.45	3.44	3.39	3.47	1.04	1.10	1.11	1.08	1.12	83	87	80	81	82
Nerve Integrity																				
<i>Select and perform tests and measures of</i>																				
- cranial nerve integrity (e.g., facial asymmetry, oculomotor function, hearing)	332	465	746	698	404	3.82	3.38	3.42	3.33	3.40	0.96	1.18	1.12	1.12	1.15	91	85	82	84	84
- spinal nerve integrity (e.g., dermatome, myotome)	353	465	746	698	404	4.17	4.10	4.00	4.03	4.07	0.84	0.93	1.00	0.95	1.02	97	94	90	91	91
- peripheral nerve integrity (e.g., sensation, strength)	351	465	746	698	404	4.28	4.23	4.24	4.18	4.35	0.70	0.83	0.85	0.86	0.84	99	95	90	92	93
- neural provocation (e.g., tapping, tension, stretch)	337	465	746	698	404	3.81	3.59	3.57	3.52	3.59	1.00	1.11	1.15	1.08	1.14	90	88	84	89	88

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Environmental & Community Integration/Reintegration (Home, Work, Job, School, Play, & Leisure)																				
Assess activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	355	457	721	688	395	4.41	4.47	4.51	4.47	4.61	0.69	0.82	0.81	0.80	0.72	99	93	87	91	90
Assess instrumental activities of daily living (IADL) (e.g., household chores, hobbies)	348	457	721	688	395	4.11	4.00	4.15	4.17	4.21	0.86	1.03	0.95	0.95	1.00	97	91	86	89	88
Assess ability to perform skills needed for integration or reintegration into the community, work, or school	313	457	721	688	395	4.04	4.13	4.22	4.22	4.31	0.81	0.94	0.92	0.93	0.89	97	91	85	90	88
Assess barriers (e.g., social, economic, physical, psychological, environmental, work conditions and activities) to home, community, work, or school integration/reintegration	322	457	721	688	395	3.99	4.18	4.13	4.19	4.24	0.82	0.89	0.92	0.91	0.91	98	91	87	90	90
Assess safety in home, community, work, or school environments	300	457	721	688	395	4.07	4.25	4.21	4.25	4.29	0.82	0.93	0.94	0.94	0.90	97	89	81	88	86
Assess ability to participate in activities with or without the use of devices, equipment, or technologies	319	457	721	688	395	4.08	4.30	4.30	4.35	4.40	0.78	0.84	0.86	0.85	0.85	97	91	86	91	90
Ergonomics and Body Mechanics																				
<i>Select and perform tests and measures of</i>																				
- ergonomics and body mechanics during functional activities	317	446	710	680	391	4.00	4.12	4.16	4.25	4.26	0.87	0.99	1.00	0.89	0.96	96	89	85	89	88
- postural alignment and position (static and dynamic)	326	446	710	680	391	4.16	4.21	4.23	4.23	4.26	0.75	0.89	0.94	0.90	0.95	99	91	86	90	90
- specific work conditions or activities	301	446	710	680	391	3.75	3.83	3.90	3.97	3.96	0.91	1.04	1.08	0.99	1.07	92	87	80	86	84
- tools, devices, equipment, and workstations related to work actions, tasks, or activities	282	446	710	680	391	3.58	3.52	3.61	3.68	3.69	0.95	1.13	1.17	1.08	1.14	88	82	76	84	81

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Functional Mobility, Balance, & Vestibular																				
<i>Select and perform tests and measures of</i>																				
- balance (dynamic and static) with or without the use of specialized equipment	326	446	710	680	391	4.27	4.60	4.54	4.58	4.62	0.67	0.69	0.73	0.65	0.67	100	91	86	90	90
- gait and locomotion (e.g., ambulation, wheelchair mobility) with or without the use of specialized equipment	327	446	710	680	391	4.42	4.72	4.67	4.69	4.72	0.64	0.58	0.61	0.60	0.57	100	91	86	91	90
- mobility during functional activities and transitional movements (e.g., transfers, bed mobility)	307	446	710	680	391	4.35	4.69	4.63	4.65	4.72	0.69	0.63	0.71	0.66	0.58	100	91	86	90	90
- vestibular function (e.g., peripheral dysfunction, central dysfunction, BPPV)	284	446	710	680	391	3.68	3.64	3.62	3.64	3.63	0.87	1.03	1.08	1.06	1.10	93	84	79	84	83
Integumentary Integrity																				
Assess skin characteristics (e.g., continuity of skin color, sensation, temperature, texture, turgor)	309	442	702	675	387	3.77	3.49	3.54	3.54	3.40	0.85	1.04	1.04	1.02	1.06	94	87	81	87	83
Assess wound characteristics (e.g., tissue involvement, depth, tunneling, burn classification, ulcer/injury classification)	261	442	702	675	387	3.48	3.17	3.17	3.18	3.16	1.05	1.17	1.18	1.18	1.20	81	74	64	68	67
Assess scar tissue characteristics (e.g., banding, pliability, sensation, and texture)	288	442	702	675	386	3.52	3.26	3.28	3.29	3.27	0.96	1.06	1.13	1.06	1.16	87	81	74	81	75
Assess activities, positioning, and postures that may produce or relieve trauma to the skin	288	442	702	675	386	3.93	3.83	3.78	3.73	3.74	0.81	1.08	1.10	1.15	1.16	95	83	77	78	77
Assess devices and equipment that may produce or relieve trauma to the skin	277	442	702	675	386	3.74	3.71	3.69	3.62	3.56	0.94	1.10	1.15	1.16	1.19	90	82	72	76	75

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Joint Integrity & Range of Motion																				
<i>Select and perform tests and measures of</i>																				
- spinal and peripheral joint stability (e.g., ligamentous integrity, joint structure)	301	440	690	664	381	4.10	4.03	4.13	4.14	4.10	0.87	1.09	1.04	1.02	1.08	95	87	81	87	86
- spinal and peripheral joint mobility (e.g., glide, end feel)	300	440	690	664	381	4.10	3.90	3.99	4.01	4.01	0.92	1.19	1.17	1.13	1.17	95	84	79	85	84
- range of motion (e.g., passive, active, functional)	313	440	690	664	381	4.45	4.54	4.62	4.57	4.68	0.67	0.75	0.68	0.67	0.58	99	90	84	88	89
- flexibility (e.g., muscle length, soft tissue extensibility)	294	440	690	664	381	4.24	4.35	4.40	4.35	4.43	0.77	0.89	0.91	0.86	0.84	98	89	83	88	88
Motor Function																				
<i>Select and perform tests and measures of</i>																				
- muscle tone (e.g., hypertonicity, hypotonicity, dystonia)	295	440	690	664	381	3.99	4.29	4.28	4.24	4.32	0.81	0.87	0.94	0.89	0.83	97	89	84	88	88
- dexterity, coordination, and agility (e.g., rapid alternating movement, finger to nose)	291	440	690	664	381	3.86	3.93	3.99	3.91	4.05	0.81	1.00	1.04	1.00	0.99	97	89	83	87	86
- ability to initiate, modify and control movement patterns and postures (e.g., catching a ball, gait)	292	440	690	664	381	4.11	4.30	4.33	4.33	4.45	0.78	0.86	0.87	0.83	0.80	98	89	84	88	88
- ability to change movement performance with practice (e.g., motor learning)	290	440	690	664	381	4.03	4.30	4.37	4.34	4.42	0.77	0.83	0.81	0.82	0.78	98	90	84	88	88
- movement quality (e.g., purpose, precision, efficiency, biomechanics, kinematics)	288	440	690	664	381	4.00	4.39	4.41	4.38	4.46	0.81	0.77	0.76	0.80	0.77	97	90	84	88	88
Muscle Performance																				
<i>Select and perform tests and measures of</i>																				
- muscle strength, power, and endurance without specialized equipment (e.g., manual muscle test, functional strength testing)	297	438	685	661	377	4.37	4.63	4.64	4.62	4.71	0.66	0.69	0.68	0.67	0.60	100	89	83	88	87

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- muscle strength, power, and endurance with specialized equipment (e.g., isokinetic testing, dynamometry)	258	438	685	661	377	3.43	3.39	3.58	3.46	3.48	1.06	1.40	1.40	1.40	1.46	80	69	65	68	65
- electrophysiological function using surface electrodes (e.g., surface EMG)	201	438	685	661	377	2.67	2.58	2.61	2.41	2.57	1.22	1.24	1.33	1.25	1.33	51	45	39	41	39
- electrophysiological function using needle insertion (e.g., nerve conduction)	190	438	685	661	377	2.41	2.31	2.34	2.17	2.34	1.25	1.20	1.28	1.18	1.31	39	37	31	33	30
- muscle integrity (e.g., ultrasound imaging)	186	438	685	661	377	2.51	2.53	2.60	2.32	2.51	1.14	1.25	1.37	1.24	1.29	45	43	35	36	34
Neuromotor Development & Sensory Integration																				
<i>Select and perform tests and measures of</i>																				
- acquisition and evolution of motor skills throughout the lifespan	209	438	685	661	377	3.06	3.15	3.30	3.14	3.39	1.09	1.24	1.28	1.26	1.29	69	68	58	62	60
- sensorimotor integration	224	438	685	661	377	3.23	3.29	3.43	3.29	3.51	1.03	1.16	1.18	1.15	1.21	76	75	67	68	67
- developmental reflexes and reactions (e.g., asymmetrical tonic neck reflex, righting reactions)	204	438	685	661	377	3.17	3.15	3.24	3.04	3.26	1.04	1.29	1.35	1.32	1.38	74	62	53	53	53
- oral motor function, phonation, and speech production	188	438	685	661	377	2.69	2.65	2.59	2.52	2.62	1.12	1.20	1.20	1.19	1.25	55	53	41	45	40
Reflex Integrity																				
<i>Select and perform tests and measures of</i>																				
- deep tendon/muscle stretch reflexes (e.g., quadriceps, biceps)	274	432	680	656	377	3.62	3.66	3.68	3.69	3.71	0.93	1.15	1.17	1.13	1.17	90	83	79	83	82
- upper motor neuron integrity (e.g., Babinski reflex, Hoffman sign)	263	432	680	656	377	3.69	3.64	3.61	3.66	3.75	0.95	1.17	1.20	1.15	1.16	89	82	77	82	81
- superficial reflexes and reactions (e.g., cremasteric reflex, abdominal reflexes)	206	432	680	656	377	3.03	2.92	2.91	2.84	2.91	1.14	1.24	1.39	1.28	1.34	65	63	59	65	62

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Pain & Sensory Integrity																				
<i>Select and perform tests and measures of</i>																				
- pain (e.g., location, intensity, frequency, central, peripheral, psychogenic)	290	432	680	656	377	4.10	4.40	4.46	4.42	4.48	0.81	0.81	0.82	0.84	0.80	97	87	82	86	87
- deep sensation (e.g., proprioception, central, kinesthesia, pressure)	281	432	680	656	377	3.78	3.79	3.84	3.79	3.82	0.83	1.10	1.08	1.04	1.07	95	85	80	85	84
- superficial sensation (e.g., touch, temperature discrimination)	278	432	680	656	377	3.78	3.94	3.92	3.93	3.92	0.87	1.01	1.03	0.97	1.03	94	86	81	85	86
- visceral organ sensitivity and integrity (e.g., palpation, auscultation)	222	432	680	656	377	3.13	2.88	2.86	2.79	2.80	1.14	1.16	1.28	1.17	1.31	69	63	58	65	58
Evaluation & Diagnosis																				
<i>Interpret each of the following types of data to determine the need for intervention or the response to intervention:</i>																				
- Cardiovascular/pulmonary system	247	431	676	653	375	3.87	4.34	4.19	4.19	4.30	0.97	0.91	0.96	0.93	0.90	90	87	80	84	84
- Lymphatic system	206	431	676	653	375	3.13	3.13	3.00	3.07	2.96	1.10	1.09	1.13	1.10	1.20	69	75	67	73	66
- Arousal, attention, cognition, and communication	237	431	676	653	375	3.71	3.80	3.80	3.73	3.82	0.93	1.08	1.11	1.13	1.13	90	82	75	78	79
- Neuromuscular system	271	431	676	653	375	3.98	4.66	4.62	4.60	4.68	0.86	0.64	0.64	0.65	0.61	95	88	82	86	87
- Functional mobility, balance, and vestibular	276	431	676	653	375	4.14	4.67	4.63	4.64	4.69	0.79	0.64	0.64	0.64	0.58	98	88	82	87	87
- Musculoskeletal system	279	431	676	653	375	4.33	4.82	4.80	4.78	4.85	0.72	0.50	0.49	0.47	0.39	99	88	83	87	87
- Integumentary system	261	431	676	653	375	3.59	3.52	3.53	3.57	3.45	0.91	1.05	1.07	1.05	1.07	89	84	78	82	81
- Anthropometric	226	431	676	653	375	3.11	2.84	2.83	2.76	2.81	1.09	1.11	1.12	1.05	1.15	71	70	65	70	67
- Gastrointestinal system	212	431	676	653	375	2.90	2.71	2.69	2.74	2.73	1.12	0.99	1.11	1.05	1.12	61	70	62	67	65
- Genitourinary system	209	431	676	653	375	2.91	2.68	2.71	2.74	2.75	1.14	1.02	1.12	1.08	1.13	62	69	61	66	63
- Need for or use of assistive and adaptive devices/technologies	273	430	671	645	373	4.05	4.52	4.38	4.42	4.51	0.83	0.78	0.93	0.82	0.76	96	87	80	84	85
- Need for or use of orthotic, protective, and supportive devices/technologies	267	430	671	645	373	3.81	4.27	4.08	4.10	4.14	0.86	0.89	1.02	0.97	0.95	93	87	79	84	83

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- Need for or use of prosthetic devices/technologies	233	430	671	645	373	3.52	3.98	3.77	3.80	3.77	0.99	1.05	1.19	1.11	1.13	85	76	70	72	74
- Barriers to home, community, work, or school integration/reintegration	266	430	671	645	373	3.81	4.21	4.12	4.17	4.19	0.89	0.92	0.98	0.94	0.96	94	85	79	84	84
- Ergonomics and body mechanics	259	430	671	645	373	3.78	4.12	4.13	4.16	4.16	0.89	0.94	0.97	0.90	0.99	94	87	81	85	85
- Pain and sensory integrity	270	430	671	645	373	3.93	4.22	4.26	4.26	4.27	0.88	0.86	0.84	0.83	0.84	95	88	82	85	87
- ADLs/IADLs and home management	267	430	671	645	373	3.99	4.40	4.39	4.47	4.49	0.80	0.81	0.88	0.74	0.82	97	87	81	85	85
- Imaging, lab values, and medications	262	430	671	645	373	3.84	3.61	3.62	3.55	3.71	0.88	1.05	1.05	1.03	1.05	94	84	76	82	84
Evaluate the patient/client's ability to assume or resume home, community, work, school, and/or leisure activities	273	430	668	641	373	4.12	4.63	4.57	4.58	4.60	0.76	0.61	0.72	0.70	0.67	98	87	81	85	86
Develop physical therapy diagnosis by integrating system and non-system data	266	430	668	641	373	4.18	4.48	4.36	4.38	4.37	0.81	0.79	0.88	0.84	0.93	97	87	80	84	84
Development of Prognosis, Plan of Care, & Goals																				
Establish PT prognosis based on information gathered during the examination process	279	429	666	640	373	4.50	4.59	4.62	4.59	4.64	0.63	0.68	0.67	0.66	0.67	99	88	81	85	86
Develop plan of care based on data gathered during the examination process, incorporating information from the patient/client, caregiver, family members, and other professionals	276	429	666	640	373	4.63	4.78	4.79	4.79	4.80	0.53	0.50	0.49	0.47	0.54	100	88	81	85	87
Revise treatment intervention plan based on treatment outcomes, change in patient/client's health status, and ongoing evaluation	278	429	666	640	373	4.60	4.79	4.77	4.79	4.80	0.54	0.48	0.53	0.49	0.52	100	88	81	85	87
Develop objective and measurable goals based on information gathered during the examination process, in collaboration with the patient/client, caregiver, family members, and/or other professionals	278	429	666	640	373	4.58	4.68	4.69	4.71	4.68	0.59	0.57	0.63	0.57	0.68	100	88	81	85	87

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Select interventions based on information gathered during the examination process, incorporating information from the patient/client, caregiver, family members, and other professionals	278	429	666	640	373	4.60	4.79	4.79	4.77	4.82	0.57	0.46	0.51	0.51	0.45	100	88	81	85	87
Modify plan of care based on patient/client's resources (e.g., financial, transportation, time, insurance benefits, available technologies)	277	429	666	640	373	4.32	4.56	4.48	4.58	4.51	0.79	0.74	0.82	0.72	0.79	98	87	80	85	86
INTERVENTIONS																				
Procedural Interventions																				
Therapeutic Exercise/Therapeutic Activities																				
<i>Perform and/or train patient/client/caregiver in</i>																				
- aerobic capacity/endurance conditioning	458	500	821	828	466	3.96	3.91	3.96	3.97	4.01	0.85	0.96	1.01	1.02	0.97	95	99	97	97	98
- balance, coordination, and agility activities	463	500	821	828	466	4.52	4.57	4.56	4.57	4.61	0.60	0.67	0.69	0.65	0.62	100	100	100	100	100
- body mechanics and postural stabilization techniques	460	500	821	828	466	4.46	4.45	4.47	4.43	4.46	0.64	0.81	0.78	0.83	0.85	100	100	100	99	99
- flexibility techniques	457	500	821	828	466	4.12	3.76	3.73	3.69	3.78	0.77	1.01	1.07	1.10	1.08	97	98	98	96	97
- neuromotor techniques (e.g., movement pattern training, neuromuscular education or re-education)	458	500	821	828	466	4.25	4.21	4.27	4.31	4.27	0.75	0.92	0.89	0.85	0.91	98	98	99	100	98
- relaxation techniques	457	500	821	828	466	3.54	3.44	3.42	3.42	3.50	0.91	1.09	1.13	1.12	1.11	89	96	95	95	96
- strength, power, and endurance exercises	460	500	821	828	466	4.41	4.33	4.38	4.44	4.52	0.70	0.83	0.80	0.75	0.70	99	100	99	100	100
- genitourinary management (e.g., pelvic floor exercises, bladder strategies)	420	500	820	828	466	3.05	2.72	2.73	2.62	2.83	1.06	1.22	1.26	1.23	1.31	68	60	56	48	52
- gastrointestinal management (e.g., bowel strategies, positioning to avoid reflux)	415	500	820	828	466	2.87	2.57	2.62	2.52	2.71	1.05	1.16	1.22	1.19	1.30	61	57	55	46	49

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- manual/mechanical airway clearance techniques (e.g., assistive devices, assistive cough, incentive spirometer, flutter valve, percussion, vibration)	419	500	820	828	466	3.19	2.77	2.85	2.82	2.90	1.06	1.24	1.26	1.25	1.33	73	58	56	47	46
- techniques to maximize ventilation and perfusion (e.g., positioning, active cycle breathing, autogenic drainage, paced breathing, pursed lip breathing)	381	500	820	828	466	3.45	3.13	3.10	3.08	3.08	1.04	1.21	1.25	1.22	1.30	81	70	66	60	63
- mechanical repositioning for vestibular dysfunction	391	500	820	828	466	3.33	3.21	3.21	3.15	3.14	0.94	1.16	1.19	1.19	1.26	82	79	73	70	67
- habituation/adaptation exercises for vestibular dysfunction	384	500	820	828	466	3.30	3.20	3.24	3.15	3.14	0.94	1.13	1.19	1.21	1.26	81	81	76	71	70
- postural drainage				828	466				2.50	2.54				1.21	1.32				40	37
Functional Training																				
Recommend barrier accommodations or modifications (e.g., ramps, grab bars, raised toilet, environmental control units)	414	500	820	828	466	3.92	3.93	3.80	3.67	3.63	0.86	1.17	1.23	1.21	1.27	95	89	87	86	84
<i>Perform and/or train patient/client in</i>																				
- the use of environmental modifications (e.g., ramps, grab bars, raised toilet, environmental control units)	408	491	795	811	453	3.91	3.88	3.82	3.69	3.72	0.89	1.17	1.25	1.22	1.22	94	89	84	85	84
- activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	419	491	795	811	453	4.29	4.27	4.19	4.12	4.14	0.77	0.94	1.02	1.08	1.05	98	96	93	94	93
- community and leisure integration or reintegration (e.g., work/school/play)	406	491	795	811	453	3.75	3.81	3.80	3.91	3.90	0.92	1.04	1.08	1.08	1.10	92	92	91	92	90
- instrumental activities of daily living (IADL) (e.g., household chores, hobbies)	403	491	795	811	453	3.79	3.88	3.85	3.93	3.94	0.95	1.00	1.04	1.05	1.10	92	94	92	93	91
- mobility techniques	418	491	795	811	453	4.30	4.36	4.31	4.31	4.34	0.73	0.79	0.86	0.89	0.84	100	97	96	96	96

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- gross motor developmental progression			795	811	453			3.46	3.51	3.43			1.30	1.28	1.37			77	72	69
- fall prevention and fall recovery strategies	420	491	795	811	453	4.43	4.55	4.43	4.37	4.41	0.68	0.73	0.88	0.92	0.87	99	97	95	95	94
- behavior modification and strategies that enhance functioning (e.g., energy conservation, pacing, pre-activity planning, reminder schedules)	383	491	795	811	453	3.74	3.95	3.86	3.80	3.76	0.88	0.99	1.04	1.12	1.12	92	95	93	93	91
Manual Therapy Techniques																				
Perform manual lymphatic drainage	315	491	779	805	446	2.78	2.66	2.61	2.58	2.59	1.14	1.20	1.22	1.17	1.26	55	43	38	36	31
Perform dry needling	295	491	779	805	446	2.27	2.90	2.89	2.91	2.88	1.18	1.37	1.44	1.39	1.48	38	35	32	32	30
Perform spinal and peripheral manual traction	356	491	779	805	446	3.51	3.15	3.16	3.13	3.25	0.96	1.19	1.28	1.21	1.25	87	76	66	70	67
Perform and/or train patient/client/caregiver in soft tissue mobilization (e.g., connective tissue massage, therapeutic massage, foam rolling)	384	491	779	804	446	3.74	3.46	3.38	3.45	3.50	0.95	1.20	1.20	1.19	1.24	89	86	82	85	83
Perform instrument-assisted soft tissue mobilization	337	491	779	804	446	3.06	3.29	3.12	3.21	3.15	1.13	1.27	1.28	1.26	1.28	68	69	64	70	67
Perform peripheral joint range of motion	392	491	779	804	446	4.23	4.12	3.98	4.02	4.11	0.82	1.03	1.05	1.03	0.99	97	95	91	94	91
Perform peripheral mobilization/manipulation (thrust)	347	485	774	798	441	3.45	3.13	3.06	2.99	2.98	1.15	1.36	1.37	1.34	1.32	79	60	61	61	61
Perform peripheral mobilization (non-thrust)	369	485	774	798	441	3.96	3.81	3.68	3.68	3.83	1.00	1.21	1.29	1.23	1.18	91	80	76	80	79
Perform spinal mobilization/manipulation (thrust)	347	485	773	798	441	3.52	3.25	3.13	3.08	3.08	1.12	1.34	1.38	1.32	1.33	82	64	60	62	59
Perform spinal mobilization (non-thrust)	333	485	774	798	441	3.72	3.77	3.64	3.63	3.75	1.05	1.20	1.31	1.26	1.20	87	78	73	76	75
Perform cervical spinal manipulation (thrust)	288	485	774	798	441	2.98	2.89	2.77	2.71	2.79	1.20	1.37	1.40	1.36	1.40	64	48	50	51	47
Perform thoracic and lumbar spinal manipulation (thrust)	312	485	774	798	441	3.40	3.37	3.23	3.19	3.23	1.15	1.35	1.38	1.32	1.32	78	65	63	64	63

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
<i>Apply taping for</i>																				
- neuromuscular reeducation	340	480	760	792	433	3.15	3.04	2.96	2.85	2.88	0.99	1.17	1.17	1.20	1.20	75	75	73	74	71
- lymphatic drainage	279	480	761	792	433	2.61	2.59	2.50	2.45	2.47	1.06	1.15	1.19	1.15	1.18	51	40	39	39	34
- pain management	325	480	760	792	433	2.96	3.01	2.83	2.77	2.83	1.00	1.23	1.20	1.17	1.19	69	70	66	70	68
Equipment & Devices																				
<i>Fabricate, apply, and/or adjust</i>																				
- adaptive devices (e.g., utensils, seating and positioning devices, steering wheel devices)	309	480	760	791	433	3.25	3.17	3.06	2.97	3.03	1.11	1.27	1.26	1.25	1.32	75	56	51	51	49
- protective devices (e.g., braces, cushions, helmets, protective taping)	327	480	760	791	433	3.35	3.38	3.21	3.14	3.21	1.00	1.20	1.17	1.20	1.29	80	69	65	63	59
- supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars, serial casts, short-stretch bandages)	333	480	760	791	433	3.30	3.36	3.20	3.08	3.09	1.01	1.22	1.15	1.19	1.30	78	71	65	64	58
- orthotic devices (e.g., braces, shoe inserts, splints)	353	480	760	791	433	3.48	3.54	3.37	3.39	3.37	0.92	1.14	1.16	1.18	1.23	87	82	77	75	69
<i>Apply and/or adjust</i>																				
- assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	353	476	750	777	428	4.23	4.52	4.45	4.33	4.35	0.76	0.80	0.88	0.95	0.95	99	94	89	92	89
- prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	278	476	750	777	428	3.26	3.57	3.29	3.27	3.19	1.07	1.15	1.26	1.27	1.36	75	64	63	59	54
- mechanical neuromuscular re-education devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	266	476	750	777	428	2.97	3.26	3.17	3.11	3.15	1.03	1.31	1.34	1.35	1.40	67	54	54	53	47
- prescribed oxygen during interventions	300	476	750	777	428	3.76	3.77	3.59	3.50	3.40	1.07	1.25	1.32	1.35	1.36	88	62	59	54	48

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
<i>Train patient/client/caregiver in the use of</i>																				
- adaptive devices (e.g., utensils, seating and positioning devices, steering wheel devices)	285	465	733	765	420	3.27	3.39	3.24	3.27	3.22	1.00	1.31	1.29	1.35	1.36	81	56	51	50	50
- assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	352	465	733	765	420	4.22	4.49	4.34	4.29	4.25	0.82	0.83	0.97	0.98	1.04	98	88	85	89	85
- orthotic devices (e.g., braces, shoe inserts, splints)	341	465	733	765	420	3.67	3.88	3.85	3.74	3.67	0.89	1.11	1.13	1.15	1.21	92	86	80	83	79
- prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	271	465	733	765	420	3.21	3.56	3.35	3.33	3.30	1.08	1.22	1.24	1.28	1.33	74	58	57	54	53
- protective devices (e.g., braces, cushions, helmets, protective taping)	309	465	733	765	420	3.30	3.66	3.51	3.46	3.45	0.96	1.16	1.16	1.24	1.22	82	70	67	64	62
- supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars, serial casts, short-stretch bandages)	313	465	733	765	420	3.27	3.55	3.44	3.35	3.28	0.96	1.20	1.19	1.23	1.25	79	72	69	68	63
- mechanical neuromuscular re-education devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	218	465	733	765	420	2.83	3.23	3.21	3.13	3.15	1.02	1.33	1.30	1.33	1.37	59	50	52	50	44
Integumentary Repair & Protection Techniques																				
<i>Perform and/or train patient/client/caregiver in</i>																				
- nonselective debridement (e.g., removal of nonselective areas of devitalized tissue)	204	460	725	758	410	2.74	2.61	2.48	2.52	2.64	1.10	1.29	1.29	1.36	1.44	53	25	20	17	16
- selective enzymatic or autolytic debridement (e.g., removal of specific areas of devitalized tissue)	199	460	725	758	410	2.71	2.62	2.49	2.40	2.68	1.11	1.25	1.36	1.34	1.48	52	24	18	15	15

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- application of topical agents (e.g., cleansers, creams, moisturizers, ointments, sealants) and dressings (e.g., hydrogels, wound coverings)	224	460	725	758	410	2.85	2.83	2.65	2.59	2.66	1.09	1.17	1.27	1.31	1.30	58	37	29	26	27
- desensitization techniques (e.g., brushing, tapping, use of textures)	289	460	725	758	410	3.10	3.02	2.96	2.98	3.05	0.96	1.08	1.16	1.12	1.17	73	65	57	64	62
- hyperbaric therapy	189	460	725	758	410	2.30	2.17	2.16	2.25	2.15	1.11	1.03	1.25	1.29	1.27	37	17	13	12	11
- negative pressure wound therapy	195	460	725	758	410	2.54	2.46	2.35	2.41	2.49	1.12	1.20	1.29	1.28	1.43	46	22	16	16	14
Perform sharp debridement (e.g., removal of specific areas of devitalized tissue)	195	460	725	758	410	2.67	2.54	2.44	2.33	2.55	1.12	1.28	1.30	1.38	1.46	50	22	19	13	14
Recommend topical agents (e.g., pharmacological to physician, over-the-counter to patient) and dressings (e.g., negative pressure wound therapy, wound coverings)	221	460	725	758	410	2.76	2.69	2.61	2.42	2.66	1.11	1.14	1.29	1.27	1.31	54	36	27	21	24
Therapeutic Modalities																				
<i>Perform and/or train patient/client/caregiver in</i>																				
- biofeedback therapy (e.g., relaxation techniques, muscle reeducation, EMG)	265	458	712	746	406	3.35	3.26	3.03	3.14	3.15	1.03	1.16	1.25	1.20	1.28	78	74	62	64	61
- iontophoresis	237	458	712	746	406	2.82	2.53	2.36	2.22	2.18	1.04	1.21	1.22	1.18	1.19	62	45	37	34	32
- phonophoresis	209	456	706	743	404	2.56	2.29	2.10	2.03	1.87	1.18	1.25	1.30	1.27	1.15	49	26	20	17	17
- electrotherapy modalities, excluding iontophoresis (e.g., NMES, TENS, FES, interferential therapy, high-voltage pulsed current)*	289	458	712	746	406	3.49	3.31	3.16	3.12	3.18	1.01	1.22	1.28	1.22	1.27	84	78	68	73	70
- cryotherapy (e.g., cold pack, ice massage, vapocoolant spray)	306	458	712	746	406	3.62	3.46	3.36	3.20	3.27	0.98	1.17	1.23	1.20	1.23	87	85	76	78	72
- hydrotherapy using contrast baths/pools	201	458	712	746	406	2.69	2.73	2.38	2.31	2.28	1.22	1.32	1.32	1.34	1.32	50	34	29	25	25
- hydrotherapy (e.g., aquatic exercise, underwater treadmill)	215	458	712	746	406	3.01	3.03	2.91	2.85	2.93	1.08	1.26	1.31	1.36	1.37	69	44	36	32	34

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- phototherapy (laser light)	185	458	712	746	406	2.26	2.23	2.08	2.10	1.96	1.17	1.20	1.28	1.24	1.23	36	25	19	20	18
- monochromatic infrared agent procedures (e.g., light emitting diodes [LEDs])	182	456	706	743	404	2.13	2.00	1.86	1.89	1.77	1.12	1.03	1.16	1.21	1.10	34	19	13	12	12
- ultrasound procedures	262	456	706	743	404	3.08	2.59	2.49	2.20	2.33	1.17	1.28	1.36	1.21	1.31	69	53	41	39	39
- diathermy	188	456	706	743	404	2.24	2.14	2.03	1.86	1.65	1.19	1.23	1.32	1.20	0.98	37	21	16	14	14
- dry heat thermotherapy (e.g., Fluidotherapy)	189	456	706	743	404	2.31	2.18	2.03	1.87	1.88	1.15	1.20	1.18	1.14	1.18	39	22	20	16	17
- hot pack thermotherapy	292	456	706	743	404	3.39	3.12	3.15	2.90	3.01	1.00	1.21	1.26	1.22	1.25	83	75	67	68	66
- paraffin bath thermotherapy	201	456	706	743	404	2.60	2.63	2.37	2.31	2.20	1.21	1.26	1.25	1.28	1.29	50	37	29	27	26
- shockwave therapy	173	456	706	743	404	2.01	2.12	1.86	1.86	1.83	1.14	1.17	1.24	1.19	1.17	29	16	12	12	14
Mechanical Modalities																				
<i>Apply and/or train patient/client/caregiver in</i>																				
- intermittent pneumatic compression	206	455	704	740	403	2.63	2.89	2.77	2.73	2.67	1.18	1.21	1.33	1.32	1.24	51	40	33	33	35
- assisted movement devices (e.g., dynamic splint, continuous passive motion devices)	251	455	704	740	403	2.90	2.90	2.69	2.68	2.58	1.05	1.20	1.28	1.20	1.22	63	53	45	44	41
- mechanical spinal traction	243	455	704	740	403	3.17	2.98	2.74	2.75	2.72	1.09	1.24	1.30	1.19	1.25	75	53	45	46	45
Non-procedural Interventions																				
Communication																				
<i>Discuss physical therapy evaluation findings, interventions, goals, prognosis, discharge planning, and plan of care with</i>																				
- physical therapists, physical therapist assistants, and/or support staff	311	454	702	739	401	4.67	4.79	4.71	4.66	4.70	0.60	0.54	0.66	0.66	0.65	99	91	85	88	85
- interprofessional/interdisciplinary team members	310	454	702	739	401	4.60	4.63	4.58	4.48	4.53	0.62	0.70	0.78	0.85	0.80	99	90	84	86	84
- patient/client/caregiver	313	454	702	739	401	4.73	4.85	4.81	4.80	4.84	0.51	0.42	0.51	0.51	0.44	100	91	85	89	86
Provide written, oral, and electronic information to the patient/client and/or caregiver	312	454	702	739	401	4.62	4.73	4.67	4.64	4.68	0.61	0.55	0.66	0.70	0.65	99	91	85	88	86

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Documentation																				
<i>Document</i>																				
- examination results	312	449	700	733	401	4.71	4.81	4.81	4.79	4.83	0.55	0.48	0.47	0.51	0.48	99	90	85	88	86
- evaluation to include diagnosis, goals, and prognosis	310	449	700	733	401	4.70	4.83	4.81	4.77	4.82	0.55	0.47	0.48	0.55	0.48	100	90	85	88	86
- intervention(s) and patient/client response(s) to intervention	312	449	700	733	401	4.72	4.84	4.82	4.80	4.85	0.53	0.43	0.49	0.51	0.44	100	90	85	89	86
- patient/client/caregiver education	310	449	700	733	401	4.65	4.76	4.79	4.77	4.82	0.58	0.55	0.49	0.54	0.46	99	90	85	89	86
- outcomes (e.g., discharge summary, reassessments)	311	449	700	733	401	4.66	4.67	4.72	4.67	4.73	0.58	0.65	0.58	0.67	0.56	99	90	85	88	86
- communication with the interdisciplinary/interprofessional team related to the patient/client's care	310	449	700	733	401	4.54	4.62	4.60	4.55	4.57	0.69	0.69	0.69	0.76	0.78	98	89	85	87	85
- rationale for billing and reimbursement	291	449	700	733	401	4.45	4.37	4.44	4.34	4.37	0.73	0.89	0.88	0.95	0.96	98	89	83	86	81
- disclosure and consent (e.g., disclosure of medical information, consent for treatment)	279	449	700	733	401	4.27	4.47	4.45	4.39	4.48	0.82	0.85	0.88	0.91	0.87	95	89	82	86	83
- letter of medical necessity (e.g., wheelchair, assistive equipment, disability parking placard)	251	449	700	733	401	3.86	4.02	3.89	3.77	3.80	0.95	1.07	1.18	1.23	1.26	91	76	70	73	69
- intervention/plan of care for specialized services and settings (e.g., individual education plan, individual family service plan, vocational transition plan)	219	449	700	733	401	3.81	4.28	4.14	4.12	4.08	1.08	1.02	1.15	1.15	1.23	87	67	63	65	62
Assign billing codes for physical therapy evaluation and treatment provided	280	454	702	739	401	4.42	4.53	4.52	4.50	4.50	0.83	0.81	0.91	0.88	0.92	96	89	82	85	81

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Education																				
<i>Educate patient/client and/or caregiver about</i>																				
- the patient/client's current condition and health status (e.g., nature of the condition, prognosis, potential benefits of physical therapy interventions, potential treatment outcomes)	300	446	698	732	400	4.60	4.84	4.82	4.78	4.85	0.57	0.41	0.46	0.50	0.41	100	89	85	88	86
- the role of the physical therapist and/or physical therapist assistant in patient/client management	301	446	698	732	400	4.56	4.75	4.73	4.71	4.77	0.62	0.55	0.57	0.58	0.52	99	89	85	88	86
- lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	301	446	698	732	400	4.33	4.48	4.47	4.41	4.42	0.73	0.77	0.79	0.83	0.84	98	89	85	87	85
- the role of physical therapy in transitional planning (e.g., hospice, palliative care, setting changes)	264	446	698	732	400	3.97	4.13	4.08	4.03	4.08	0.98	1.11	1.15	1.16	1.16	91	78	72	72	67
<i>Educate the healthcare team about</i>																				
- the role of the physical therapist and/or physical therapist assistant in patient/client management	291	446	698	732	400	4.15	4.49	4.37	4.34	4.36	0.87	0.85	0.95	0.91	0.95	95	86	83	83	82
- safe patient handling (e.g., injury prevention, ergonomics, use of equipment)	282	446	698	732	400	4.12	4.49	4.44	4.37	4.40	0.87	0.83	0.89	0.92	0.97	96	85	81	82	79
Educate community groups on lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	241	446	697	730	399	3.68	3.66	3.59	3.66	3.66	1.04	1.08	1.16	1.14	1.22	88	72	67	66	62
Participate in the clinical education of students	260	446	697	730	399	3.78	3.98	4.00	3.95	4.01	1.09	1.00	1.02	1.07	1.07	88	74	73	70	68
Patient/client & Staff Safety																				
Emergency Procedures																				
Implement emergency procedures (e.g., CPR, AED, calling a code)	224	446	697	730	399	4.20	4.23	4.03	4.00	3.99	0.92	0.93	1.08	1.12	1.16	94	75	78	78	74
Perform first aid	245	446	697	730	399	4.00	4.00	3.84	3.76	3.80	0.98	1.05	1.11	1.18	1.24	92	76	76	78	75

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Implement disaster response procedures	199	446	697	730	399	3.68	3.74	3.65	3.66	3.66	1.11	1.12	1.17	1.20	1.27	84	68	71	71	62
Environmental Safety																				
Perform risk assessment of the physical environment (e.g., barrier-free environment, outlets, windows, floors, lighting)	243	429	666	640	373	3.76	4.14	4.10	4.20	4.14	0.98	0.96	1.08	0.96	1.00	90	83	74	80	77
Prepare and maintain a safe working environment for performing interventions (e.g., unobstructed walkways, equipment availability)	266	429	666	640	373	4.17	4.40	4.44	4.40	4.42	0.91	0.86	0.85	0.87	0.84	94	86	77	82	83
Perform regular equipment inspections and/or maintenance (e.g., modalities, assistive devices)	248	429	666	640	373	3.75	3.94	4.10	3.99	4.08	1.01	1.05	1.04	1.10	1.05	88	82	71	76	73
Infection Control																				
Perform and/or train patient/client and/or caregiver on appropriate infection control practices (e.g., universal precautions, hand hygiene, isolation, airborne precautions, equipment cleaning)	259	429	666	640	373	3.88	4.11	4.06	4.15	4.08	0.99	1.08	1.14	1.06	1.10	90	81	72	79	78
Research & Evidence-Based Practice																				
Search the literature for current best evidence	280	429	665	639	373	4.00	4.09	4.09	4.05	4.08	0.88	0.91	0.89	0.91	0.89	96	87	80	85	86
Evaluate the quality of published data	268	429	665	639	373	3.87	3.95	3.90	3.88	3.87	0.94	0.95	1.00	1.02	0.99	93	84	78	82	83
Integrate current best evidence, clinical experience, and patient values in clinical practice (e.g., clinical prediction rules, patient preference)	278	429	665	639	373	4.20	4.28	4.26	4.27	4.35	0.85	0.84	0.86	0.82	0.79	97	87	80	85	87
Design, direct, and/or participate in research activities	207	429	665	639	373	3.29	3.17	3.08	3.10	2.91	1.06	1.14	1.25	1.23	1.25	75	67	58	60	60
Compare intervention outcomes with normative data	235	429	665	639	373	3.62	3.60	3.59	3.60	3.58	1.06	1.06	1.08	1.08	1.10	86	78	71	75	75

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Professional Responsibilities																				
Supervise physical therapist assistant(s) and support personnel (licensed/unlicensed)	275	444	693	726	398	4.23	4.49	4.48	4.41	4.41	0.83	0.80	0.87	0.91	0.99	97	82	74	75	70
Assign tasks to other personnel (licensed/unlicensed) to assist with patient/client care	279	444	693	726	398	4.10	4.21	4.27	4.13	4.08	0.86	0.95	0.99	1.01	1.10	95	84	76	79	75
Discuss ongoing patient care with the interprofessional/interdisciplinary team members	293	444	693	726	398	4.26	4.55	4.54	4.43	4.45	0.81	0.76	0.75	0.84	0.85	98	88	83	86	83
Refer patient/client to specialists or other healthcare providers when necessary	290	444	693	726	398	4.18	4.52	4.46	4.41	4.56	0.79	0.71	0.79	0.83	0.71	98	88	83	87	85
Disclose financial interest in recommended products or services to the patient/client	208	444	693	726	398	3.26	3.73	3.67	3.58	3.69	1.25	1.21	1.28	1.28	1.36	73	64	60	61	53
Provide notice and information about alternative care when the physical therapist terminates provider relationship with the patient/client	266	444	693	726	398	3.59	4.01	4.07	3.91	4.00	1.02	1.04	1.05	1.06	1.11	87	80	76	79	76
Document transfer of patient/client care to another physical therapist (therapist of record)	247	444	693	726	398	3.52	3.94	3.90	3.74	3.92	1.11	1.14	1.19	1.21	1.27	82	75	73	75	70
Report healthcare providers that are suspected to not perform their professional responsibilities with reasonable skill and safety to the appropriate authorities	203	444	693	726	398	4.13	4.27	4.15	4.07	4.15	0.92	0.90	1.06	1.09	1.09	95	68	80	81	78
Report suspected cases of abuse to the appropriate authority	207	444	693	726	398	4.31	4.57	4.46	4.41	4.49	0.85	0.72	0.89	0.95	0.89	95	70	83	84	83
Report suspected illegal or unethical acts performed by healthcare providers to the relevant authority	195	443	691	723	397	4.30	4.59	4.47	4.40	4.35	0.83	0.74	0.86	0.96	1.02	95	70	83	84	82
Advocate for public access to physical therapy and other healthcare services	245	443	691	723	397	4.02	4.34	4.25	4.26	4.19	0.96	0.85	0.98	0.98	1.04	93	78	82	81	81

Table B.1. (Continued)

	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Determine own need for professional development	298	443	691	723	397	4.28	4.60	4.59	4.55	4.59	0.78	0.67	0.70	0.71	0.72	97	88	84	87	85
Participate in learning and/or development activities (e.g., journal clubs, self-directed reading, continuing competence activities) to maintain the currency of knowledge, skills, and abilities	297	443	691	723	397	4.22	4.46	4.45	4.45	4.42	0.82	0.78	0.82	0.81	0.89	96	88	84	86	84
Practice within the federal and jurisdiction regulations and professional standards	293	443	691	723	397	4.66	4.80	4.71	4.70	4.72	0.67	0.49	0.64	0.64	0.67	98	88	84	87	85
Participate in professional organizations	263	443	691	723	397	3.65	3.82	3.90	3.67	3.73	1.03	1.14	1.13	1.18	1.22	87	83	81	83	81
Perform community based screenings (e.g., fall risk, posture, musculoskeletal, flexibility, sports-specific)	241	443	691	723	397	3.61	3.87	3.79	3.71	3.69	1.00	1.06	1.18	1.13	1.16	88	75	74	75	71
Participate in performance improvement and quality reporting activities (e.g., Physician Quality Reporting System, standardized outcomes measurement, application of health informatics)	258	443	691	723	397	3.72	3.99	3.93	3.85	3.77	1.02	1.07	1.12	1.13	1.17	88	79	76	78	76

Note. Boldface mean (Red) indicates the mean importance value was less than 2.50. Light red shading indicates the 2021 mean importance value was below 2.50 (Criticality Threshold). Light orange shading indicates the 2021 mean importance value was between 2.50 (including) and 3.00 (excluding).

Table B.2. PTA Work Activity Survey Results

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
DATA COLLECTION																				
Information Gathering & Synthesis																				
<i>Interview patients/clients, caregivers, and family to obtain patient/client history and current information (e.g., medical, surgical, medications, social, cultural, language preference, economic) to</i>																				
- review prior and current level of function/activity	263	264	515	281	244	4.21	4.55	4.54	4.58	4.59	0.84	0.76	0.74	0.66	0.80	96	99	98	99	97
- establish general health status	259	264	515	281	244	4.21	4.36	4.32	4.40	4.35	0.85	0.82	0.87	0.79	0.88	96	100	96	99	97
- identify red flags (e.g., fever, malaise, unexplained weight change) and contraindications	263	264	515	281	244	4.40	4.60	4.54	4.58	4.59	0.81	0.73	0.78	0.75	0.78	97	99	99	98	98
- identify patient/client's, family/caregiver's goals, values, and preferences	262	264	515	281	244	4.16	4.30	4.29	4.42	4.22	0.83	0.82	0.87	0.75	0.87	96	100	98	99	97
- determine impact of medications on plan of care (e.g., medication reconciliation, timing of intervention delivery, adherence)	262	264	515	281	244	3.98	3.78	3.92	3.94	3.83	0.96	1.11	1.07	1.02	1.12	92	96	93	95	91
Administer standardized questionnaires (e.g., pain inventory, fall risk assessment)	264	264	515	281	244	4.05	3.66	3.75	3.76	3.88	0.92	1.07	1.04	1.00	1.07	94	95	93	94	94
Review medical records (e.g., lab values, diagnostic tests, imaging, specialty reports, narrative, consults, physical therapy documentation) prior to carrying out the PT plan of care	268	264	515	281	244	4.42	4.10	4.14	4.12	4.14	0.76	0.96	0.98	0.99	0.99	98	98	97	96	97

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Gather information/discuss patient/client's current health status with interprofessional/interdisciplinary team members	267	264	515	281	244	4.35	4.05	4.09	4.14	4.15	0.77	0.90	0.92	0.96	0.97	98	99	96	97	98
Identify signs/symptoms of change in patient/client's health status that require intervention by physical therapist	266	264	515	281	244	4.52	4.53	4.54	4.59	4.56	0.65	0.71	0.68	0.68	0.69	99	100	99	99	100
Identify signs/symptoms of change in patient/client's health status that require intervention by interprofessional/interdisciplinary team members	263	264	515	281	244	4.40	4.39	4.38	4.46	4.47	0.75	0.84	0.80	0.80	0.73	98	98	99	98	98
Systems Review																				
Check patient/client's current affect, cognition, communication, and learning preferences (e.g., ability to convey needs, consciousness, orientation, expected emotional/behavioral responses)	232	264	515	281	244	4.28	4.15	4.24	4.22	4.22	0.72	0.94	0.88	0.88	0.96	99	99	98	98	97
<i>Recognize changes in status of the</i>																				
- patient/client's quality of speech, hearing, and vision (e.g., dysarthria, pitch/tone, use of corrective lenses, use of hearing aids)	228	256	497	271	231	4.18	3.77	3.83	3.98	3.88	0.84	1.08	1.07	1.04	1.13	96	91	89	92	87
- vestibular system (e.g., dizziness, vertigo)	232	256	497	271	231	4.21	4.02	4.00	4.13	4.10	0.77	0.94	0.98	0.95	1.00	97	93	91	93	90

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- gastrointestinal system (e.g., difficulty swallowing, nausea, change in appetite/diet, change in bowel function)	227	256	497	271	231	3.89	3.40	3.40	3.49	3.51	0.94	1.14	1.15	1.11	1.17	93	89	81	87	82
- genitourinary system (e.g., changes in bladder function, catheter complications)	215	256	497	271	231	3.78	3.43	3.36	3.44	3.51	1.07	1.18	1.13	1.22	1.20	89	84	80	82	78
- reproductive system (e.g., sexual and/or menstrual dysfunction, menopause status)	196	256	497	271	231	2.78	2.51	2.45	2.62	2.88	1.42	1.18	1.16	1.24	1.38	54	62	57	66	60
- cardiovascular/pulmonary system (e.g., blood pressure, heart rate, respiration rate)	231	256	497	271	231	4.54	4.40	4.31	4.42	4.35	0.63	0.82	0.91	0.85	0.89	100	96	95	94	93
- lymphatic system (e.g., primary and/or secondary edema)	230	256	497	271	231	4.07	3.84	3.74	3.86	3.64	0.91	0.96	1.07	1.03	1.17	95	91	88	88	79
- integumentary system (e.g., presence of scar formation, skin integrity, discoloration)	232	256	497	271	231	4.16	4.00	3.92	3.99	4.01	0.83	0.96	1.00	1.06	0.97	95	96	94	93	92
- musculoskeletal system (e.g., gross symmetry, strength, range of motion)	233	256	497	271	231	4.52	4.64	4.62	4.66	4.70	0.62	0.62	0.65	0.60	0.57	100	97	97	96	94
- neuromuscular system (e.g., gross coordination, motor function, balance, locomotion, gross sensory function)	223	256	497	271	231	4.49	4.70	4.63	4.66	4.65	0.63	0.59	0.62	0.61	0.64	100	97	97	96	95

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Tests & Measures																				
Cardiovascular/Pulmonary																				
<i>Perform tests and measures of</i>																				
- cardiovascular function (e.g., blood pressure, heart rate, heart sounds)	210	252	490	265	225	4.33	4.31	4.20	4.28	4.11	0.83	0.93	0.98	0.92	1.11	97	93	92	91	87
- pulmonary function (e.g., respiratory rate, breathing patterns, breath sounds, chest excursion)	200	252	490	265	225	4.08	4.09	3.97	3.94	3.91	0.98	1.06	1.02	1.08	1.21	91	88	87	90	84
- perfusion and gas exchange (e.g., oxygen saturation)	197	252	490	265	225	4.07	4.09	4.02	4.02	4.06	1.09	1.08	1.05	1.18	1.13	91	86	86	84	83
- peripheral circulation (e.g., capillary refill, blood pressure in upper versus lower extremities)	182	252	490	265	225	3.45	3.48	3.42	3.52	3.41	1.19	1.24	1.15	1.13	1.29	78	77	80	81	76
- critical limb ischemia (e.g., peripheral pulses, skin perfusion pressure)	178	252	490	265	225	3.48	3.39	3.35	3.44	3.33	1.17	1.26	1.20	1.21	1.31	76	74	76	78	73
- physiological responses to position change (e.g., orthostatic hypotension, skin color, blood pressure, heart rate)	206	252	490	265	225	4.08	4.24	4.17	4.14	4.19	0.92	0.90	0.93	1.00	0.94	93	92	91	91	88
- aerobic capacity under maximal and submaximal conditions (e.g., endurance, exercise tolerance, metabolic equivalents, perceived exertion)	197	252	490	265	225	3.69	3.82	3.94	4.07	3.96	1.18	1.11	1.03	1.01	1.09	83	87	88	86	84

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Anthropometric																				
<i>Perform tests and measures of</i>																				
- body composition (e.g., percent body fat, lean muscle mass)	161	252	490	265	225	2.72	2.55	2.58	2.63	2.73	1.39	1.20	1.13	1.15	1.27	53	62	63	66	64
- body dimensions (e.g., height, weight, girth, limb length, head circumference/shape)	183	252	490	265	225	3.10	2.66	2.70	2.70	2.83	1.22	1.20	1.10	1.23	1.21	68	70	70	67	71
Quantify and qualify edema (e.g., pitting, volume, circumference)	202	252	490	265	225	3.51	3.47	3.42	3.53	3.42	1.02	1.12	1.07	1.15	1.22	86	88	84	84	81
Arousal, Attention, & Cognition																				
<i>Perform tests and measures of</i>																				
- arousal and orientation (e.g., level of consciousness, time, person, place, situation)	186	246	472	256	215	3.80	3.89	3.78	3.89	3.84	1.05	1.11	1.17	1.11	1.19	90	83	80	79	74
- attention and cognition (e.g., ability to process commands, delirium, confusion)	181	246	472	256	215	3.78	3.96	3.90	3.93	3.92	1.01	1.01	1.03	1.10	1.13	89	86	85	82	79
- communication (e.g., expressive and receptive skills, following instructions)	178	246	472	256	215	3.72	3.93	3.90	4.00	3.94	1.03	1.04	1.00	1.01	1.10	89	88	87	84	82
- recall (including memory and retention)	173	246	472	256	215	3.59	3.63	3.51	3.63	3.63	1.13	1.07	1.09	1.07	1.16	84	84	83	80	78
Nerve Integrity																				
<i>Perform tests and measures of</i>																				
- cranial nerve integrity (e.g., facial asymmetry, oculomotor function, hearing)	155	246	472	256	215	3.27	3.36	3.20	3.40	3.31	1.27	1.19	1.15	1.19	1.20	72	73	70	73	69

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- spinal nerve integrity (e.g., dermatome, myotome)	169	246	472	256	215	3.46	3.60	3.46	3.64	3.52	1.16	1.08	1.17	1.09	1.18	78	81	76	80	74
- peripheral nerve integrity (e.g., sensation, strength)	185	246	472	256	215	3.75	3.88	3.79	3.93	3.88	0.98	1.01	1.01	1.00	1.04	89	88	82	86	80
- neural provocation (e.g., tapping, tension, stretch)	169	246	472	256	215	3.47	3.61	3.43	3.60	3.54	1.09	1.03	1.13	1.15	1.11	83	87	79	78	77
Environmental & Community Integration/Reintegration (Home, Work, Job, School, Play, & Leisure)																				
Collect data on patient/client's ability to perform activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	196	242	460	247	212	4.37	4.38	4.38	4.43	4.50	0.71	0.90	0.88	0.84	0.78	98	90	86	85	84
Collect data on patient/client's ability to perform instrumental activities of daily living (IADL) (e.g., household chores, hobbies)	195	242	460	247	212	4.04	4.07	4.09	4.16	4.27	0.95	1.02	0.99	0.97	0.90	92	89	86	84	82
Collect data on patient/client's ability to perform skills needed for integration or reintegration into the community, work, or school	175	242	460	247	212	3.89	4.09	4.16	4.15	4.24	1.03	0.96	0.97	0.95	0.91	91	89	85	86	84
Collect data on barriers (e.g., social, economic, physical, psychological, environmental, work conditions and activities) to home, community, work, or school integration/reintegration	171	242	460	247	212	3.78	3.88	3.97	3.92	4.02	1.03	1.05	1.07	1.05	1.02	89	86	84	82	81
Collect data on safety in home, community, work, or school environments	176	242	460	247	212	3.89	4.05	4.14	4.08	4.14	1.02	1.04	0.99	1.00	0.99	90	88	84	82	82

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Collect data on patient/client's ability to participate in activities with or without the use of devices, equipment, or technologies	181	242	460	247	212	4.06	4.19	4.30	4.24	4.29	0.87	0.95	0.82	0.89	0.90	94	90	87	86	85
Ergonomics and Body Mechanics																				
<i>Perform tests and measures of</i>																				
- ergonomics and body mechanics during functional activities	183	240	452	244	210	3.95	4.36	4.37	4.33	4.42	0.96	0.88	0.79	0.88	0.80	90	91	87	85	84
- postural alignment and position (static and dynamic)	183	240	452	244	210	4.08	4.43	4.43	4.38	4.49	0.88	0.77	0.78	0.78	0.72	93	91	87	86	85
Functional Mobility, Balance, & Vestibular																				
<i>Perform tests and measures of</i>																				
- balance (dynamic and static) with or without the use of specialized equipment	185	240	452	244	210	4.30	4.63	4.63	4.60	4.67	0.67	0.62	0.57	0.60	0.54	99	91	87	86	85
- gait and locomotion (e.g., ambulation, wheelchair mobility) with or without the use of specialized equipment	185	240	452	244	210	4.42	4.70	4.68	4.67	4.72	0.63	0.58	0.57	0.62	0.52	99	90	87	86	85
- mobility during functional activities and transitional movements (e.g., transfers, bed mobility)	187	240	452	244	210	4.39	4.66	4.63	4.60	4.60	0.67	0.63	0.64	0.63	0.69	98	89	87	86	84
- vestibular function (e.g., peripheral dysfunction, central dysfunction, BPPV)	159	240	452	244	210	3.62	3.76	3.82	3.78	3.82	1.10	1.12	1.06	1.05	1.15	82	80	78	78	76

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Integumentary Integrity																				
Observe skin characteristics (e.g., continuity of skin color, sensation, temperature, texture, turgor)	173	239	450	244	206	3.92	3.73	3.81	3.68	3.85	0.84	1.05	1.05	1.03	1.09	95	88	81	82	80
Collect data on wound characteristics (e.g., tissue involvement, depth, tunneling, burn classification, ulcer/injury classification)	139	239	450	244	206	3.61	3.22	3.23	3.26	3.30	1.19	1.25	1.29	1.24	1.31	84	71	58	61	59
Observe scar tissue characteristics (e.g., banding, pliability, sensation, and texture)	162	239	450	244	206	3.59	3.30	3.26	3.33	3.44	1.04	1.20	1.20	1.15	1.19	86	77	69	74	70
Collect data on patient/client's activities, positioning, and postures that produce or relieve trauma to the skin	163	239	450	244	206	3.87	3.83	3.83	3.88	3.95	0.99	1.12	1.13	1.11	1.16	91	80	75	73	73
Identify devices and equipment that produce or relieve trauma to the patient/client's skin	164	239	450	244	206	3.79	3.79	3.74	3.79	3.86	1.02	1.12	1.15	1.15	1.18	90	79	73	73	72
Joint Integrity & Range of Motion																				
<i>Perform tests and measures of</i>																				
- spinal joint stability (e.g., ligamentous integrity, joint structure)	146	237	444	241	205	3.59	3.78	3.74	3.83	3.87	1.20	1.09	1.11	1.07	1.15	83	76	71	75	71
- peripheral joint stability (e.g., ligamentous integrity, joint structure)	157	237	444	241	205	3.71	3.96	3.88	3.93	3.86	1.06	1.01	1.05	1.03	1.12	87	81	77	79	73
- spinal joint mobility (e.g., glide, end feel)	143	237	444	241	205	3.62	3.62	3.67	3.75	3.80	1.21	1.22	1.14	1.11	1.16	83	73	71	74	68
- peripheral joint mobility (e.g., glide, end feel)	163	237	444	241	205	3.83	3.88	3.89	4.01	3.93	1.01	1.09	1.07	1.00	1.11	88	81	77	81	73
- range of motion (e.g., passive, active, functional)	180	237	444	241	205	4.30	4.54	4.54	4.55	4.56	0.75	0.71	0.72	0.69	0.73	99	89	85	85	83

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- flexibility (e.g., muscle length, soft tissue extensibility)	157	237	444	241	205	4.00	4.35	4.36	4.41	4.37	0.85	0.87	0.83	0.81	0.78	95	88	84	85	82
Motor Function																				
<i>Perform tests and measures of</i>																				
- muscle tone (e.g., hypertonicity, hypotonicity, dystonia)	152	235	442	240	202	3.85	3.97	3.94	4.00	4.00	0.91	1.06	0.99	1.00	0.98	93	83	79	80	79
- dexterity, coordination, and agility (e.g., rapid alternating movement, finger to nose)	145	235	442	240	202	3.72	3.68	3.62	3.70	3.77	0.99	1.13	1.10	1.09	1.07	88	80	77	79	73
- ability to initiate, modify and control movement patterns and postures (e.g., catching a ball, gait)	164	235	442	240	202	4.08	4.23	4.20	4.25	4.28	0.81	0.89	0.91	0.82	0.87	97	88	83	84	80
- ability to change movement performance with practice (e.g., motor learning)	156	235	442	240	202	3.90	4.17	4.15	4.17	4.19	0.84	0.91	0.88	0.89	0.91	96	87	83	83	79
- movement quality (e.g., purpose, precision, efficiency, biomechanics, kinematics)	151	235	442	240	202	3.90	4.11	4.13	4.20	4.26	0.89	0.93	0.90	0.90	0.88	95	88	83	84	80
Muscle Performance																				
<i>Perform tests and measures of</i>																				
- muscle strength, power, and endurance without specialized equipment (e.g., manual muscle test, functional strength testing)	162	235	442	240	202	4.12	4.30	4.36	4.42	4.41	0.83	0.92	0.80	0.76	0.79	96	87	84	83	81

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- muscle strength, power, and endurance with specialized equipment (e.g., isokinetic testing, dynamometry)	137	235	442	240	202	3.60	3.74	3.81	3.95	3.89	1.21	1.27	1.19	1.18	1.26	82	71	70	72	67
Neuromotor Development & Sensory Integration																				
<i>Perform tests and measures of</i>																				
- acquisition and evolution of motor skills throughout the lifespan	114	235	442	240	202	3.19	3.44	3.51	3.75	3.55	1.34	1.18	1.16	1.09	1.25	69	74	68	70	66
- sensorimotor integration	125	235	442	240	202	3.24	3.52	3.54	3.63	3.60	1.30	1.11	1.06	1.06	1.13	68	77	72	75	70
- developmental reflexes and reactions (e.g., asymmetrical tonic neck reflex, righting reactions)	115	235	442	240	202	3.29	3.42	3.32	3.64	3.53	1.26	1.22	1.20	1.14	1.25	70	67	63	67	61
Reflex Integrity																				
<i>Perform tests and measures of</i>																				
- deep tendon/muscle stretch reflexes (e.g., quadriceps, biceps)	134	233	437	237	201	3.40	3.53	3.42	3.54	3.53	1.10	1.18	1.18	1.14	1.16	77	73	70	71	70
- upper motor neuron integrity (e.g., Babinski reflex, Hoffman sign)	119	233	436	237	201	3.22	3.28	3.09	3.28	3.29	1.26	1.22	1.25	1.19	1.23	70	62	57	65	59
- superficial reflexes and reactions (e.g., cremasteric reflex, abdominal reflexes)	108	233	436	237	201	3.07	3.11	2.96	3.12	3.10	1.36	1.26	1.27	1.19	1.29	65	59	54	62	55
Pain & Sensory Integrity																				
<i>Perform tests and measures of</i>																				
- pain (e.g., location, intensity, frequency, central, peripheral, psychogenic)	148	233	436	237	201	4.01	4.38	4.30	4.35	4.30	0.88	0.87	0.88	0.79	0.97	96	84	81	83	78

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- deep sensation (e.g., proprioception, kinesthesia, pressure)	143	233	436	237	201	3.51	3.76	3.59	3.82	3.72	1.03	1.14	1.16	1.07	1.11	85	74	72	76	71
- superficial sensation (e.g., touch, temperature discrimination)	147	233	436	237	201	3.50	3.63	3.59	3.66	3.77	0.93	1.17	1.15	1.11	1.07	86	76	72	79	72
Plan of Care & Goals																				
Modify and/or progress within the plan of care based on patient/client's resources (e.g., financial, transportation, time, insurance benefits, available technologies)	156	232	434	235	199	4.18	4.25	4.30	4.32	4.38	0.96	0.97	0.96	0.97	0.87	94	82	77	79	78
INTERVENTIONS																				
Procedural Interventions																				
Therapeutic Exercise/Therapeutic Activities																				
<i>Perform and/or train patient/client/caregiver in</i>																				
- aerobic capacity/endurance conditioning	269	293	534	386	220	4.10	4.00	4.12	4.13	4.15	0.80	0.97	0.99	1.00	1.01	96	98	96	99	95
- balance, coordination, and agility activities	278	293	534	386	220	4.55	4.60	4.67	4.68	4.67	0.57	0.64	0.60	0.58	0.61	100	100	100	100	100
- body mechanics and postural stabilization techniques	279	293	534	386	220	4.49	4.58	4.57	4.60	4.68	0.62	0.68	0.70	0.72	0.61	100	100	100	99	100
- flexibility techniques	276	293	534	386	220	4.12	3.84	3.83	3.91	4.01	0.80	1.03	1.05	1.06	1.03	98	98	97	98	97
- neuromotor techniques (e.g., movement pattern training, neuromuscular education or reeducation)	276	293	534	386	220	4.16	4.06	4.14	4.15	4.26	0.80	0.99	0.93	0.91	0.86	97	98	99	99	99
- relaxation techniques	271	293	534	386	220	3.62	3.36	3.36	3.34	3.53	0.91	1.13	1.17	1.17	1.20	91	94	94	94	95
- strength, power, and endurance exercises	273	293	534	386	220	4.46	4.26	4.35	4.34	4.42	0.66	0.80	0.86	0.87	0.80	99	100	99	99	99

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- genitourinary management (e.g., pelvic floor exercises, bladder strategies)	249	293	533	386	220	3.06	2.67	2.68	2.80	2.68	1.18	1.23	1.20	1.22	1.25	65	55	57	53	53
- gastrointestinal management (e.g., bowel strategies, positioning to avoid reflux)	240	293	533	386	220	2.85	2.42	2.54	2.69	2.57	1.18	1.15	1.19	1.27	1.25	55	48	51	45	50
- manual/mechanical airway clearance techniques (e.g., assistive devices, assistive cough, incentive spirometer, flutter valve, percussion, vibration)	247	293	533	386	220	3.17	2.71	2.75	2.96	2.88	1.26	1.33	1.27	1.37	1.35	65	54	54	47	52
- techniques to maximize ventilation and perfusion (e.g., positioning, active cycle breathing, autogenic drainage, paced breathing, pursed-lip breathing)	228	293	533	386	220	3.58	3.09	3.17	3.21	3.18	1.16	1.22	1.25	1.23	1.28	84	73	69	65	69
- mechanical repositioning for vestibular dysfunction	211	293	533	386	220	3.13	2.78	2.88	2.99	2.90	1.27	1.15	1.25	1.20	1.24	68	59	62	58	59
- habituation/adaptation exercises for vestibular dysfunction	206	293	533	386	220	3.14	2.81	3.01	2.99	2.98	1.26	1.19	1.25	1.20	1.18	67	64	65	61	64
- postural drainage				386	220				2.62	2.59				1.28	1.24				40	45
Functional Training																				
<i>Perform and/or train patient/client in</i>																				
- the use of environmental modifications (e.g., ramps, grab bars, raised toilet, environmental control units)	236	289	525	375	217	4.13	4.09	3.97	3.99	3.92	0.86	1.12	1.25	1.26	1.24	96	88	86	83	82

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- activities of daily living (ADL) (e.g., bed mobility, transfers, household mobility, dressing, self-care, toileting, sexual relations)	245	289	525	375	217	4.43	4.35	4.30	4.29	4.20	0.77	0.98	1.05	1.07	1.11	98	95	93	92	91
- community and leisure integration or reintegration (e.g., work/school/play)	224	289	525	375	217	3.76	3.68	3.73	3.79	3.87	1.06	1.07	1.18	1.20	1.14	90	89	87	87	86
- Instrumental Activities of Daily Living (IADL) (e.g., household chores, hobbies)	229	289	525	375	217	3.86	3.87	3.93	3.98	4.08	0.98	1.06	1.08	1.07	1.03	92	92	92	92	91
- mobility techniques	245	289	525	375	217	4.33	4.30	4.26	4.37	4.34	0.79	0.82	0.89	0.81	0.85	98	97	97	97	97
- gross motor developmental progression			525	375	217			3.68	3.83	3.70			1.15	1.14	1.17			87	85	85
- fall prevention and fall recovery strategies	242	289	525	375	217	4.45	4.55	4.45	4.46	4.47	0.72	0.68	0.89	0.88	0.80	99	98	96	95	96
- behavior modification and strategies that enhance functioning (e.g., energy conservation, pacing, pre-activity planning, reminder schedules)	237	289	525	375	217	4.04	3.91	3.83	3.86	3.80	0.88	1.09	1.13	1.15	1.07	95	90	91	90	89
Manual Therapy Techniques																				
Perform manual lymphatic drainage	174	285	518	365	210	3.00	2.61	2.61	2.68	2.63	1.29	1.14	1.22	1.24	1.26	64	44	40	38	39
Perform spinal manual traction	186	285	518	365	209	3.45	3.12	3.12	3.16	3.36	1.26	1.24	1.26	1.23	1.22	78	63	61	62	60
Perform peripheral manual traction	183	285	518	365	209	3.34	3.11	3.02	3.09	3.15	1.33	1.26	1.28	1.21	1.29	72	63	59	61	59

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Perform and/or train patient/client/caregiver in soft tissue mobilization (e.g., connective tissue massage, therapeutic massage, foam rolling)	227	285	517	365	209	3.90	3.53	3.56	3.64	3.71	0.93	1.28	1.23	1.23	1.24	95	84	82	81	78
Perform instrument-assisted soft tissue mobilization	193	285	517	365	209	3.42	3.32	3.41	3.50	3.64	1.19	1.25	1.30	1.30	1.19	79	69	71	67	73
Perform peripheral joint range of motion	227	285	517	365	209	4.31	4.13	4.08	4.13	4.22	0.81	1.08	1.07	1.03	0.95	97	91	88	86	85
Perform peripheral mobilization/manipulation (thrust)	166	285	517	365	209	3.06	2.92	2.96	3.15	2.95	1.47	1.37	1.37	1.29	1.36	63	41	40	42	41
Perform peripheral mobilization (non-thrust)	188	285	517	365	209	3.55	3.45	3.38	3.52	3.64	1.22	1.33	1.37	1.27	1.24	81	67	65	69	67
Perform spinal mobilization/manipulation (thrust)	153	285	517	365	209	2.88	2.56	2.60	2.78	2.65	1.44	1.34	1.29	1.29	1.34	58	32	32	33	34
Perform spinal mobilization (non-thrust)	170	285	517	365	209	3.27	3.26	3.21	3.31	3.33	1.39	1.36	1.39	1.33	1.36	70	57	55	55	55
<i>Apply taping for</i>																				
- neuromuscular reeducation	176	284	514	364	206	3.26	4.10	4.09	3.94	3.95	1.13	1.04	1.13	1.21	1.19	77	81	80	78	76
- lymphatic drainage	150	284	514	364	206	2.87	3.01	2.83	3.00	3.01	1.35	1.34	1.23	1.28	1.35	61	47	45	45	42
- pain management	174	284	514	364	206	3.22	4.06	4.10	3.97	4.05	1.17	1.14	1.04	1.19	1.03	74	82	83	78	79
Equipment & Devices																				
<i>Apply and/or adjust</i>																				
- adaptive devices (e.g., utensils, seating and positioning devices, steering wheel devices)	187	283	504	361	200	3.39	3.65	3.59	3.58	3.68	1.21	1.30	1.33	1.32	1.32	78	72	67	65	65
- protective devices (e.g., braces, cushions, helmets, protective taping)	203	283	504	361	200	3.65	3.70	3.65	3.66	3.69	1.08	1.18	1.18	1.22	1.21	87	83	81	78	77

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars serial casts, short-stretch bandages)	207	283	504	361	200	3.57	3.57	3.53	3.57	3.57	1.05	1.16	1.26	1.21	1.29	85	84	78	77	76
- orthotic devices (e.g., braces, shoe inserts, splints)	211	283	503	361	200	3.82	3.91	3.81	3.78	3.82	0.97	1.04	1.12	1.16	1.16	91	90	87	85	84
- assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	221	283	504	361	200	4.29	4.57	4.49	4.48	4.48	0.75	0.74	0.84	0.89	0.84	99	96	93	92	89
- prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	179	283	504	361	200	3.46	3.64	3.62	3.53	3.50	1.18	1.19	1.25	1.25	1.29	77	74	72	67	67
- mechanical neuromuscular re-education devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	149	283	504	361	200	2.99	3.12	3.13	3.12	3.16	1.33	1.35	1.42	1.40	1.48	62	50	51	47	47
- prescribed oxygen during interventions	186	283	504	361	200	4.02	4.02	3.98	3.84	3.77	1.13	1.20	1.22	1.30	1.33	90	70	66	63	61
<i>Train patient/client/caregiver in the use of</i>																				
- adaptive devices (e.g., utensils, seating and positioning devices, steering wheel devices)	167	277	493	357	197	3.49	3.60	3.59	3.60	3.58	1.20	1.33	1.35	1.31	1.34	81	63	62	60	

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- assistive devices/technologies (e.g., canes, crutches, walkers, wheelchairs, tilt tables, standing frames)	206	276	493	357	197	4.35	4.55	4.50	4.49	4.45	0.72	0.76	0.87	0.84	0.90	100	92	89	91	
- orthotic devices (e.g., braces, shoe inserts, splints)	193	276	493	357	197	3.82	4.04	3.99	4.06	3.93	0.91	1.02	1.12	1.10	1.13	94	88	85	84	61
- prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	154	276	493	357	197	3.40	3.65	3.61	3.73	3.74	1.28	1.22	1.34	1.25	1.29	77	66	68	64	87
- protective devices (e.g., braces, cushions, helmets, protective taping)	175	276	493	357	197	3.50	3.62	3.64	3.68	3.62	1.12	1.24	1.29	1.23	1.36	81	74	74	74	82
- supportive devices (e.g., compression garments, corsets, elastic wraps, neck collars, serial casts, short-stretch bandages)	187	276	493	357	197	3.45	3.66	3.65	3.67	3.64	1.05	1.14	1.27	1.18	1.33	86	79	74	77	63
- mechanical neuromuscular re-education devices/technologies (e.g., weighted vests, therapeutic suits, body weight supported treadmill)	133	276	493	357	197	2.83	3.31	3.25	3.22	3.26	1.36	1.35	1.46	1.45	1.45	56	48	50	46	66

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Integumentary Repair & Protection Techniques																				
<i>Perform and/or train patient/client/caregiver in</i>																				
- nonselective debridement (e.g., removal of nonselective areas of devitalized tissue)	127	272	492	353	193	2.53	2.67	2.46	2.61	2.73	1.44	1.35	1.32	1.29	1.33	46	21	18	19	22
- selective enzymatic or autolytic debridement (e.g., removal of specific areas of devitalized tissue)	122	271	491	353	193	2.48	2.65	2.38	2.60	2.65	1.45	1.36	1.29	1.27	1.34	43	19	18	18	21
- application of topical agents (e.g., cleansers, creams, moisturizers, ointments, sealants) and dressings (e.g., hydrogels, wound coverings)	135	271	491	353	193	2.68	2.85	2.66	2.76	2.99	1.33	1.32	1.25	1.31	1.25	49	36	35	33	36
- desensitization techniques (e.g., brushing, tapping, use of textures)	159	271	491	353	193	2.91	2.99	2.98	3.00	3.02	1.20	1.21	1.20	1.21	1.17	62	59	57	53	53
- hyperbaric therapy	118	271	491	353	193	2.28	2.52	2.19	2.49	2.32	1.37	1.31	1.22	1.25	1.22	38	16	14	15	17
- negative pressure wound therapy	118	271	491	353	193	2.28	2.61	2.31	2.62	2.67	1.33	1.30	1.31	1.34	1.30	36	19	16	19	22
Perform sharp debridement (e.g., removal of specific areas of devitalized tissue)	117	271	491	353	193	2.27	2.64	2.25	2.54	2.44	1.38	1.38	1.26	1.36	1.22	34	16	16	15	19
Therapeutic Modalities																				
<i>Perform and/or train patient/client/caregiver in</i>																				
- biofeedback therapy (e.g., relaxation techniques, muscle reeducation, EMG)	170	270	491	352	191	3.41	3.42	3.36	3.49	3.36	1.05	1.21	1.31	1.21	1.27	83	68	65	68	62
- iontophoresis	147	270	491	352	191	3.01	3.02	2.76	2.89	2.68	1.30	1.39	1.38	1.37	1.45	67	51	42	45	38
- phonophoresis	133	270	488	352	189	2.82	2.85	2.62	2.70	2.78	1.40	1.38	1.39	1.43	1.49	60	32	27	29	25

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- electrotherapy modalities, excluding iontophoresis (e.g., NMES, TENS, FES, interferential therapy, high-voltage pulsed current)*	191	270	491	352	191	3.93	4.05	3.98	3.86	3.98	0.98	1.15	1.16	1.22	1.14	91	80	81	78	77
- cryotherapy (e.g., cold pack, ice massage, vapocoolant spray)	195	270	491	352	191	3.87	4.01	3.87	3.91	3.86	0.97	1.12	1.18	1.16	1.23	93	86	85	82	76
- hydrotherapy using contrast baths/pools	126	270	491	352	191	2.98	2.90	2.74	3.03	2.84	1.31	1.41	1.48	1.47	1.50	62	34	32	35	32
- hydrotherapy (e.g., aquatic exercise, underwater treadmill)	134	270	491	352	191	3.13	3.31	3.18	3.25	3.36	1.30	1.38	1.50	1.42	1.41	65	41	35	35	37
- phototherapy (laser light)	120	270	491	352	191	2.58	2.58	2.65	2.74	2.62	1.39	1.26	1.46	1.40	1.43	47	27	25	29	26
- monochromatic infrared agent procedures (e.g., light emitting diodes [LEDs])	116	270	488	352	189	2.44	2.57	2.29	2.34	2.44	1.35	1.35	1.35	1.31	1.30	43	20	18	19	20
- ultrasound procedures	185	270	488	352	189	3.69	3.58	3.39	3.28	3.36	1.05	1.35	1.36	1.33	1.33	87	74	67	67	59
- diathermy	128	270	488	352	189	2.62	3.04	2.76	2.61	2.54	1.30	1.41	1.46	1.37	1.32	51	31	30	28	26
- dry heat thermotherapy (e.g., Fluidotherapy)	118	270	488	352	189	2.54	2.95	2.62	2.61	2.63	1.31	1.34	1.42	1.39	1.38	47	30	25	26	28
- hot pack thermotherapy	185	270	488	352	189	3.76	3.84	3.89	3.83	3.82	1.02	1.25	1.19	1.23	1.17	91	83	77	79	73
- paraffin bath thermotherapy	138	270	488	352	189	2.80	3.12	2.89	2.98	2.95	1.29	1.38	1.44	1.38	1.36	57	40	37	37	40
- shockwave therapy	111	270	488	352	189	2.15	2.51	2.20	2.39	2.54	1.32	1.34	1.39	1.32	1.42	33	15	15	19	19
Mechanical Modalities																				
<i>Apply and/or train patient/client/caregiver in</i>																				
- intermittent pneumatic compression	127	270	487	352	189	2.67	3.11	2.82	2.92	3.21	1.33	1.31	1.35	1.34	1.25	53	39	35	36	36
- assisted movement devices (e.g., dynamic splint, continuous passive motion devices)	152	270	487	352	189	3.13	3.15	3.13	3.03	3.38	1.24	1.32	1.29	1.38	1.25	70	53	51	46	43
- mechanical spinal traction	138	270	487	352	189	3.30	3.57	3.14	3.33	3.74	1.28	1.30	1.35	1.33	1.13	73	54	48	50	48

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Non-procedural Interventions																				
Communication																				
<i>Discuss physical therapy evaluation findings, interventions, goals, prognosis, discharge planning, and plan of care with</i>																				
- the supervising physical therapist	201	269	486	351	189	4.65	4.81	4.74	4.76	4.77	0.61	0.54	0.63	0.63	0.64	100	92	88	87	83
- interprofessional/interdisciplinary team members	194	269	486	351	189	4.52	4.53	4.51	4.50	4.49	0.71	0.73	0.84	0.83	0.83	99	90	87	85	81
- patient/client/caregiver	198	269	486	351	189	4.56	4.73	4.70	4.73	4.66	0.62	0.60	0.65	0.62	0.70	99	91	90	90	85
Provide written, oral, and electronic information to the patient/client and/or caregiver	192	269	486	351	189	4.43	4.60	4.57	4.59	4.59	0.80	0.75	0.81	0.73	0.73	98	90	89	89	84
Documentation																				
Document																				
- data collection results	188	268	486	350	189	4.41	4.45	4.44	4.49	4.55	0.85	0.87	0.88	0.85	0.85	96	90	86	86	81
- intervention(s) and patient/client response(s) to intervention	198	268	486	350	189	4.60	4.73	4.69	4.70	4.79	0.62	0.63	0.61	0.67	0.49	99	91	91	89	86
- patient/client/caregiver education	196	268	486	350	189	4.55	4.67	4.63	4.69	4.71	0.62	0.67	0.68	0.64	0.54	99	91	90	90	86
- communication with the interdisciplinary/interprofessional team related to the patient/client's care	194	268	486	350	189	4.46	4.40	4.51	4.50	4.51	0.68	0.88	0.81	0.81	0.76	99	90	89	87	82
- rationale for billing and reimbursement	188	268	486	350	189	4.44	4.32	4.42	4.40	4.55	0.84	0.96	0.88	0.96	0.79	97	87	85	83	80
- disclosure and consent (e.g., disclosure of medical information, consent for treatment)	170	268	486	350	189	4.21	4.26	4.32	4.35	4.49	1.00	1.01	0.98	0.99	0.89	94	85	83	82	77
Assign billing codes for physical therapy treatment provided	157	268	486	350	189	4.04	4.29	4.34	4.35	4.46	1.19	1.07	1.06	1.01	0.88	89	77	75	75	74

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Education																				
<i>Educate patient/client and/or caregiver about</i>																				
- the patient/client's current condition and health status (e.g., nature of the condition, potential benefits of physical therapy interventions, potential treatment outcomes)	197	266	486	347	188	4.40	4.69	4.69	4.72	4.65	0.73	0.60	0.59	0.63	0.68	99	91	90	89	85
- the role of the physical therapist and/or physical therapist assistant in patient/client management	197	266	486	347	188	4.26	4.54	4.56	4.61	4.53	0.84	0.77	0.73	0.73	0.76	97	91	91	89	86
- lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	194	266	486	347	188	4.20	4.34	4.36	4.41	4.47	0.84	0.91	0.89	0.84	0.85	97	89	90	89	81
- the role of physical therapy in transitional planning (e.g., hospice, palliative care, setting changes)	170	266	486	347	188	3.82	4.00	4.01	4.03	4.09	1.08	1.10	1.18	1.21	1.20	89	78	79	75	68
<i>Educate the healthcare team about</i>																				
- the role of the physical therapist and/or physical therapist assistant in patient/client management	171	266	486	347	188	3.92	4.25	4.28	4.29	4.22	1.03	0.95	0.98	1.00	1.06	90	86	87	83	79
- safe patient handling (e.g., injury prevention, ergonomics, use of equipment)	181	266	486	347	188	4.13	4.46	4.63	4.68	4.43	0.89	0.85	0.71	0.69	0.85	97	86	90	89	82

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- Educate community groups on lifestyle and behavioral changes to promote wellness (e.g., nutrition, physical activity, tobacco cessation)	140	266	483	346	188	3.72	3.78	3.67	3.87	3.85	1.19	1.13	1.17	1.11	1.20	85	66	67	66	57
Participate in the clinical education of students	149	266	483	346	188	3.81	3.95	3.70	3.77	3.67	1.18	1.03	1.18	1.15	1.31	86	71	65	64	52
Patient/client & Staff Safety																				
Emergency Procedures																				
Implement emergency procedures (e.g., CPR, AED, calling a code)	144	266	483	346	188	4.27	4.16	4.06	4.12	3.99	0.97	1.07	1.12	1.12	1.25	94	73	80	75	69
Perform first aid	145	266	483	346	188	4.13	4.05	3.89	3.91	3.87	1.00	1.13	1.22	1.19	1.29	94	70	77	76	71
Implement disaster response procedures	131	266	483	346	188	4.02	3.88	3.70	3.69	3.70	1.08	1.18	1.22	1.20	1.30	90	65	75	67	62
Environmental Safety																				
Perform risk assessment of the physical environment (e.g., barrier-free environment, outlets, windows, floors, lighting)	149	266	483	346	188	4.01	3.94	3.87	3.98	4.03	1.12	1.17	1.17	1.12	1.20	89	72	72	71	64
Prepare and maintain a safe working environment for performing interventions (e.g., unobstructed walkways, equipment availability)	191	266	483	346	188	4.38	4.37	4.34	4.43	4.36	0.78	0.93	0.95	0.86	0.98	98	85	85	83	78
Perform regular equipment inspections and/or maintenance (e.g., modalities, assistive devices)	171	266	483	346	188	4.18	4.12	4.08	4.15	4.13	0.95	1.04	1.06	1.03	1.11	95	79	78	77	66

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Infection Control																				
Perform and/or train patient/client and/or caregiver on appropriate infection control practices (e.g., universal precautions, hand hygiene, isolation, airborne precautions, equipment cleaning)	152	232	434	235	199	4.01	4.02	3.94	4.12	4.06	0.95	1.18	1.13	1.06	1.15	93	80	72	77	70
Research & Evidence-Based Practice																				
Search the literature for current best evidence	160	232	434	235	199	3.76	3.71	3.66	3.83	3.82	1.00	1.06	1.08	1.01	1.01	88	80	75	79	73
Evaluate the quality of published data	147	232	434	235	199	3.44	3.47	3.43	3.56	3.63	1.13	1.15	1.20	1.09	1.17	78	72	67	74	65
Integrate current best evidence, clinical experience, and patient values in clinical practice (e.g., clinical prediction rules, patient preference)	160	232	434	235	199	3.84	3.91	3.91	3.88	4.04	0.99	1.04	1.05	1.01	0.96	87	80	75	79	74
Design and/or direct research activities	103	232	434	235	199	2.80	2.84	2.82	2.90	3.07	1.37	1.22	1.19	1.23	1.30	57	48	43	48	43
Participate in research activities	110	232	433	235	199	2.94	2.70	2.79	2.85	2.86	1.34	1.24	1.18	1.24	1.29	58	45	46	47	43
Compare intervention outcomes with normative data	117	232	433	235	199	3.05	3.02	2.99	3.16	3.29	1.27	1.24	1.18	1.19	1.30	66	52	50	55	50
Professional Responsibilities																				
Supervise support personnel (e.g., physical therapy aide/technician)	137	232	433	235	199	3.60	3.51	3.58	3.72	3.71	1.13	1.21	1.21	1.25	1.15	83	67	54	61	57
Assign tasks to other personnel (e.g., physical therapy aide/technician) to assist with patient/client care	143	232	433	235	199	3.57	3.42	3.44	3.62	3.61	1.20	1.20	1.22	1.23	1.17	80	69	56	64	59
Disclose financial interest in recommended products or services to patient/client	114	232	433	232	197	2.81	3.00	2.98	3.20	3.18	1.39	1.30	1.30	1.28	1.20	56	53	43	50	46

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Communicate with the physical therapist when the expectations of the PTA are beyond their knowledge, skills, and abilities	162	232	433	232	197	4.48	4.58	4.60	4.61	4.58	0.65	0.72	0.73	0.71	0.72	99	86	83	82	80
Report healthcare providers that are suspected to not perform their professional responsibilities with reasonable skill and safety to the appropriate authorities	125	232	433	232	197	4.34	4.45	4.39	4.42	4.37	0.91	0.89	0.94	0.91	0.94	96	74	80	78	75
Report suspected cases of abuse to the appropriate authority	126	232	433	232	197	4.50	4.64	4.67	4.64	4.65	0.81	0.71	0.72	0.75	0.67	97	76	83	81	79
Report suspected illegal or unethical acts performed by healthcare providers to the relevant authority	117	232	433	232	197	4.44	4.62	4.61	4.60	4.58	0.93	0.71	0.77	0.78	0.75	96	75	82	80	78
Advocate for public access to physical therapy and other healthcare services	124	231	431	231	195	3.94	3.96	3.98	4.04	4.16	1.14	1.08	1.11	1.07	1.06	88	74	70	74	67
Determine own need for professional development	163	231	431	231	195	4.21	4.27	4.36	4.33	4.43	0.81	0.90	0.86	0.85	0.83	97	85	83	81	78
Participate in learning and/or development activities (e.g., journal clubs, self-directed reading, continuing competence activities) to maintain the currency of knowledge, skills, and abilities	160	231	431	231	195	4.17	4.24	4.30	4.27	4.21	0.84	0.95	0.95	0.88	1.05	97	84	82	82	74
Practice within the federal and jurisdiction regulations and professional standards	162	231	431	231	195	4.76	4.68	4.75	4.68	4.72	0.50	0.68	0.62	0.63	0.62	99	87	83	82	78
Participate in professional organizations	134	231	431	231	195	3.52	3.56	3.45	3.49	3.48	1.01	1.27	1.21	1.22	1.18	83	75	76	77	69

Table B.2. (Continued)

PTA WAs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Participate in performance improvement and quality reporting activities (e.g., Physician Quality Reporting System, standardized outcomes measurement, application of health informatics)	122	231	431	231	195	3.57	3.76	3.72	3.78	3.75	1.07	1.16	1.18	1.07	1.10	85	73	70	72	67

Note. Boldface mean (Red) indicates the mean importance value was less than 2.50. Light red shading indicates the 2021 mean importance value was below 2.50 (Criticality Threshold). Light orange shading indicates the 2021 mean importance value was between 2.50 (including) and 3.00 (excluding).

Table B.3. PT Knowledge and Skill Requirements Survey Results

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
CARDIOVASCULAR/PULMONARY SYSTEM																				
Physical Therapy Examination																				
Cardiovascular/pulmonary system tests/measures, including outcome measures, and their applications according to current best evidence	1,019	274	1,032	982	972	3.73	3.88	4.06	4.03	4.07	1.00	0.96	0.94	0.95	0.93	87	100	100	99	99
Anatomy and physiology of the cardiovascular/pulmonary system as related to tests/measures	1,021	274	1,032	982	972	3.80	3.85	4.05	4.01	4.00	0.98	0.94	0.93	0.94	0.95	90	100	100	100	99
Movement analysis as related to the cardiovascular/pulmonary system (e.g., rib cage excursion, breathing pattern)	1,020	274	1,032	982	972	3.68	3.74	3.93	3.93	3.86	0.98	0.97	0.94	0.93	0.95	87	99	100	100	99
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the cardiovascular/pulmonary systems	1,018	274	1,032	982	972	3.79	3.90	4.08	4.07	4.00	0.98	0.97	0.89	0.89	0.90	89	99	100	100	100
Cardiovascular/pulmonary system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	1,021	274	1,032	982	972	3.86	3.86	4.07	4.05	4.02	0.96	0.96	0.87	0.86	0.89	90	100	100	100	99
Non-pharmacological medical management of the cardiovascular/pulmonary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,012	274	1,032	982	972	3.25	3.35	3.54	3.52	3.51	0.99	1.00	0.98	0.96	0.99	76	98	99	99	99
The impact of pharmacology used to treat the cardiovascular/pulmonary system on physical therapy management	1,008	274	1,032	982	972	3.10	3.11	3.72	3.72	3.69	0.97	0.99	0.93	0.93	0.94	71	96	99	99	99

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Interventions																				
Cardiovascular/pulmonary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,021	274	1,032	982	972	4.09	4.03	4.14	4.13	4.13	0.96	0.98	0.89	0.89	0.89	93	100	100	100	100
Anatomy and physiology of the cardiovascular/pulmonary system as related to physical therapy interventions, daily activities, and environmental factors	1,021	274	1,032	982	972	4.19	4.08	4.23	4.20	4.13	0.88	0.90	0.82	0.87	0.90	95	99	100	100	100
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions	1,022	274	1,032	982	972	4.38	4.37	4.49	4.45	4.43	0.82	0.77	0.71	0.75	0.76	97	100	100	100	100
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions used on other systems	927	262	974	928	899	4.21	4.44	4.53	4.50	4.49	0.87	0.75	0.68	0.73	0.75	96	96	94	94	92
LYMPHATIC SYSTEM																				
Physical Therapy Examination																				
Lymphatic system tests/measures, including outcome measures, and their applications according to current best evidence	955	267	989	946	928	2.77	2.90	3.08	3.02	2.96	0.97	0.96	0.98	0.99	0.96	56	93	93	92	91
Anatomy and physiology of the lymphatic system as related to tests/measures	964	267	989	946	928	2.97	2.97	3.19	3.13	3.08	1.01	0.95	1.02	1.01	0.98	64	93	93	93	92
Movement analysis as related to the lymphatic system (e.g., compensatory movement, extremity range of motion)	968	267	989	946	928	3.20	3.15	3.38	3.30	3.23	1.05	1.08	1.03	1.03	1.00	72	92	94	93	93
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the lymphatic system	966	267	989	946	928	3.13	3.12	3.35	3.32	3.21	1.05	1.01	1.00	0.98	0.98	68	94	94	94	93

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Lymphatic system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	967	267	989	946	928	3.12	3.06	3.30	3.26	3.17	1.02	0.97	0.98	0.98	0.97	68	94	94	94	93
Non-pharmacological medical management of the lymphatic system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	957	267	989	946	928	2.77	2.82	3.06	2.99	2.94	0.94	0.97	0.99	0.95	0.96	55	91	92	92	91
Interventions																				
Lymphatic system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	967	267	989	946	928	3.12	3.25	3.41	3.38	3.31	1.02	1.08	1.02	1.04	1.02	68	93	94	94	93
Anatomy and physiology of the lymphatic system as related to interventions, daily activities, and environmental factors	967	267	989	946	928	3.33	3.29	3.46	3.38	3.30	1.05	1.04	1.00	1.05	1.02	75	94	94	94	93
Adverse effects or complications on the lymphatic system from physical therapy interventions	968	267	989	946	928	3.68	3.48	3.71	3.63	3.54	1.09	1.11	1.00	1.02	1.07	83	93	95	95	93
Adverse effects or complications on the lymphatic system from physical therapy interventions used on other systems	926	262	974	928	899	3.78	3.90	4.09	4.01	3.96	1.05	1.07	1.00	1.02	1.09	87	94	94	94	91
MUSCULOSKELETAL SYSTEM																				
Physical Therapy Examination																				
Musculoskeletal system tests/measures, including outcome measures, and their applications according to current best evidence	1,036	290	1,036	1,018	1,020	4.70	4.74	4.76	4.73	4.70	0.56	0.51	0.52	0.59	0.56	99	100	100	100	100
Anatomy and physiology of the musculoskeletal system as related to tests/measures	1,036	290	1,036	1,018	1,020	4.75	4.68	4.74	4.75	4.69	0.51	0.56	0.54	0.52	0.56	100	100	100	100	100

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Movement analysis as related to the musculoskeletal system	1,036	290	1,036	1,018	1,020	4.60	4.66	4.70	4.71	4.67	0.61	0.58	0.55	0.53	0.55	100	100	100	100	100
Joint biomechanics and their applications	1,036	290	1,036	1,018	1,020	4.44	4.46	4.55	4.54	4.49	0.75	0.74	0.66	0.68	0.69	98	100	100	100	100
Physical therapy ultrasound imaging of the musculoskeletal system	973	290	1,036	1,018	1,020	2.67	2.69	2.80	2.73	2.70	1.13	1.05	1.08	1.11	1.08	49	88	89	87	87
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the musculoskeletal system	1,036	274	1,006	993	979	4.44	4.57	4.58	4.57	4.53	0.73	0.62	0.61	0.63	0.67	99	94	97	98	96
Differential diagnoses related to diseases/conditions of the connective tissue	1,036	274	1,006	993	979	4.26	4.34	4.34	4.36	4.31	0.82	0.72	0.74	0.75	0.78	97	94	97	97	96
Musculoskeletal system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	1,036	274	1,006	993	979	4.51	4.55	4.54	4.56	4.46	0.67	0.60	0.64	0.62	0.69	99	94	97	98	96
Connective tissue diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	1,036	274	1,006	993	979	4.27	4.32	4.31	4.33	4.25	0.80	0.73	0.77	0.74	0.80	97	94	97	97	96
Non-pharmacological medical management of the musculoskeletal system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,033	274	1,006	993	979	3.64	3.81	3.80	3.86	3.80	0.93	0.82	0.87	0.84	0.89	89	94	97	97	95
The impact of pharmacology used to treat the musculoskeletal system on physical therapy management	1,010	274	1,006	993	979	3.18	3.27	3.72	3.73	3.65	0.87	0.86	0.86	0.86	0.89	78	94	97	97	96

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
The impact of regenerative medicine (e.g., platelet rich plasma, stem cells) on physical therapy prognosis and interventions related to musculoskeletal diseases/conditions	996	274	1,006	993	979	2.72	2.93	3.20	3.15	3.14	0.91	0.93	0.96	0.95	0.94	57	89	95	94	94
Interventions																				
Musculoskeletal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,010	290	1,036	1,018	1,020	4.54	4.75	4.67	4.73	4.64	0.69	0.49	0.59	0.54	0.61	99	100	100	100	100
Anatomy and physiology of the musculoskeletal system as related to physical therapy interventions, daily activities, and environmental factors	1,010	290	1,036	1,018	1,020	4.71	4.77	4.73	4.76	4.71	0.51	0.46	0.52	0.50	0.52	100	100	100	100	100
Adverse effects or complications on the musculoskeletal system from physical therapy interventions	1,010	290	1,036	1,018	1,020	4.66	4.73	4.73	4.71	4.66	0.58	0.52	0.53	0.55	0.59	100	100	100	100	100
Adverse effects or complications on the musculoskeletal system from physical therapy interventions used on other systems	928	262	974	928	899	4.48	4.79	4.78	4.81	4.78	0.71	0.46	0.45	0.46	0.49	99	96	94	94	92
NEUROMUSCULAR & NERVOUS SYSTEM																				
Physical Therapy Examination																				
Neuromuscular and nervous systems tests/measures, including outcome measures, and their applications according to current best evidence	953	268	977	960	933	4.49	4.62	4.58	4.58	4.60	0.70	0.63	0.66	0.64	0.63	99	92	94	94	92
Anatomy and physiology of the neuromuscular and nervous systems as related to tests/measures	953	268	977	960	933	4.53	4.58	4.57	4.57	4.56	0.67	0.65	0.65	0.63	0.65	99	92	94	94	92
Movement analysis as related to the neuromuscular and nervous systems	952	268	977	960	933	4.38	4.58	4.56	4.56	4.58	0.80	0.65	0.67	0.64	0.64	97	92	94	94	92

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Diagnostic electromyography (EMG) using surface electrodes	879	268	977	960	933	2.43	2.49	2.62	2.58	2.59	0.99	1.01	0.99	1.00	1.04	39	77	84	81	79
Diagnostic electrophysiology (EMG/NCV) using needle insertion	839	268	977	960	933	2.27	2.35	2.47	2.45	2.45	1.02	1.00	1.02	1.03	1.06	31	72	79	77	75
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the nervous system (CNS, PNS, ANS)	951	268	977	960	933	4.16	4.25	4.25	4.33	4.24	0.88	0.89	0.82	0.81	0.85	96	92	94	94	91
Nervous system (CNS, PNS, ANS) diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	952	268	977	960	933	4.31	4.38	4.39	4.44	4.30	0.80	0.78	0.76	0.76	0.81	98	92	94	94	91
Non-pharmacological medical management of the neuromuscular and nervous systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	947	268	977	960	933	3.55	3.65	3.71	3.78	3.69	0.96	0.90	0.89	0.89	0.94	86	92	94	94	91
The impact of pharmacology used to treat the neuromuscular and nervous systems on physical therapy management	947	268	977	960	933	3.22	3.24	3.75	3.75	3.67	0.98	0.93	0.92	0.89	0.94	76	91	94	94	91
The impact of regenerative medicine (e.g., platelet rich plasma, stem cells) on physical therapy prognosis and interventions related to the neuromuscular and nervous systems				960	933				3.03	3.01				0.99	1.04				89	86
Interventions																				
Neuromuscular and nervous systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	953	264	955	937	899	4.48	4.65	4.59	4.66	4.60	0.74	0.60	0.64	0.57	0.62	98	91	92	92	88

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Anatomy and physiology of the neuromuscular and nervous systems as related to physical therapy interventions, daily activities, and environmental factors	928	264	955	937	899	4.58	4.59	4.59	4.63	4.60	0.63	0.58	0.64	0.59	0.61	99	91	92	92	88
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions	928	264	955	937	899	4.53	4.59	4.57	4.57	4.51	0.67	0.62	0.65	0.65	0.68	99	91	92	92	88
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions used on other systems	928	262	974	928	899	4.46	4.77	4.78	4.80	4.77	0.71	0.49	0.46	0.45	0.48	99	96	94	94	93
Motor control as related to neuromuscular and nervous systems physical therapy interventions	928	264	955	937	899	4.42	4.54	4.54	4.54	4.52	0.75	0.64	0.66	0.67	0.67	99	91	92	92	88
Motor learning as related to the neuromuscular and nervous systems physical therapy interventions	928	264	955	937	899	4.41	4.56	4.52	4.50	4.49	0.75	0.61	0.69	0.71	0.69	99	91	92	92	88
INTEGUMENTARY SYSTEM																				
<i>Physical Therapy Examination</i>																				
Integumentary system tests/measures, including outcome measures, and their applications according to current best evidence	947	257	943	908	867	3.33	3.32	3.51	3.48	3.38	0.99	0.96	0.98	0.99	0.98	78	93	90	91	87
Anatomy and physiology of the integumentary system as related to tests/measures	948	257	943	908	867	3.41	3.41	3.60	3.53	3.47	1.00	0.96	0.97	0.98	0.99	80	93	91	91	88
Movement analysis as related to the integumentary system (e.g., friction, shear, pressure, and scar mobility)	951	257	943	908	867	3.75	3.82	3.97	3.92	3.86	0.97	0.94	0.89	0.93	0.95	89	93	91	92	88

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the integumentary system	951	257	943	908	867	3.39	3.43	3.64	3.58	3.50	1.03	0.99	0.93	0.97	0.98	79	92	91	91	88
Integumentary system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	951	257	943	908	867	3.42	3.37	3.67	3.57	3.51	1.01	0.98	0.93	0.94	0.96	80	92	91	92	88
Non-pharmacological medical management of the integumentary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	946	257	943	908	867	3.02	3.02	3.37	3.29	3.23	0.98	0.97	0.99	0.96	1.00	67	91	90	91	87
The impact of pharmacology used to treat the integumentary system on physical therapy management	945	257	943	908	867	2.82	2.79	3.43	3.31	3.26	0.98	0.97	0.99	0.99	1.03	58	89	90	91	86
Interventions																				
Integumentary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	951	257	943	908	867	3.64	3.62	3.76	3.72	3.58	1.02	1.01	0.96	0.96	0.99	86	93	91	92	88
Anatomy and physiology of the integumentary system as related to physical therapy interventions, daily activities, and environmental factors	950	257	943	908	867	3.71	3.73	3.83	3.80	3.67	1.00	0.95	0.94	0.94	1.00	88	93	91	92	88
Adverse effects or complications on the integumentary system from physical therapy and medical/surgical interventions	951	257	943	908	867	3.89	3.88	4.01	3.99	3.85	1.00	0.99	0.91	0.93	0.98	90	94	91	92	88
Adverse effects or complications on the integumentary system from physical therapy interventions used on other systems	927	262	974	928	899	3.97	4.10	4.30	4.22	4.17	0.99	0.96	0.84	0.86	0.92	90	96	94	94	92

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
METABOLIC & ENDOCRINE SYSTEMS																				
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Differential diagnoses related to diseases/conditions of the metabolic and endocrine systems	902	261	938	924	887	3.37	3.53	3.61	3.67	3.63	0.99	0.93	0.96	0.94	0.97	81	89	89	90	86
Metabolic and endocrine system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	902	261	938	924	887	3.41	3.58	3.65	3.68	3.63	0.98	0.94	0.95	0.92	0.96	83	89	90	90	86
Non-pharmacological medical management of the metabolic and endocrine systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	894	261	938	924	887	2.98	3.16	3.28	3.36	3.31	1.00	0.94	0.98	0.92	0.98	66	87	88	89	85
The impact of pharmacology used to treat the metabolic and endocrine systems on physical therapy management	891	261	938	924	887	2.85	2.90	3.38	3.41	3.37	0.97	0.93	0.97	0.95	0.99	62	85	89	89	85
Interventions																				
Metabolic and endocrine systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	899	261	938	924	887	3.57	3.67	3.63	3.67	3.60	1.05	1.00	1.01	0.98	1.01	83	89	89	89	86
Anatomy and physiology of the metabolic and endocrine systems as related to physical therapy interventions, daily activities, and environmental factors	901	261	938	924	887	3.60	3.64	3.62	3.67	3.61	1.04	1.05	0.99	0.99	1.01	84	88	89	89	86
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions	900	261	938	924	887	3.85	3.85	3.81	3.85	3.77	1.00	0.98	0.98	1.01	0.99	89	89	90	89	86

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions used on other systems	927	262	974	928	899	3.80	3.87	4.08	4.04	3.99	1.05	1.05	0.97	0.97	1.02	87	95	94	94	92
GASTROINTESTINAL SYSTEM																				
Physical Therapy Examination																				
Gastrointestinal system tests/measures, including outcome measures, and their applications according to current best evidence (e.g., bowel dysfunction impact questionnaires, Murphy test, Rovsing test, McBurney point sign)	856	258	926	912	870	2.69	2.83	2.99	3.02	3.00	1.02	1.00	1.03	1.04	1.08	53	83	84	85	79
Anatomy and physiology of the gastrointestinal system as related to tests/measures	865	258	926	912	870	2.88	2.94	3.09	3.10	3.06	1.02	1.03	1.03	1.01	1.07	61	83	85	86	80
Movement analysis as related to the gastrointestinal system (e.g., effects of muscular tension or trigger points, positioning for bowel movement)	866	258	926	912	870	2.96	2.96	3.10	3.10	3.12	1.10	1.11	1.04	1.05	1.10	61	82	85	86	81
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Gastrointestinal system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	869	258	926	912	870	2.96	2.99	3.12	3.12	3.11	1.03	1.02	1.03	1.02	1.07	64	84	85	86	81
Differential diagnoses related to diseases/conditions of the gastrointestinal system	871	258	926	912	870	3.03	3.09	3.19	3.20	3.17	1.08	1.03	1.05	1.06	1.08	64	84	85	86	81
Non-pharmacological medical management of the gastrointestinal system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	861	258	926	912	870	2.64	2.71	2.89	2.86	2.88	0.96	0.98	0.97	0.96	1.02	50	81	84	85	80

PT KSRs	Importance																				
	n					M					SD					%Imp					
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	
The impact of pharmacology used to treat the gastrointestinal system on physical therapy management	854	258	926	912	870	2.49	2.57	3.06	3.06	3.03	0.91	0.93	1.00	0.97	1.04	44	80	85	87	81	
Interventions																					
Gastrointestinal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., positioning for reflux prevention, bowel programs)	867	258	926	912	870	3.09	3.09	3.18	3.14	3.16	1.12	1.09	1.05	1.05	1.08	66	84	85	86	82	
Anatomy and physiology of the gastrointestinal system as related to physical therapy interventions, daily activities, and environmental factors	872	258	926	912	870	3.26	3.23	3.28	3.29	3.23	1.10	1.08	1.06	1.05	1.11	73	85	86	87	81	
Adverse effects or complications on the gastrointestinal system from physical therapy interventions	872	258	926	912	870	3.43	3.38	3.46	3.46	3.37	1.12	1.09	1.11	1.09	1.13	76	86	86	87	82	
Adverse effects or complications on the gastrointestinal system from physical therapy interventions used on other systems	926	262	974	928	899	3.61	3.73	3.94	3.85	3.82	1.12	1.12	1.06	1.09	1.09	80	95	93	93	92	
GENITOURINARY SYSTEM																					
Physical Therapy Examination																					
Genitourinary system tests/measures, including outcome measures, and their applications according to current best evidence	844	255	917	903	859	2.77	2.93	3.01	3.04	3.06	1.04	1.09	1.05	1.06	1.06	54	80	83	84	79	
Anatomy and physiology of the genitourinary system as related to tests/measures	851	255	917	903	858	2.88	2.95	3.07	3.14	3.11	1.07	1.11	1.07	1.06	1.08	57	81	84	84	79	
Physical therapy ultrasound imaging of the genitourinary system	780	255	917	903	858	2.22	2.25	2.44	2.43	2.44	0.98	1.01	1.02	1.03	1.04	30	66	72	72	68	

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Foundations for Evaluation, Differential Diagnosis and Prognosis																				
Genitourinary system diseases/conditions and their pathophysiology to establish and carry out plan of care, including prognosis	846	255	917	903	858	2.80	2.90	3.00	3.03	3.02	1.09	1.09	1.05	1.03	1.05	54	80	83	84	78
Differential diagnoses related to diseases/conditions of the genitourinary system	855	255	917	903	858	2.90	3.02	3.07	3.13	3.10	1.10	1.11	1.08	1.06	1.06	58	81	83	84	80
Non-pharmacological medical management of the genitourinary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	844	255	917	903	858	2.54	2.64	2.80	2.83	2.81	1.00	1.04	1.00	0.99	1.01	44	77	81	83	77
The impact of pharmacology used to treat the genitourinary system on physical therapy management	835	255	917	903	858	2.42	2.49	2.95	2.92	2.91	0.95	1.00	1.04	1.02	1.05	40	74	82	83	78
Interventions																				
Genitourinary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., bladder programs, biofeedback, pelvic floor retraining)	855	255	917	903	858	3.03	3.13	3.15	3.20	3.17	1.12	1.16	1.08	1.10	1.10	63	81	84	85	79
Anatomy and physiology of the genitourinary system as related to physical therapy interventions, daily activities, and environmental factors	855	255	917	903	858	3.17	3.24	3.22	3.25	3.21	1.14	1.17	1.10	1.09	1.10	68	82	84	85	80
Adverse effects or complications on the genitourinary system from physical therapy interventions	853	255	917	903	858	3.29	3.28	3.33	3.37	3.30	1.17	1.19	1.14	1.13	1.13	71	82	84	85	80
Adverse effects or complications on the genitourinary system from physical therapy interventions used on other systems	927	262	974	928	899	3.56	3.63	3.90	3.81	3.78	1.17	1.17	1.11	1.12	1.15	78	94	93	93	91

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
SYSTEM INTERACTIONS																				
<i>Foundations for Evaluation, Differential Diagnosis and Prognosis</i>																				
Differential diagnoses related to diseases/conditions where the primary impact is on more than one system	928	253	917	888	844	4.03	4.22	4.33	4.34	4.25	0.93	0.81	0.70	0.74	0.76	94	92	89	90	87
Diseases/conditions where the primary impact is on more than one system (e.g., cancer, multi-trauma, sarcoidosis, autoimmune disorders, pregnancy) to establish and carry out plan of care, including prognosis	927	253	917	888	843	4.10	4.22	4.33	4.29	4.24	0.87	0.81	0.72	0.76	0.76	95	92	89	90	87
The impact of co-morbidities/co-existing conditions on patient/client management (e.g., diabetes and hypertension; obesity and arthritis; dementia and hip fracture)	915	253	917	888	843	4.43	4.43	4.52	4.54	4.46	0.71	0.71	0.65	0.64	0.68	99	92	89	90	87
Psychological and psychiatric conditions that impact patient/client management (e.g., grief, depression, schizophrenia)	915	253	917	888	843	3.97	4.00	4.16	4.19	4.08	0.88	0.88	0.80	0.82	0.84	95	92	89	90	87
Dimensions of pain that impact patient/client management (e.g., psychological, social, physiological, neurological, mechanical)	915	253	917	888	843	4.26	4.26	4.38	4.41	4.31	0.79	0.81	0.72	0.73	0.72	97	92	89	90	87
Non-pharmacological medical management of multiple systems (e.g., diagnostic imaging and other medical tests, surgical procedures)	914	253	917	888	843	3.66	3.85	4.04	3.98	3.91	0.92	0.91	0.84	0.86	0.88	90	92	89	90	87
The impact of pharmacology used to treat multiple systems, including polypharmacy, on physical therapy management	913	253	917	888	843	3.42	3.53	3.99	3.93	3.86	0.98	0.98	0.88	0.89	0.91	82	92	89	90	87

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
EQUIPMENT, DEVICES, & TECHNOLOGIES																				
<i>Applications and adjustments, indications, contraindications, and precautions of:</i>																				
- assistive and adaptive devices/technologies (e.g., walkers, wheelchairs, adaptive seating systems and positioning devices, mechanical lifts)	876	254	913	896	854	4.59	4.60	4.64	4.62	4.65	0.69	0.65	0.67	0.66	0.66	99	88	88	88	84
- prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	874	254	913	896	854	4.01	3.98	4.14	4.08	4.12	1.04	0.94	0.92	0.98	0.99	90	87	88	87	83
- protective, supportive, and orthotic devices/technologies (e.g., braces, helmets, taping, compression garments, serial casts, shoe inserts, splints)	875	254	913	896	854	4.14	4.06	4.25	4.22	4.22	0.94	0.94	0.88	0.89	0.90	94	87	88	88	83
THERAPEUTIC MODALITIES																				
<i>Applications, indications, contraindications, and precautions of:</i>																				
- thermal modalities	902	252	912	886	839	4.15	3.71	3.81	3.70	3.68	0.99	1.19	1.11	1.18	1.16	91	88	86	86	83
- iontophoresis	889	252	912	886	839	3.73	3.00	3.15	2.98	2.99	1.19	1.18	1.20	1.23	1.24	80	82	81	80	76
- electrotherapy modalities, excluding iontophoresis (e.g., neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), functional electrical stimulation (FES), interferential therapy, high-voltage pulsed current)	899	252	912	886	839	4.14	3.82	3.92	3.80	3.77	0.97	1.06	1.03	1.09	1.07	93	91	87	88	85
- laser light therapy	875	252	912	886	839	3.44	2.72	2.92	2.85	2.65	1.29	1.26	1.22	1.23	1.23	70	76	77	77	69
- LED light therapy	875	252	912	886	839	3.44	2.72	2.92	2.85	2.47	1.29	1.26	1.22	1.23	1.21	70	76	77	77	65
- phonophoresis	875	252	912	886	839	3.45	2.65	2.82	2.69	2.61	1.31	1.24	1.23	1.29	1.27	70	73	75	72	67

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- ultrasound modalities, excluding phonophoresis	888	252	912	886	839	3.83	3.17	3.33	3.15	3.15	1.17	1.30	1.29	1.31	1.31	82	82	80	79	75
- mechanical modalities (e.g., mechanical motion devices, traction devices)	896	252	909	886	838	3.97	3.62	3.77	3.73	3.63	1.06	1.12	1.08	1.10	1.12	88	89	86	88	84
- biofeedback	896	252	909	886	838	3.57	3.42	3.50	3.51	3.37	1.12	1.03	1.09	1.08	1.07	80	89	85	87	83
- diathermy	828	252	909	886	838	3.06	2.21	2.55	2.37	2.40	1.40	1.23	1.31	1.23	1.27	54	57	64	63	60
- intermittent compression	893	252	909	886	838	3.57	2.86	3.13	3.09	3.04	1.16	1.16	1.16	1.18	1.16	78	80	81	82	78
- shockwave therapy	740	252	909	886	838	2.45	2.09	2.40	2.30	2.24	1.26	1.09	1.21	1.20	1.15	33	58	63	62	59
SAFETY & PROTECTION																				
Factors influencing safety and injury prevention (e.g., safe patient handling, fall prevention, equipment maintenance, environmental safety)	874	254	913	896	854	4.79	4.76	4.77	4.78	4.73	0.51	0.53	0.55	0.52	0.59	99	88	88	88	84
The function and implications and related precautions of intravenous lines, tubes, catheters, monitoring devices, and mechanical ventilators/oxygen delivery devices	872	254	913	896	854	4.29	4.34	4.33	4.26	4.26	0.88	0.88	0.86	0.89	0.92	96	87	88	87	83
Emergency preparedness (e.g., CPR, first aid, disaster response)	873	254	913	896	854	4.52	4.56	4.58	4.57	4.51	0.78	0.76	0.73	0.74	0.79	97	88	88	88	83
Infection control procedures (e.g., standard/universal precautions, isolation techniques, sterile technique)	874	254	913	896	854	4.69	4.63	4.66	4.70	4.62	0.62	0.72	0.66	0.63	0.71	99	88	88	88	83
Signs/symptoms of physical, sexual, and psychological abuse and neglect	874	254	913	896	854	4.38	4.50	4.51	4.48	4.45	0.81	0.74	0.75	0.76	0.79	97	88	88	88	83
PROFESSIONAL RESPONSIBILITIES																				
Standards of documentation	873	253	909	893	851	4.68	4.70	4.68	4.70	4.64	0.55	0.54	0.58	0.58	0.62	100	87	88	88	83
Standards of professional ethics	873	253	909	893	851	4.80	4.84	4.82	4.84	4.74	0.46	0.43	0.45	0.43	0.54	100	87	88	88	83
Standards of billing, coding, and reimbursement	872	253	909	893	851	4.27	4.53	4.41	4.44	4.35	0.87	0.69	0.77	0.79	0.84	96	87	88	88	83
Patient/client rights (e.g., ADA, IDEA, HIPAA, patient bill of rights)	873	253	909	893	851	4.57	4.68	4.68	4.75	4.59	0.67	0.61	0.61	0.55	0.69	99	87	88	88	83

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Obligations for reporting illegal, unethical, or unprofessional behaviors (e.g., fraud, abuse, neglect)	873	253	909	893	851	4.61	4.70	4.69	4.76	4.64	0.63	0.59	0.60	0.54	0.65	99	87	88	88	83
State and federal laws, rules, regulations, and industry standards set by state and accrediting bodies (e.g., state licensing entities, Joint Commission, CARF, CMS)	872	253	909	893	851	4.43	4.61	4.61	4.63	4.48	0.79	0.70	0.68	0.67	0.75	97	87	88	88	83
Risk management and quality assurance (e.g., policies and procedures, incident reports, peer chart review)	871	252	904	890	851	4.07	4.02	3.92	3.93	3.88	0.95	0.87	0.91	0.96	0.94	92	87	87	87	83
Human resource legal issues (e.g., OSHA, sexual harassment)	872	252	904	890	851	3.96	3.99	3.93	4.03	3.87	0.99	0.93	0.94	0.97	0.99	91	87	87	87	83
Roles and responsibilities of the PT, PTA, other healthcare professionals, and support staff	873	252	904	890	851	4.55	4.58	4.56	4.56	4.45	0.66	0.67	0.68	0.67	0.74	99	87	87	87	83
Cultural factors and/or characteristics that affect patient/client management (e.g., language differences, disability, ethnicity, customs, demographics, religion)	873	252	904	890	851	4.23	4.25	4.24	4.34	4.23	0.86	0.86	0.88	0.81	0.89	96	87	87	87	83
Socioeconomic factors that affect patient/client management	872	252	904	890	851	3.93	4.19	4.17	4.27	4.16	0.90	0.87	0.89	0.82	0.89	93	87	87	87	83
Applications and utilization of health information technology (e.g., electronic medical records, telemedicine)	872	252	904	890	851	3.88	4.05	4.03	4.13	4.07	0.98	0.96	0.94	0.88	0.93	91	86	86	87	83
The provision and utilization of telehealth (i.e., the use of telecommunication technologies to provide health care information and services)					851					3.45					1.09					81

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
TEACHING & LEARNING THEORIES																				
Teaching and learning theories and techniques	897	251	904	886	836	3.70	3.93	3.91	3.93	3.92	1.05	1.00	0.99	0.99	1.00	85	90	86	89	85
Health behavior change models (e.g., social cognitive theory, health belief model)	896	251	904	886	836	3.42	3.55	3.65	3.73	3.66	1.07	1.11	1.02	1.00	1.07	78	88	86	89	84
Communication methods and techniques (e.g., motivational interviewing, health information brochures/handouts, feedback techniques)	903	251	904	886	836	3.86	4.04	4.12	4.14	4.10	1.02	1.04	0.91	0.92	0.96	89	90	87	89	85
RESEARCH & EVIDENCE-BASED PRACTICE																				
Techniques for accessing evidence (e.g., peer-reviewed publications, scientific proceedings, guidelines, clinical prediction rules)	902	251	904	886	836	3.86	3.98	4.02	4.11	4.03	1.01	0.97	0.93	0.88	0.95	90	91	87	90	85
Research methodology and interpretation (e.g., qualitative, quantitative, levels of evidence)	901	251	904	886	836	3.53	3.71	3.69	3.81	3.75	1.05	1.02	1.02	0.96	1.02	83	90	86	89	85
Measurement science (e.g., reliability, validity)	902	251	904	886	836	3.65	3.74	3.77	3.88	3.82	1.04	1.00	0.99	0.97	0.99	86	90	86	89	85
Statistics (e.g., t-test, chi-square, correlation coefficient, ANOVA, likelihood ratio, effect size, confidence interval)	882	251	904	886	836	2.93	2.88	3.07	3.12	3.00	1.11	1.04	1.10	1.07	1.10	61	83	82	85	79
Data collection techniques (e.g., surveys, direct observation)	892	251	904	886	836	3.18	3.13	3.32	3.32	3.26	1.08	1.02	1.07	1.02	1.09	70	87	85	87	82
SKILLS																				
Active listening - Giving full attention to what other people are saying, taking time to understand the points being made, asking questions as appropriate, and not interrupting at inappropriate times	905	251	903	884	833	4.72	4.77	4.80	4.82	4.80	0.55	0.51	0.48	0.46	0.51	100	92	88	90	86
Speaking - Talking to others to convey information effectively	905	251	903	884	833	4.69	4.75	4.77	4.78	4.77	0.56	0.51	0.49	0.49	0.52	100	92	88	90	86

PT KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Reading Comprehension - Understanding written sentences and paragraphs in work related documents	905	251	903	884	833	4.51	4.57	4.58	4.58	4.60	0.73	0.69	0.64	0.65	0.66	99	91	88	90	86
Critical Thinking - Using logic and clinical reasoning to identify the strengths and weaknesses of alternative solutions, conclusions or approaches to problems	905	251	903	884	833	4.77	4.80	4.83	4.83	4.81	0.50	0.48	0.43	0.45	0.47	100	91	88	90	86
Social Perceptiveness - Being aware of others' reactions and understanding why they react as they do	903	251	903	884	833	4.57	4.73	4.72	4.73	4.69	0.68	0.55	0.54	0.53	0.58	99	92	87	90	86
Time Management - Managing one's own time and the time of others	905	251	903	884	833	4.58	4.71	4.72	4.70	4.67	0.67	0.56	0.53	0.57	0.62	99	92	88	90	86
Coordination - Adjusting actions in relation to others' actions	903	249	902	880	830	4.48	4.51	4.55	4.55	4.52	0.74	0.64	0.65	0.63	0.70	98	91	87	90	85
Writing - Communicating effectively in writing as appropriate for the needs of the audience	904	249	902	880	830	4.48	4.44	4.49	4.44	4.48	0.75	0.71	0.71	0.71	0.71	98	91	87	90	85
Active Learning - Understanding the implications of new information for both current and future problem solving and decision-making	904	249	902	880	830	4.55	4.59	4.64	4.63	4.61	0.70	0.64	0.59	0.59	0.61	98	91	87	90	85
Persuasion - Persuading others to change their minds or behavior	901	249	902	880	830	3.89	3.91	4.02	3.99	3.96	1.01	0.96	0.90	0.94	0.94	90	90	87	88	85
Negotiation - Bringing others together and trying to reconcile differences	900	249	902	880	830	3.78	3.98	4.14	4.10	4.05	1.02	0.96	0.86	0.88	0.91	88	90	87	89	85
Service Orientation - Actively looking for ways to help people	902	249	902	880	830	4.08	4.35	4.36	4.37	4.30	0.93	0.82	0.80	0.79	0.85	93	91	87	89	85

Note. Boldface mean (Red) indicates the mean importance value was less than 2.50. Light red shading indicates the 2021 mean importance value was below 2.50 (Criticality Threshold). Light orange shading indicates the 2021 mean importance value was between 2.50 (including) and 3.00 (excluding).

Table B.4. PTA Knowledge and Skill Requirements Survey Results

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
CARDIOVASCULAR/PULMONARY SYSTEM																				
Physical Therapy Data Collection																				
Cardiovascular/pulmonary system tests/measures, including outcome measures, and their applications according to current best evidence	1,123	625	696	565	463	3.59	3.91	3.93	3.97	4.03	1.06	0.97	0.99	0.95	0.98	82	99	99	99	99
Anatomy and physiology of the cardiovascular/pulmonary system as related to tests/measures	1,126	625	696	565	463	3.64	3.86	3.91	4.02	3.97	1.04	0.96	0.98	0.94	0.97	85	99	99	99	100
Movement analysis as related to the cardiovascular/pulmonary system (e.g., rib cage excursion, breathing pattern)	1,127	625	696	565	463	3.60	3.71	3.80	3.93	3.89	1.01	0.97	1.00	0.93	0.95	84	100	99	100	99
Diseases/Conditions that Impact Effective Treatment																				
Cardiovascular/pulmonary system diseases/conditions and their pathophysiology to carry out the established plan of care	1,129	625	696	565	463	3.84	3.98	4.05	4.09	4.04	0.94	0.90	0.91	0.89	0.91	91	100	99	99	100
Non-pharmacological medical management of the cardiovascular/pulmonary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,116	625	696	565	463	3.02	3.23	3.33	3.42	3.34	1.03	0.98	1.00	1.02	0.99	66	97	98	98	98
The impact of pharmacology used to treat the cardiovascular/pulmonary system on physical therapy management	1,099	625	696	565	463	2.84	3.07	3.52	3.56	3.49	0.99	0.96	0.98	0.97	1.00	58	96	99	99	98
Interventions																				
Cardiovascular/pulmonary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,127	625	696	565	463	4.00	4.13	4.12	4.24	4.16	0.96	0.91	0.88	0.86	0.86	92	100	99	99	99

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Anatomy and physiology of the cardiovascular/pulmonary system as related to physical therapy interventions, daily activities, and environmental factors	1,130	625	696	565	463	4.08	4.20	4.15	4.28	4.17	0.91	0.87	0.86	0.84	0.85	94	100	100	100	100
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions	1,130	625	696	565	463	4.33	4.48	4.41	4.50	4.41	0.83	0.71	0.74	0.74	0.80	97	100	100	100	100
Adverse effects or complications on the cardiovascular/pulmonary system from physical therapy interventions used on other systems	1,044	587	643	516	426	4.12	4.39	4.30	4.40	4.39	0.89	0.78	0.80	0.78	0.78	95	94	92	90	92
LYMPHATIC SYSTEM																				
Physical Therapy Data Collection																				
Lymphatic system tests/measures, including outcome measures, and their applications according to current best evidence	1,063	604	671	534	435	2.79	2.99	3.08	3.23	3.15	1.05	0.99	0.95	0.99	1.03	55	92	93	91	91
Anatomy and physiology of the lymphatic system as related to tests/measures	1,074	604	671	534	435	2.95	3.04	3.17	3.31	3.25	1.05	0.99	0.98	1.00	1.02	63	93	94	92	92
Movement analysis as related to the lymphatic system (e.g., compensatory movement, extremity range of motion)	1,078	604	671	534	435	3.32	3.35	3.44	3.63	3.49	1.07	1.05	1.04	0.99	1.01	74	94	94	93	91
Diseases/Conditions that Impact Effective Treatment																				
Lymphatic system diseases/conditions and their pathophysiology to carry out the established plan of care	1,082	604	671	534	435	3.24	3.31	3.39	3.56	3.46	1.06	1.04	0.99	0.96	0.96	73	94	94	93	92
Non-pharmacological medical management of the lymphatic system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,064	604	671	534	435	2.70	2.88	2.99	3.13	3.09	0.98	0.95	0.95	0.96	1.00	53	92	92	90	90

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Interventions																				
Lymphatic system interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,076	604	671	534	435	3.26	3.37	3.41	3.61	3.50	1.06	1.07	1.01	0.97	1.03	72	94	94	93	92
Anatomy and physiology of the lymphatic system as related to interventions, daily activities, and environmental factors	1,083	604	671	534	435	3.36	3.43	3.47	3.69	3.54	1.08	1.06	1.02	1.00	1.00	75	94	95	92	92
Adverse effects or complications on the lymphatic system from physical therapy interventions	1,086	604	671	534	435	3.70	3.77	3.75	3.95	3.77	1.09	1.10	1.05	0.98	1.04	83	95	95	93	92
Adverse effects or complications on the lymphatic system from physical therapy interventions used on other systems	1,042	587	643	518	426	3.72	3.70	3.63	3.86	3.72	1.06	1.07	1.05	1.05	1.07	85	93	90	90	90
MUSCULOSKELETAL SYSTEM																				
Physical Therapy Data Collection																				
Musculoskeletal system tests/measures, including outcome measures, and their applications according to current best evidence	1,162	647	662	583	521	4.31	4.46	4.45	4.43	4.43	0.85	0.77	0.79	0.79	0.76	96	100	100	99	100
Anatomy and physiology of the musculoskeletal system as related to tests/measures	1,164	647	662	583	521	4.51	4.56	4.56	4.56	4.51	0.73	0.69	0.67	0.68	0.72	98	100	100	100	100
Movement analysis as related to the musculoskeletal system	1,164	647	662	583	521	4.38	4.46	4.52	4.51	4.45	0.77	0.72	0.68	0.67	0.71	98	100	100	100	100
Joint biomechanics and their applications	1,165	647	662	583	521	4.33	4.37	4.46	4.40	4.34	0.80	0.78	0.71	0.77	0.78	97	100	100	100	100
Diseases/Conditions that Impact Effective Treatment																				
Musculoskeletal system diseases/conditions and their pathophysiology to carry out the established plan of care	1,164	625	641	561	499	4.26	4.30	4.39	4.36	4.28	0.81	0.74	0.70	0.72	0.77	97	97	97	96	96

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Connective tissue diseases/conditions and their pathophysiology to carry out the established plan of care	1,164	625	641	561	499	4.07	4.12	4.23	4.19	4.11	0.90	0.82	0.76	0.79	0.83	95	97	97	96	95
Non-pharmacological medical management of the musculoskeletal system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,156	625	641	561	499	3.37	3.55	3.64	3.52	3.57	1.00	0.96	0.88	0.93	0.90	80	96	96	95	95
The impact of pharmacology used to treat the musculoskeletal system on physical therapy management	1,145	625	641	561	499	3.06	3.26	3.63	3.51	3.50	1.03	0.98	0.90	0.90	0.90	69	94	96	96	95
Interventions																				
Musculoskeletal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,165	647	662	583	521	4.49	4.63	4.64	4.63	4.59	0.72	0.59	0.59	0.60	0.62	99	100	100	100	100
Anatomy and physiology of the musculoskeletal system as related to physical therapy interventions, daily activities, and environmental factors	1,166	647	662	583	521	4.63	4.63	4.66	4.68	4.58	0.62	0.62	0.58	0.58	0.62	99	100	100	100	100
Adverse effects or complications on the musculoskeletal system from physical therapy interventions	1,153	647	662	583	521	4.50	4.65	4.67	4.67	4.60	0.68	0.61	0.60	0.57	0.60	99	100	100	100	100
Adverse effects or complications on the musculoskeletal system from physical therapy interventions used on other systems	1,045	587	643	516	426	4.38	4.53	4.43	4.49	4.47	0.77	0.70	0.73	0.74	0.74	98	94	92	91	92

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
NEUROMUSCULAR & NERVOUS SYSTEM																				
Physical Therapy Data Collection																				
Neuromuscular and nervous systems tests/measures, including outcome measures, and their applications according to current best evidence	1,076	624	641	561	499	3.99	4.06	4.08	4.08	4.03	0.91	0.89	0.86	0.85	0.88	93	96	97	96	95
Anatomy and physiology of the neuromuscular and nervous systems as related to tests/measures	1,078	624	641	561	499	4.09	4.16	4.19	4.17	4.10	0.88	0.86	0.82	0.83	0.85	95	96	97	96	96
Movement analysis as related to the neuromuscular and nervous systems	1,078	624	640	561	499	4.12	4.24	4.31	4.27	4.21	0.87	0.83	0.77	0.79	0.80	96	96	97	96	96
Diseases/Conditions that Impact Effective Treatment																				
Nervous system (CNS, PNS, ANS) diseases/conditions and their pathophysiology to carry out the established plan of care	1,079	625	640	561	499	4.00	4.06	4.15	4.11	3.98	0.91	0.90	0.85	0.87	0.87	94	96	97	96	95
Non-pharmacological medical management of the neuromuscular and nervous systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,074	624	640	561	499	3.32	3.51	3.64	3.59	3.55	1.03	1.01	0.90	0.94	0.91	78	95	96	95	95
The impact of pharmacology used to treat the neuromuscular and nervous systems on physical therapy management	1,061	624	640	561	499	3.09	3.25	3.68	3.63	3.52	1.05	0.99	0.94	0.93	0.94	68	94	96	96	95
Interventions																				
Neuromuscular and nervous systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,078	601	615	545	474	4.25	4.40	4.41	4.42	4.33	0.86	0.74	0.69	0.72	0.77	95	93	93	93	91

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Anatomy and physiology of the neuromuscular and nervous systems as related to physical therapy interventions, daily activities, and environmental factors	1,079	601	615	545	474	4.34	4.38	4.40	4.42	4.31	0.79	0.75	0.71	0.71	0.79	97	93	93	93	91
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions	1,079	601	615	545	474	4.38	4.44	4.42	4.45	4.34	0.78	0.74	0.74	0.71	0.75	97	93	93	93	91
Adverse effects or complications on the neuromuscular and nervous systems from physical therapy interventions used on other systems	1,045	587	643	516	426	4.36	4.53	4.42	4.46	4.50	0.78	0.70	0.73	0.75	0.71	98	94	92	91	92
Motor control as related to neuromuscular and nervous systems physical therapy interventions	1,079	601	615	545	474	4.33	4.34	4.39	4.36	4.32	0.76	0.76	0.72	0.73	0.76	98	93	93	93	91
Motor learning as related to the neuromuscular and nervous systems physical therapy interventions	1,069	601	615	545	474	4.11	4.32	4.37	4.34	4.26	0.86	0.79	0.74	0.75	0.79	96	93	93	93	91
INTEGUMENTARY SYSTEM																				
Physical Therapy Data Collection																				
Integumentary system tests/measures, including outcome measures, and their applications according to current best evidence	1,056	569	621	506	414	3.22	3.32	3.41	3.52	3.46	1.06	0.97	0.98	1.01	0.98	72	89	87	87	88
Anatomy and physiology of the integumentary system as related to tests/measures	1,061	569	621	506	414	3.35	3.43	3.47	3.62	3.52	1.03	0.98	0.97	1.02	0.99	77	90	88	88	88
Movement analysis as related to the integumentary system (e.g., friction, shear, pressure, and scar mobility)	1,065	569	621	506	414	3.77	3.87	3.89	4.03	3.94	0.96	0.91	0.89	0.93	0.92	90	91	89	89	88

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Diseases/Conditions that Impact Effective Treatment																				
Integumentary system diseases/conditions and their pathophysiology to carry out the established plan of care	1,063	569	621	506	414	3.58	3.65	3.73	3.83	3.71	0.98	0.95	0.93	0.92	0.98	85	90	89	89	89
Non-pharmacological medical management of the integumentary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,050	569	621	506	414	2.97	3.13	3.24	3.36	3.31	1.04	0.96	0.96	0.99	1.02	64	89	87	87	87
The impact of pharmacology used to treat the integumentary system on physical therapy management	1,041	569	621	506	414	2.77	2.88	3.32	3.41	3.32	1.06	0.98	0.97	1.00	1.02	55	86	87	87	87
Interventions																				
Integumentary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,065	569	621	505	414	3.66	3.72	3.71	3.85	3.74	1.01	0.95	0.95	0.96	0.98	87	91	88	88	89
Anatomy and physiology of the integumentary system as related to physical therapy interventions, daily activities, and environmental factors	1,066	569	621	505	414	3.75	3.80	3.78	3.97	3.80	1.00	0.94	0.95	0.95	0.97	88	90	89	88	89
Adverse effects or complications on the integumentary system from physical therapy and medical/surgical interventions	1,066	569	621	505	414	3.88	3.98	3.93	4.06	3.94	1.00	0.95	0.94	0.94	0.96	89	91	88	88	89
Adverse effects or complications on the integumentary system from physical therapy interventions used on other systems	1,043	587	643	516	426	3.95	4.07	4.01	4.14	4.11	0.97	0.90	0.88	0.93	0.89	92	94	92	90	92

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
METABOLIC & ENDOCRINE SYSTEMS																				
<i>Diseases/Conditions that Impact Effective Treatment</i>																				
Metabolic and endocrine system diseases/conditions and their pathophysiology to carry out the established plan of care	1,038	593	607	535	464	3.21	3.43	3.53	3.49	3.39	0.99	0.98	0.94	0.94	0.93	76	90	90	91	88
Non-pharmacological medical management of the metabolic and endocrine systems (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	1,029	593	607	535	464	2.92	3.15	3.34	3.27	3.17	0.97	0.98	0.95	0.94	0.92	65	89	90	91	86
The impact of pharmacology used to treat the metabolic and endocrine systems on physical therapy management	1,019	593	607	535	464	2.77	2.98	3.34	3.31	3.20	0.98	0.99	0.96	0.97	0.94	57	87	90	90	86
<i>Interventions</i>																				
Metabolic and endocrine systems physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence	1,039	593	607	535	464	3.40	3.53	3.58	3.58	3.47	1.06	1.03	0.96	0.97	0.98	80	89	90	91	88
Anatomy and physiology of the metabolic and endocrine systems as related to physical therapy interventions, daily activities, and environmental factors	1,041	593	607	535	464	3.42	3.56	3.62	3.64	3.47	1.06	1.06	0.97	0.97	0.97	79	90	91	91	87
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions	1,042	593	607	535	464	3.65	3.77	3.75	3.77	3.67	1.06	1.04	0.99	0.96	0.97	85	90	91	91	88
Adverse effects or complications on the metabolic and endocrine systems from physical therapy interventions used on other systems	1,041	587	643	516	426	3.70	3.74	3.71	3.88	3.87	1.09	1.03	1.00	1.00	0.99	84	93	92	90	91

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
GASTROINTESTINAL SYSTEM																				
Physical Therapy Data Collection																				
Gastrointestinal system tests/measures, including outcome measures, and their applications according to current best evidence (e.g., bowel dysfunction impact questionnaires, Murphy test, Rovsing test, McBurney point sign)	980	586	596	528	451	2.64	2.77	2.93	2.88	2.84	1.04	1.05	0.99	0.96	1.03	49	81	85	85	78
Anatomy and physiology of the gastrointestinal system as related to tests/measures	989	586	596	528	451	2.77	2.86	3.02	3.00	2.92	1.06	1.04	0.99	0.98	1.06	54	84	87	87	79
Movement analysis as related to the gastrointestinal system (e.g., effects of muscular tension or trigger points, positioning for bowel movement)	996	586	596	528	451	2.93	2.97	3.12	3.17	3.03	1.04	1.09	1.05	1.00	1.05	61	83	86	88	80
Diseases/Conditions that Impact Effective Treatment																				
Gastrointestinal system diseases/conditions and their pathophysiology to carry out the established plan of care	1,000	586	596	528	451	2.92	3.02	3.14	3.19	3.04	1.01	1.08	1.03	0.99	1.04	63	84	87	88	80
Non-pharmacological medical management of the gastrointestinal system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	984	586	596	528	451	2.63	2.78	2.92	2.92	2.86	0.98	1.01	0.99	0.95	1.02	49	83	84	86	80
The impact of pharmacology used to treat the gastrointestinal system on physical therapy management	974	586	596	528	451	2.48	2.64	3.03	3.02	2.93	0.93	0.98	1.01	0.97	1.04	43	81	85	87	80

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Interventions																				
Gastrointestinal system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., positioning for reflux prevention, bowel programs)	1,003	586	596	528	451	3.06	3.15	3.16	3.22	3.12	1.07	1.09	1.06	1.03	1.05	67	85	86	88	81
Anatomy and physiology of the gastrointestinal system as related to physical therapy interventions, daily activities, and environmental factors	1,006	586	596	528	451	3.17	3.20	3.26	3.31	3.20	1.10	1.11	1.05	1.02	1.04	69	85	87	88	82
Adverse effects or complications on the gastrointestinal system from physical therapy interventions	1,008	586	596	528	451	3.35	3.37	3.41	3.46	3.35	1.11	1.14	1.07	1.03	1.07	74	86	87	89	83
Adverse effects or complications on the gastrointestinal system from physical therapy interventions used on other systems	1,041	587	643	516	426	3.57	3.59	3.58	3.75	3.70	1.14	1.09	1.04	1.06	1.07	80	92	91	89	91
GENITOURINARY SYSTEM																				
Physical Therapy Data Collection																				
Genitourinary system tests/measures, including outcome measures, and their applications according to current best evidence	963	579	589	519	438	2.57	2.78	2.89	2.90	2.83	1.00	1.05	1.04	1.02	1.04	45	81	82	83	75
Anatomy and physiology of the genitourinary system as related to tests/measures	971	579	589	519	438	2.70	2.82	2.95	2.95	2.88	1.04	1.04	1.05	1.03	1.05	50	82	82	83	76
Diseases/Conditions that Impact Effective Treatment																				
Genitourinary system diseases/conditions and their pathophysiology to carry out the established plan of care	977	579	589	519	438	2.74	2.89	2.99	3.02	2.95	1.03	1.06	1.05	1.03	1.04	52	82	84	84	78

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Non-pharmacological medical management of the genitourinary system (e.g., diagnostic imaging, laboratory test values, other medical tests, surgical procedures)	964	579	589	519	438	2.52	2.68	2.82	2.84	2.79	0.97	0.97	1.01	0.98	1.01	44	81	82	82	76
The impact of pharmacology used to treat the genitourinary system on physical therapy management	951	579	589	519	438	2.40	2.52	2.91	2.95	2.87	0.95	0.95	1.04	1.01	1.03	38	77	82	83	77
Interventions																				
Genitourinary system physical therapy interventions and their applications for rehabilitation, health promotion, and performance according to current best evidence (e.g., bladder programs, biofeedback, pelvic floor retraining)	978	579	589	519	438	2.94	3.05	3.13	3.17	3.08	1.08	1.09	1.04	1.09	1.06	59	83	85	85	79
Anatomy and physiology of the genitourinary system as related to physical therapy interventions, daily activities, and environmental factors	982	579	589	519	438	3.01	3.08	3.15	3.23	3.12	1.11	1.11	1.07	1.08	1.07	61	83	85	85	79
Adverse effects or complications on the genitourinary system from physical therapy interventions	983	579	589	519	438	3.13	3.21	3.24	3.31	3.25	1.15	1.17	1.11	1.13	1.11	65	84	85	85	80
Adverse effects or complications on the genitourinary system from physical therapy interventions used on other systems	1,040	587	643	516	426	3.50	3.49	3.48	3.67	3.65	1.19	1.15	1.10	1.11	1.11	76	91	90	88	90
SYSTEM INTERACTIONS																				
Diseases/Conditions that Impact Effective Treatment																				
Diseases/conditions where the primary impact is on more than one system (e.g., cancer, multi-trauma, sarcoidosis, autoimmune disorders, pregnancy) to carry out the established plan of care	1,044	564	607	497	402	4.03	4.20	4.13	4.24	4.22	0.92	0.82	0.85	0.83	0.77	94	90	87	88	87

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
The impact of co-morbidities/co-existing conditions on patient/client management (e.g., diabetes and hypertension; obesity and arthritis; dementia and hip fracture)	1,045	564	607	497	402	4.31	4.46	4.42	4.46	4.49	0.79	0.66	0.70	0.69	0.67	97	90	87	88	87
Psychological and psychiatric conditions that impact patient/client management (e.g., grief, depression, schizophrenia)	1,041	564	607	497	402	3.73	4.06	4.01	4.09	4.14	0.91	0.85	0.88	0.86	0.81	90	90	87	88	87
Dimensions of pain that impact patient/client management (e.g., psychological, social, physiological, neurological, mechanical)	1,042	564	607	497	402	4.00	4.27	4.23	4.30	4.30	0.87	0.76	0.80	0.79	0.75	95	90	87	88	87
Non-pharmacological medical management of multiple systems (e.g., diagnostic imaging and other medical tests, surgical procedures)	1,031	564	607	497	402	3.29	3.57	3.72	3.74	3.76	1.01	0.95	0.95	0.95	0.94	77	89	86	87	86
The impact of pharmacology used to treat multiple systems, including polypharmacy, on physical therapy management	1,018	564	607	497	402	3.06	3.30	3.72	3.74	3.71	1.00	1.00	0.95	0.98	0.98	69	88	86	87	86
EQUIPMENT, DEVICES, & TECHNOLOGIES																				
<i>Applications and adjustments, indications, contraindications, and precautions of:</i>																				
- assistive and adaptive devices/technologies (e.g., walkers, wheelchairs, adaptive seating systems and positioning devices, mechanical lifts)	998	575	584	515	434	4.64	4.73	4.74	4.71	4.69	0.63	0.53	0.50	0.54	0.59	99	89	88	88	83
- prosthetic devices/technologies (e.g., lower-extremity and upper-extremity prostheses, microprocessor-controlled prosthetic devices)	994	575	584	515	434	4.18	4.17	4.34	4.30	4.21	0.98	0.90	0.84	0.90	0.90	92	88	88	88	83

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
- protective, supportive, and orthotic devices/technologies (e.g., braces, helmets, taping, compression garments, serial casts, shoe inserts, splints)	997	575	584	515	434	4.20	4.25	4.37	4.32	4.25	0.93	0.85	0.81	0.84	0.88	94	89	88	88	83
THERAPEUTIC MODALITIES																				
<i>Applications, indications, contraindications, and precautions of:</i>																				
- thermal modalities	1,037	561	598	494	395	4.48	4.15	4.14	4.31	4.12	0.78	1.03	1.01	0.92	1.03	97	88	85	86	84
- iontophoresis	1,022	561	598	494	395	4.01	3.31	3.22	3.37	3.25	1.15	1.25	1.28	1.24	1.28	85	84	77	81	77
- electrotherapy modalities, excluding iontophoresis (e.g., neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), functional electrical stimulation (FES), interferential therapy, high-voltage pulsed current)	1,033	561	598	494	395	4.49	4.15	4.14	4.29	4.17	0.77	1.02	0.99	0.90	1.01	97	88	85	87	84
- laser light therapy	1,015	561	598	494	395	3.75	2.98	3.00	3.16	2.85	1.27	1.24	1.27	1.30	1.31	78	79	75	77	70
- LED light therapy	1,015	561	598	494	395	3.75	2.98	3.00	3.16	2.68	1.27	1.24	1.27	1.30	1.27	78	79	75	77	68
- phonophoresis	1,007	561	598	494	395	3.76	2.94	2.96	3.11	2.90	1.28	1.31	1.31	1.31	1.33	77	76	73	76	71
- ultrasound modalities, excluding phonophoresis	1,027	561	598	494	395	4.31	3.78	3.82	3.95	3.66	0.94	1.22	1.21	1.15	1.23	93	85	81	85	80
- mechanical modalities (e.g., mechanical motion devices, traction devices)	1,028	561	598	494	395	4.24	3.77	3.78	3.93	3.73	0.98	1.08	1.16	1.10	1.11	92	88	82	85	83
- biofeedback	1,022	561	598	494	395	3.76	3.45	3.32	3.54	3.41	1.19	1.13	1.19	1.11	1.17	81	86	79	85	80
- diathermy	987	561	598	494	395	3.65	2.73	2.82	3.05	2.80	1.34	1.40	1.39	1.33	1.38	72	68	67	74	66
- intermittent compression	1,028	561	598	494	395	3.83	3.26	3.29	3.55	3.30	1.17	1.14	1.17	1.10	1.23	83	85	80	84	78
SAFETY & PROTECTION																				
Factors influencing safety and injury prevention (e.g., safe patient handling, fall prevention, equipment maintenance, environmental safety)	996	575	584	515	434	4.78	4.82	4.80	4.83	4.72	0.50	0.44	0.47	0.44	0.58	99	89	88	88	83

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
The function and implications and related precautions of intravenous lines, tubes, catheters, monitoring devices, and mechanical ventilators/oxygen delivery devices	995	575	584	515	434	4.34	4.37	4.38	4.38	4.27	0.89	0.85	0.87	0.82	0.88	95	89	88	88	83
Emergency preparedness (e.g., CPR, first aid, disaster response)	996	575	584	515	434	4.51	4.57	4.54	4.62	4.49	0.77	0.72	0.75	0.67	0.75	97	89	88	88	83
Infection control procedures (e.g., standard/universal precautions, isolation techniques, sterile technique)	995	575	584	515	434	4.72	4.74	4.69	4.74	4.65	0.60	0.56	0.63	0.54	0.64	99	89	88	88	83
Signs/symptoms of physical, sexual, and psychological abuse and neglect	995	575	584	515	434	4.39	4.47	4.47	4.47	4.37	0.86	0.75	0.78	0.77	0.85	96	89	88	88	83
PROFESSIONAL RESPONSIBILITIES																				
Standards of documentation	994	572	584	512	431	4.68	4.74	4.71	4.69	4.60	0.58	0.57	0.55	0.57	0.61	100	88	88	88	83
Standards of professional ethics	994	572	584	512	431	4.79	4.83	4.82	4.82	4.72	0.47	0.44	0.45	0.45	0.57	100	88	88	88	83
Standards of billing, coding, and reimbursement	993	572	584	512	431	4.21	4.37	4.34	4.23	4.16	0.98	0.90	0.86	0.88	0.93	92	88	88	87	82
Patient/client rights (e.g., ADA, IDEA, HIPAA, patient bill of rights)	994	572	584	512	431	4.63	4.72	4.71	4.70	4.64	0.66	0.58	0.56	0.59	0.65	99	88	88	88	82
Obligations for reporting illegal, unethical, or unprofessional behaviors (e.g., fraud, abuse, neglect)	994	572	584	512	431	4.65	4.75	4.72	4.69	4.67	0.63	0.54	0.57	0.63	0.57	99	88	88	88	83
State and federal laws, rules, regulations, and industry standards set by state and accrediting bodies (e.g., state licensing entities, Joint Commission, CARF, CMS)	994	572	584	512	431	4.50	4.60	4.58	4.57	4.54	0.80	0.71	0.67	0.72	0.70	96	88	88	87	83
Risk management and quality assurance (e.g., policies and procedures, incident reports, peer chart review)	991	572	584	512	431	4.14	4.26	4.29	4.25	4.16	0.98	0.92	0.87	0.87	0.90	92	88	88	87	83
Human resource legal issues (e.g., OSHA, sexual harassment)	990	572	584	512	431	4.09	4.20	4.20	4.22	4.19	0.99	0.93	0.93	0.90	0.89	91	88	88	87	83

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Roles and responsibilities of the PT, PTA, other healthcare professionals, and support staff	994	572	584	512	431	4.64	4.71	4.71	4.73	4.65	0.65	0.58	0.56	0.53	0.61	99	88	88	88	83
Cultural factors and/or characteristics that affect patient/client management (e.g., language differences, disability, ethnicity, customs, demographics, religion)	993	571	582	510	430	4.26	4.18	4.07	4.22	4.11	0.89	0.87	0.89	0.81	0.86	95	88	87	87	82
Socioeconomic factors that affect patient/client management	992	571	582	510	430	3.79	4.08	3.97	4.09	3.99	0.97	0.89	0.89	0.86	0.88	90	88	87	87	82
Applications and utilization of health information technology (e.g., electronic medical records, telemedicine)	992	571	582	510	430	3.86	4.02	4.01	4.00	4.05	0.99	0.93	0.96	0.90	0.89	90	88	87	87	82
The provision and utilization of telehealth (i.e., the use of telecommunication technologies to provide health care information and services)					430					3.30				1.05					80	
TEACHING & LEARNING THEORIES																				
Teaching and learning theories and techniques	987	571	582	510	430	3.61	3.87	3.88	3.96	3.86	1.03	0.97	0.99	0.93	0.94	85	88	87	87	82
Health behavior change models (e.g., social cognitive theory, health belief model)	984	571	582	510	430	3.35	3.70	3.75	3.82	3.63	1.07	1.01	0.99	0.95	1.00	78	87	86	86	82
Communication methods and techniques (e.g., motivational interviewing, health information brochures/handouts, feedback techniques)	989	571	582	510	430	3.64	3.93	3.89	3.94	3.77	1.09	0.98	1.01	1.00	0.97	84	88	87	86	82

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
RESEARCH & EVIDENCE-BASED PRACTICE																				
Techniques for accessing evidence (e.g., peer-reviewed publications, scientific proceedings, guidelines, clinical prediction rules)	1,018	559	596	494	395	3.29	3.56	3.55	3.64	3.59	1.11	1.07	1.02	1.04	1.07	74	87	84	86	84
Research methodology and interpretation (e.g., qualitative, quantitative, levels of evidence)	1,017	559	596	494	395	3.07	3.31	3.39	3.46	3.40	1.07	1.08	1.02	1.06	1.07	69	85	83	85	83
Measurement science (e.g., reliability, validity)	1,021	559	596	494	395	3.29	3.45	3.55	3.64	3.56	1.10	1.10	1.01	1.03	1.03	75	85	84	86	84
Data collection techniques (e.g., surveys, direct observation)	1,021	559	596	494	395	3.12	3.28	3.45	3.55	3.37	1.12	1.10	1.06	1.09	1.06	69	85	83	85	82
SKILLS																				
Active listening - Giving full attention to what other people are saying, taking time to understand the points being made, asking questions as appropriate, and not interrupting at inappropriate times	1,032	558	593	493	394	4.75	4.84	4.79	4.83	4.81	0.53	0.42	0.51	0.46	0.47	100	89	85	87	85
Speaking - Talking to others to convey information effectively	1,032	558	593	493	394	4.73	4.83	4.77	4.80	4.76	0.53	0.42	0.49	0.45	0.52	100	89	85	87	85
Reading Comprehension - Understanding written sentences and paragraphs in work related documents	1,032	558	593	493	394	4.63	4.73	4.67	4.72	4.67	0.62	0.53	0.57	0.55	0.60	99	89	85	87	85
Critical Thinking - Using logic and clinical reasoning to identify the strengths and weaknesses of alternative solutions, conclusions or approaches to problems	1,032	558	593	493	394	4.70	4.79	4.80	4.83	4.74	0.56	0.48	0.46	0.43	0.51	100	89	85	87	85
Social Perceptiveness - Being aware of others' reactions and understanding why they react as they do	1,032	558	593	493	394	4.60	4.75	4.70	4.76	4.69	0.66	0.53	0.55	0.51	0.57	99	89	85	87	85

Table B.4. (Continued)

PTA KSRs	Importance																			
	n					M					SD					%Imp				
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021
Time Management - Managing one's own time and the time of others	1,032	558	593	493	394	4.62	4.76	4.73	4.73	4.70	0.62	0.50	0.53	0.55	0.56	100	89	85	87	85
Coordination - Adjusting actions in relation to others' actions	1,032	558	592	492	393	4.52	4.60	4.54	4.57	4.53	0.69	0.61	0.67	0.64	0.64	99	89	85	87	85
Writing - Communicating effectively in writing as appropriate for the needs of the audience	1,032	558	592	492	393	4.54	4.60	4.54	4.58	4.53	0.70	0.61	0.66	0.62	0.66	99	89	85	87	85
Active Learning - Understanding the implications of new information for both current and future problem solving and decision-making	1,032	558	592	492	393	4.55	4.65	4.56	4.64	4.57	0.66	0.59	0.65	0.57	0.62	99	89	85	87	85
Persuasion - Persuading others to change their minds or behavior	1,028	558	592	492	393	3.89	3.92	3.90	4.02	3.91	1.06	0.99	1.01	0.97	0.93	89	88	84	86	85
Negotiation - Bringing others together and trying to reconcile differences	1,022	558	592	492	393	3.84	4.06	4.03	4.13	4.04	1.03	0.93	0.90	0.92	0.92	88	89	85	86	84
Service Orientation - Actively looking for ways to help people	1,029	558	592	492	393	4.30	4.45	4.39	4.53	4.43	0.84	0.76	0.77	0.71	0.75	96	89	85	87	85

Note. Boldface mean (Red) indicates the mean importance value was less than 2.50. Light red shading indicates the 2021 mean importance value was below 2.50 (Criticality Threshold). Light orange shading indicates the 2021 mean importance value was between 2.50 (including) and 3.00 (excluding).

Appendix C. Notable Mean Differences Across Years

Table C.1: Statistics and Formatting Key:

- **Sample Size (n):** Count of respondents that provided usable data
- **Mean Importance (M):** Based on responses for scale points 1 through 5
- **Standard Deviation of Importance (SD):** Based on responses for scale points 1 through 5
- **Mean Difference (M-Diff):** Difference between mean importance ratings across years (Y0=2016, Y1=2018, Y2=2019, Y3=2020, Y4=2021)

- **Boldface Mean (Red):** Mean importance value was less than 2.50 (Criticality Threshold)
- **Boldface M-Diff (Green):** Mean difference value was greater than 0.50
- **Boldface M-Diff (Red):** Mean difference value was less than -0.50

Table C.1. Notable Mean Differences Across Years

	Importance															M-Diff							
	n					M					SD												
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	Y1-0	Y2-1	Y2-0	Y3-1	Y3-0	Y4-1	Y4-0	
PT KSRs																							
The impact of pharmacology used to treat the cardiovascular/pulmonary system on physical therapy management	1,008	274	1,032	982	972	3.10	3.11	3.72	3.72	3.69	0.97	0.99	0.93	0.93	0.94	0.01	0.61	0.00	0.61	0.62	0.58	0.59	
The impact of pharmacology used to treat the metabolic and endocrine systems on physical therapy management	891	261	938	924	887	2.85	2.90	3.38	3.41	3.37	0.97	0.93	0.97	0.95	0.99	0.06	0.48	0.03	0.51	0.56	0.46	0.52	
The impact of pharmacology used to treat the gastrointestinal system on physical therapy management	854	258	926	912	870	2.49	2.57	3.06	3.06	3.03	0.91	0.93	1.00	0.97	1.04	0.09	0.49	-0.01	0.48	0.57	0.46	0.55	
Applications, indications, contraindications, and precautions of: iontophoresis	889	252	912	886	839	3.73	3.00	3.15	2.98	2.99	1.19	1.18	1.20	1.23	1.24	-0.73	0.15	-0.17	-0.02	-0.75	-0.01	-0.75	
Applications, indications, contraindications, and precautions of: laser light therapy	875	252	912	886	839	3.44	2.72	2.92	2.85	2.65	1.29	1.26	1.22	1.23	1.23	-0.71	0.20	-0.07	0.13	-0.59	-0.08	-0.79	
Applications, indications, contraindications, and precautions of: LED light therapy	875	252	912	886	839	3.44	2.72	2.92	2.85	2.47	1.29	1.26	1.22	1.23	1.21	-0.71	0.20	-0.07	0.13	-0.59	-0.25	-0.96	
Applications, indications, contraindications, and precautions of: phonophoresis	875	252	912	886	839	3.45	2.65	2.82	2.69	2.61	1.31	1.24	1.23	1.29	1.27	-0.80	0.17	-0.13	0.04	-0.76	-0.04	-0.84	
Applications, indications, contraindications, and precautions of: ultrasound modalities, excluding phonophoresis	888	252	912	886	839	3.83	3.17	3.33	3.15	3.15	1.17	1.30	1.29	1.31	1.31	-0.66	0.16	-0.19	-0.03	-0.69	-0.03	-0.69	
Applications, indications, contraindications, and precautions of: diathermy	828	252	909	886	838	3.06	2.21	2.55	2.37	2.40	1.40	1.23	1.31	1.23	1.27	-0.85	0.34	-0.17	0.17	-0.69	0.19	-0.66	

	Importance															M-Diff							
	n					M					SD					M-Diff							
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	Y1-0	Y2-1	Y2-0	Y3-1	Y3-0	Y4-1	Y4-0	
Application, indications, contraindications, and precautions of: Intermittent compression	893	252	909	886	838	3.57	2.86	3.13	3.09	3.04	1.16	1.16	1.16	1.18	1.16	-0.71	0.27	-0.44	0.22	-0.48	0.18	-0.53	
PT WAs																							
Interpret each of the following types of data to determine the need for intervention or the response to intervention: Neuromuscular system	271	431	676	653	375	3.98	4.66	4.62	4.60	4.68	0.86	0.64	0.64	0.65	0.61	0.68	-0.04	-0.02	-0.06	0.62	0.02	0.70	
Interpret each of the following types of data to determine the need for intervention or the response to intervention: Functional mobility, balance, and vestibular	276	431	676	653	375	4.14	4.67	4.63	4.64	4.69	0.79	0.64	0.64	0.64	0.58	0.53	-0.04	0.01	-0.03	0.50	0.02	0.56	
Interpret each of the following types of data to determine the need for intervention or the response to intervention: Musculoskeletal system	279	431	676	653	375	4.33	4.82	4.80	4.78	4.85	0.72	0.50	0.49	0.47	0.39	0.49	-0.02	0.48	-0.04	0.46	0.03	0.52	
Interpret each of the following types of data to determine the need for intervention or the response to intervention: ADLs/IADLs and home management	267	430	671	645	373	3.99	4.40	4.39	4.47	4.49	0.80	0.81	0.88	0.74	0.82	0.41	-0.01	0.41	0.08	0.49	0.09	0.50	
Perform dry needling	295	491	779	805	446	2.27	2.90	2.89	2.91	2.88	1.18	1.37	1.44	1.39	1.48	0.62	-0.01	0.02	0.01	0.63	-0.02	0.60	
Perform and/or train patient/client/caregiver in iontophoresis	237	458	712	746	406	2.82	2.53	2.36	2.22	2.18	1.04	1.21	1.22	1.18	1.19	-0.29	-0.18	-0.13	-0.31	-0.60	-0.35	-0.64	
Perform and/or train patient/client/caregiver in phonophoresis	209	456	706	743	404	2.56	2.29	2.10	2.03	1.87	1.18	1.25	1.30	1.27	1.15	-0.27	-0.19	-0.07	-0.26	-0.53	-0.42	-0.69	
Perform and/or train patient/client/caregiver in ultrasound procedures	262	456	706	743	404	3.08	2.59	2.49	2.20	2.33	1.17	1.28	1.36	1.21	1.31	-0.49	-0.10	-0.30	-0.39	-0.88	-0.26	-0.75	

	Importance															M-Diff							
	n					M					SD					M-Diff							
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	Y1-0	Y2-1	Y2-0	Y3-1	Y3-0	Y4-1	Y4-0	
Perform and/or train patient/client/caregiver in diathermy	188	456	706	743	404	2.24	2.14	2.03	1.86	1.65	1.19	1.23	1.32	1.20	0.98	-0.10	-0.11	-0.21	-0.28	-0.38	-0.49	-0.59	
PTA KSRs																							
The impact of pharmacology used to treat the cardiovascular/pulmonary system on physical therapy management	1,099	625	696	565	463	2.84	3.07	3.52	3.56	3.49	0.99	0.96	0.98	0.97	1.00	0.23	0.45	0.04	0.49	0.72	0.42	0.65	
The impact of pharmacology used to treat the integumentary system on physical therapy management	1,041	569	621	506	414	2.77	2.88	3.32	3.41	3.32	1.06	0.98	0.97	1.00	1.02	0.11	0.44	0.10	0.53	0.64	0.45	0.55	
The impact of pharmacology used to treat multiple systems, including polypharmacy, on physical therapy management	1,018	564	607	497	402	3.06	3.30	3.72	3.74	3.71	1.00	1.00	0.95	0.98	0.98	0.24	0.42	0.02	0.44	0.68	0.41	0.65	
Applications, indications, contraindications, and precautions of: iontophoresis	1,022	561	598	494	395	4.01	3.31	3.22	3.37	3.25	1.15	1.25	1.28	1.24	1.28	-0.71	-0.09	0.15	0.06	-0.64	-0.06	-0.77	
Applications, indications, contraindications, and precautions of: laser light therapy	1,015	561	598	494	395	3.75	2.98	3.00	3.16	2.85	1.27	1.24	1.27	1.30	1.31	-0.77	0.02	0.16	0.18	-0.59	-0.14	-0.91	
Applications, indications, contraindications, and precautions of: LED light therapy	1,015	561	598	494	395	3.75	2.98	3.00	3.16	2.68	1.27	1.24	1.27	1.30	1.27	-0.77	0.02	-0.75	0.18	-0.59	-0.31	-1.08	
Applications, indications, contraindications, and precautions of: phonophoresis	1,007	561	598	494	395	3.76	2.94	2.96	3.11	2.90	1.28	1.31	1.31	1.31	1.33	-0.82	0.02	0.15	0.17	-0.65	-0.04	-0.87	
Applications, indications, contraindications, and precautions of: Ultrasound modalities, excluding phonophoresis	1,027	561	598	494	395	4.31	3.78	3.82	3.95	3.66	0.94	1.22	1.21	1.15	1.23	-0.53	0.04	-0.49	0.17	-0.36	-0.12	-0.65	

	Importance															M-Diff							
	n					M					SD												
	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	2016	2018	2019	2020	2021	Y1-0	Y2-1	Y2-0	Y3-1	Y3-0	Y4-1	Y4-0	
Applications, indications, contraindications, and precautions of: Mechanical modalities (e.g., mechanical motion devices, traction devices)	1,028	561	598	494	395	4.24	3.77	3.78	3.93	3.73	0.98	1.08	1.16	1.10	1.11	-0.47	0.01	-0.46	0.16	-0.31	-0.04	-0.51	
Applications, indications, contraindications, and precautions of: diathermy	987	561	598	494	395	3.65	2.73	2.82	3.05	2.80	1.34	1.40	1.39	1.33	1.38	-0.92	0.09	0.23	0.32	-0.59	0.07	-0.85	
Applications, indications, contraindications, and precautions of: Intermittent compression	1,028	561	598	494	395	3.83	3.26	3.29	3.55	3.30	1.17	1.14	1.17	1.10	1.23	-0.57	0.03	-0.54	0.29	-0.27	0.04	-0.52	
PTA WAs																							
Apply taping for neuromuscular reeducation	176	284	514	364	206	3.26	4.10	4.09	3.94	3.95	1.13	1.04	1.13	1.21	1.19	0.84	-0.02	-0.15	-0.16	0.68	-0.15	0.69	
Apply taping for pain management	174	284	514	364	206	3.22	4.06	4.10	3.97	4.05	1.17	1.14	1.04	1.19	1.03	0.84	0.04	-0.13	-0.09	0.75	-0.01	0.83	
Perform and/or train patient/client/caregiver in application of topical agents (e.g., cleansers, creams, moisturizers, ointments, sealants) and dressings (e.g., hydrogels, wound coverings)	117	271	491	353	193	2.27	2.64	2.25	2.76	2.99	1.38	1.38	1.26	1.31	1.25	0.37	-0.39	-0.02	0.12	0.49	0.35	0.72	
Apply and/or train patient/client/caregiver in intermittent pneumatic compression	127	270	487	352	189	2.67	3.11	2.82	2.92	3.21	1.33	1.31	1.35	1.34	1.25	0.44	-0.30	0.15	-0.19	0.25	0.10	0.54	

Note. Values in green font indicate an increase in mean importance of greater than 0.5. Values in red font indicate a decrease in mean importance of greater than 0.5.